Pharmacological characterisation of the hP2Y11 and xlP2Y11 receptors. by Drew, C.M.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS 
Degree p V \ 0  Year j X o o b  Name of Author
COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to approved libraries within the United Kingdom, for consultation solely on the 
premises of those libraries. Application should be made to: Inter-Library Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University of London theses may not be reproduced without explicit written 
permission from the Senate House Library. Enquiries should be addressed to the 
Theses Section of the Library. Regulations concerning reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A. Before 1962. Permission granted only upon the prior written consent of the
author. (The Senate House Library will provide addresses where possible).
B. 1962-1974. In many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C. 1975 - 1988. Most theses may be copied upon completion of a Copyright
Declaration.
D. 1989 onwards. Most theses may be copied.
This thesis comes within category D.
This copy has been deposited in the Library of ______________ __
This copy has been deposited in the Senate House Library, Senate House,
C:\Documents and Settings\lproctor\Local SettingsVTemporary Internet FiIes\OLKS\Copyright - thesis (2).doc aokbinder
92 3965 
setts.com
LOANS
Malet Street, London WC1E 7HU.

Pharmacological Characterisation of 
the hP2Yn and XlP2Yn receptors.
Christian M. Drew
Thesis submitted to University College London 
for the degree of Doctor of Philosophy. 
November 2005
Department of Biochemistry and Molecular Biology, 
University College London,
Gower Street,
London.
WC1E 6BT
UMI Number: U591941
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591941
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
ABSTRACT
Extracellular nucleotides and nucleosides are important signalling molecules 
that exert a diverse range of physiological responses throughout the body. These 
chemical messengers often transduce their effects through interaction with 
specific cell surface receptors called purinoceptors. The P2Y purinoceptor family 
binds extracellular nucleotides, principally ATP, ADP, UTP and UDP. 
Conformational change of the P2Y purinoceptors upon ligand binding conveys 
a signal to intracellular heterotrimeric G proteins, which are activated, 
transducing the signal further downstream by acting at different effector 
enzymes to influence second messenger production.
In this thesis I present the first pharmacological characterisation of a non­
mammalian P2Yh receptor orthologue, Xenopus laevis P2Yn (XlP2Yn), and 
extend the pharmacological profile of the human P2Yn receptor (hP2Yn). 
Second messenger assays were employed to record the intracellular cyclic AMP 
(cAMP) accumulation and Ca2+ mobilisation generated by both the human and 
Xenopus laevis P2Y receptors in response to various P2Y agonists and 
antagonists. In a manner similar to its human orthologue, I have shown that 
XlP2Yn is activated by nucleotides and nucleotide analogues, mobilising 
calcium from intracellular stores, and increasing cAMP production through the 
activation of adenylyl cyclase. When compared to previously published data, 
XlP2Yn exhibits a novel rank order of agonist and antagonist potency, revealing 
a receptor functionally similar but pharmacologically distinct from both the 
human and canine P2Yn receptor orthologues (hP2Yn and cP2Yn).
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Chapter 1
Introduction.
1.1 Introduction.
This Chapter reviews the importance of the G protein-coupled receptor (GPCR) 
P2Y purinoceptor family. An introduction and overview of the P2Y 
purinoceptor family is given, followed by a brief review of the literature 
describing the pharmacological characterisation of the human and canine P2Yn 
receptors. An overview of GPCR-induced G protein activation and the 
pathways involved in the formation of intracellular second messengers is also 
given, followed by the aims and objectives of this thesis.
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1.2 The purinoceptor family.
Working on behalf of the Medical Research Council, in 1929, Drury and Szent- 
Gyorgyi revealed simple extracts from a minced bullock's heart were able to 
have a definite and transient effect upon mammalian heart rate, arterial pressure 
and intestinal movements. A crystalline substance, isolated from the extract, 
was identified as adenosine 5'-monophosphate (AMP), undoubtedly derived 
from adenosine 5'-triphosphate (ATP). For some years before these experiments, 
interest had been stimulated in the adenyl group of compounds, due to the 
recognition of their importance in the glycolytic process of muscular activity. 
Drury and Szent-Gyorgyi's experiments, however, were the first to demonstrate 
addition of the compounds were able to influence characteristic biological 
actions.
Since the initial study in 1929, which had itself revealed divergent roles for ATP, 
extracellular purines, such as adenosine and ADP, and pyrimidines, such as 
UDP and UTP, have been found to mediate diverse biological responses 
including regulation of blood flow, mast cell degranulation and smooth muscle 
relaxation (Bumstock 1972 and 1976; Gordon 1986; Boarder et al., 1994). 
Regulated pathways or the loss of plasma membrane integrity have been shown 
as the primary routes for the release of ATP and other nucleotides from cells. 
Following the initial proposal that purines and pyrimidines could mediate their 
effects through distinct cell-surface receptors (Bumstock, 1976). The receptors 
have since been divided into two main classes, the adenosine receptors (PI) and 
the P2 purinoceptors (Bumstock, 1978). The terms 'purinergic' and 'purinergic 
receptor' were first used in a study reviewing the evidence of non-adrenergic
-20-
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and non-cholinergic, purine nucleotide induced responses in the autonomic
nervous system (Bumstock, 1972). The 'purinergic receptor' term later evolved
to 'purinoceptor' (Bumstock, 1976).
The PI receptor family consists of the Ai, A2A, A2B, A3 . These receptor subtypes 
are guanine nucleotide binding protein (G protein) coupled receptors, or G 
protein-coupled receptors (GPCRs), activated, as highlighted above, by 
adenosine (Olah and Stiles, 1994). The sub classification of the PI family has 
been achieved through both pharmacological and molecular studies. The Ai and 
A2 receptors were initially described in studies that revealed the stimulation (via 
Ai) and inhibition (via A2) of adenylyl cyclase following extracellular addition of 
adenosine to cultured mammalian cells (van Calker et al., 1979). Subdivision of 
the A2 subtype was proposed following studies of distinct high and low affinity 
binding sites for adenosine in the central nervous system (Daly et al., 1983). The 
subdivision of the PI family reflects the different molecular and 
pharmacological characteristics of its members.
Initially divided into six subtypes (P2X, P2Y, P2U, P2t, P2z and P2d) (Bumstock and 
Kennedy, 1985), the P2 nomenclature was changed to enable the sub 
classification into ionotropic (P2X and P22:) and the metabotropic (P2Y P2U and P2T) 
families (Dubyakand and el-Moatassim, 1993). P2 purinoceptor classification 
was changed further into more manageable ionotropic, P2X and metabotropic, 
P2Y families. P2 nomenclature now correctly encompasses the receptors, which 
may be activated, by purines, pyrimidines, distinct nucleotides and more 
recently sugar-conjugated nucleotides. The P2 family of receptors are sub­
classified into P2X and P2Y receptors, proposed initially by the agonist
- 2 1  -
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potencies of adenine nucleotides on contraction in various tissues (Abbrachio 
and Bumstock, 1994). The P2X family consists of ionotropic ligand-gated ion 
channels, whereas the P2Y family are metabotropic GPCRs. There are seven 
members of the P2X family (P2Xi -  P2X7) each composed of intracellular N- and 
C-terminal domains linked by two transmembrane regions to an extracellular 
loop. The subunits form homomeric or heteromeric assemblies to produce 
functional channels. Nucleotide binding and activation of the P2X receptors 
enable the non-selective passage of cations across the plasma membrane (within 
as little as 10 ms) (Bean 1992; North 19%). This influx may activate intracellular 
proteins (via the action of Ca2+) or depolarisation/excitation of the host cells 
(mediated by the influx of extracellular ions) (Strobaek et al., 19%; Nakamura, 
2000). As outlined above the P2Y receptors are nucleotide receptors which 
couple and signal through G proteins upon agonist stimulation. Expression of 
multiple P2Y receptors is considered to be canonical for all tissues (Ralevic and 
Bumstock, 1998). There are currently 8 functional members of the mammalian 
P2Y receptor family (hP2Yi, hP2Y2, hP2Y4, hP2Y6/ hP2Yn, hP2Y12, hP2Yi3), unlike 
the P2X receptors there is evidence to suggest that there may be more P2Y 
receptor subtypes (P2YAp4A)(Fredholm et al., 1997). The structure and 
pharmacology of the P2Y family members is discussed in the following section.
1.3 P2Y receptor subtypes.
The mammalian P2Y purinoceptor family is currently composed of eight 
members (P2Yi, % 4, e, 11, 12,13  and P2Yw) (Table 1.1). The first two P2Y receptors
-22-
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were cloned in 1993. Heterologous expression of the receptors in oocytes 
revealed ATP addition could generate a Ca2+ response, revealing functional 
nucleotide receptors were present. These receptors, which activated the 
phospholipase C (PLC) signalling pathway, were designated P2Yi and P2Y2. 
Subsequently isolated P2Y subtypes have been assigned with increasing 
subscript numbers. P2Yi and P2Y2, initially isolated from chick brain and 
murine cells, respectively (Lustig et al., 1993; Webb et al., 1993), have since been 
isolated from a variety of human tissues, signalling in a similar manner to the 
chick and murine clones Qanssens et al., 1996; Bowler et al., 1995). The repertoire 
of valid human P2Y receptors was next added to by the cloning and 
characterisation of the hP2Y4 receptor, a receptor found to be selective for the 
pyrimidines UTP and UDP, again activating the PLC pathway (Communi et al., 
1995). hP2Y&, a receptor again preferentially stimulated by pyrimidines leading 
to increased PLC activation, was the next receptor to be designated as a valid 
human P2Y receptor (Communi et al., 1996).
The P2Yn receptor, initially cloned from a human placenta library was shown to 
possess the unique ability, upon agonist addition to stimulate the generation of 
second messengers associated with the stimulation of adenylyl cyclase and PLC 
(discussed further in section 1.4). Following the isolation of an adenylyl cyclase- 
linked receptor, three additional hP2Y receptors have been shown to couple to 
the adenylyl cyclase pathway, ADP activated hP2Yi2 and hP2Yi3, and UDP- 
glucose activated hP2Yw (Chhatriwala et al., 2004; Marteau et al., 2003; 
Abbracchio et al., 19% ). Upon agonist stimulation, hP2Yi2, hP2Yi3 and hP2Yu 
negatively couple to the adenylyl cyclase through inhibitory G proteins. There
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are however, some recent data that casts doubt on the ability of the hP2Yu to 
induce a valid intracellular response (Scrivens and Dickenson, 2005).
Cysteinyl leukotrienes have been shown to regulate numerous cell functions 
important in inflammatory processes and diseases such as asthma through the 
activation of cysteinyl leukotriene type 1 and type 2 receptors (CysLTIR & 
CysLT2R) (Lynch et al., 1999; Heise et al., 2000). The CysLTIR & CysLT2R 
receptors are included in Table 1.1 because studies have shown UDP can 
activate these dual specificity receptors, resulting in intracellular calcium 
mobilisation (Mellor et al., 1998; Mellor et al., 2003).
Many non-human and non-mammalian functional P2Y receptors that are not 
listed above have been cloned. These, for the most part, share similar rank 
orders of agonist potency with their human and mammalian orthologues. The 
exceptions to this rule include the rat P2 Y4 and P2Y6 receptors. Although 
relatively similar in sequence, the pharmacologies differ significantly (Kennedy 
et al., 2001; Bailey et al., 2001). The dissimilar agonist profiles of the human and 
canine P2Yn receptor are discussed in section 1.4.
The missing subscript numbers in the P2Y family represent either non­
mammalian orthologues or receptors which were initially designated as P2Y 
receptors due to a degree of sequence identity, but are unresponsive to 
stimulation by various nucleotides. These proteins are called 'orpham receptors' 
to highlight the lack of evidence of functionality. The p2y3 receptor, isolated 
from chick brain, has been shown to be a functional P2Y receptor activating PLC 
with an agonist potency order of UDP > UTP > ADP > 2MeSATP > ATP (Webb
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et al., 1995 and 1996). It is not designated as a 'PlY^ because the mammalian 
orthologue has been designated as the P2Y6 receptor. Similarly, P2Ys is not 
included in the functional mammalian P2Y subtype list because the Xenopus 
p2y8 has been shown to be a P2Yi orthologue.
p2y5 is not present as a valid member of the P2Y family, because of the human, 
turkey and chick orthologues, chick has been shown to indisputably bind 
nucleotides, no functional responses have been recorded for the subtype. 
Similarly, p2yl0, is, to date, unable to elicit a functional response. The P2Y7 and 
P2Yg subtypes are not included in the family because, although initially 
proposed as nucleotide receptors through pharmacological and sequence 
identity studies, respectively, both have since been found to be receptors for 
leukotriene and lysophosphatic acid, respectively. More recently, GPR80 
(GPR99) was reported to be 'deorphanised' and renamed as the P2Yis receptor 
based on the proposed ability of AMP and adenosine to activate the receptor, 
inducing intracellular responses (Inbe et al., 2004). Studies have since been 
unable to reproduce this activation, and have revealed the P2Yis receptor is 
activated by citric acid cycle intermediates. It has been declassified as functional 
P2Y receptor (Abbrachio et al., 2005). The next new valid member of the P2Y 
receptor family will therefore be P2Yi6.
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Receptor Nucleotide selectivity Signalling 
pathway (s)
Second
messengers
P2Y, 2MeSADP>ADP>2MeSATP Gq/PLC Ca2+ T
P2Y2 ATP-UTP Gq/PLC Ca2+ T
P2Y4 UTP»GTP~ITP 
a (UTP>ATP>GTP>CTP)
Gq/PLC Ca2+ T
P2Y6 UDP»UTP»ADP 
C(UTP > ADP =2MeSADP)
Gq/PLC Ca2+ f
P2Y„ 2MeSATP>ATP>2MeSADP>ADP 
b (2MeSADP>2MeSATP>ADP>ATP)
Gq/PLC*
Gs/AC
Ca2+ T* 
cAMPj
P2Y12 2MeSADP>ADP Gi/AC cAMP 1
P2Y,3 2MeSADP Gi/AC cAMP 1
P2Y.4 UDP-glucose Gi/AC cAMP 1
CysLTIR UDP Gq/PLC Ca2+ t
CysLT2R UDP Gq/PLC Ca2+ T
Table 1.1
Pharmacological profiles, signalling pathways and second messenger responses of 
the mammalian P2Y receptors.
Functional mammalian P2Y rank order of agonist potencies, the signalling pathways 
activated and the intracellular second messenger response are shown. a rat P2Y4, 
bcanine P2Yn and crat P2Y6 receptors have been shown to posses different receptor 
pharmacologies to their hP2Y orthologues a(Kennedy et al., 2000) b(Qi et al., 200 lb) 
c(Bailey et al., 2001). * hP2Yn receptor has been shown to mobilise Ca2+ in an IP- 
independent manner (White et al., 2003).
Chapter 1: Introduction.
1.4 Pharmacological characterisation of the hP2Yu receptor.
In 1997, Communi et al. presented the first paper to document a P2Y receptor, 
provisionally named P2Yn, capable of generating cAMP, IP and Ca2+ 
mobilisation - second messenger responses typical of phosphoinositide and 
adenylyl cyclase pathway stimulation. Using a hP2Yi probe, a moderate 
stringency screen of a human cDNA placenta library uncovered partial 
sequences of a novel G protein-coupled receptor, which, when screened in a 
human genomic DNA library, revealed a sequence, interrupted by an intron, of 
approximately 1113 base pairs - encoding a protein of 371 amino acids. 
Sequence analysis revealed the open reading frame contained 33 and 28 percent 
amino acid sequence identity to the hP2Yi and hP2Y2 receptors, respectively.
Following its isolation the ability of the hP2Yn receptor to signal through the 
phosphoinositide-signalling pathway, to which the majority of the previously 
studied P2Y receptors are able to activate, was investigated. The experiments 
revealed the receptor was able to induce both inositol phosphate (IP) 
accumulation and Ca2+ mobilisation in 1321Nl-hP2Yn cells in response to the 
extracellular addition of ATP. Although the magnitude of the Ca2+ response to 
ATP was not reported and further Ca2+ mobilisation studies were not conducted 
with other agonists, the ligand-screening studies and subsequent concentration- 
response experiments recording IP accumulation, revealed ATP and 2MeSATP 
to be the most potent of the nucleotides tested in the study. Whilst similarly 
efficacious, these two agonists were shown possess a rank order of potency of: 
ATP > 2MeSATP. A variety of other nucleotides including ADP, 2MeSADP,
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AMP, UTP and UDP, were shown to induce minimal IP accumulation in the 
cells.
In a similar manner to the investigation into IP accumulation, experiments were 
undertaken to measure the ability of the hP2Yn receptor to induce cAMP 
accumulation. CHO-hP2Yn cells were used because significant endogenous 
cAMP production was generated by 1321N1 cells in response to the degradation 
of the adenine nucleotides into adenosine. The experiments revealed the 
receptor to be activated by extracellular nucleotides - producing concentration- 
dependent cAMP responses. The investigation revealed that ATP and 2MeSATP 
were not only comparably efficacious at the highest concentrations tested, but 
also possessed the same rank order of potency recorded for the IP accumulation 
studies undertaken in the 1321Nl-hP2Yn cells, namely: ATP > 2MeSATP.
Further pharmacological characterisation, using CHO-hP2Yn and 1321N1- 
hP2Yn cells for the measurement of cAMP and IP accumulation, respectively 
(Communi et al., 1999). The agonist-induced responses in both cell lines 
revealed the potency order of the ligands, for both cAMP and IP accumulation 
assays, were almost identical (ATPyS » BzATP > dATP > ATP > ADPpS > 
2MeSATP). All of the ligands presented in the study's potency order, except 
ADPpS were able to generate similar maximal IP and cAMP second messenger 
responses, revealing the agonists to be similarly efficacious at the highest 
concentrations tested. The study exposed the ATP analogue, AR-C67085, as the 
most potent agonist, and also revealed ADPpS and AMPaS to be partial 
agonists.
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1.4.1 Canine P2Yn receptor produces IP and cAMP responses.
The cloning and characterisation of what was initially labelled a canine T2Yn- 
like' receptor (cP2Yn) from Madin Darby canine kidney (MDCK-D1) cells, 
revealed the receptor was able to induce both IP and cAMP second messenger 
responses (Zambon et al., 2001). The investigations into the cP2Yn receptor were 
undertaken to elucidate cP2Yn's signalling ability and, ultimately, complement 
previous investigations of MDCK-D1 cells. P2Y agonist treatment of the MDCK- 
D1 cells had previously been shown to activate phospholipase D (Balboa et al., 
1994), phospholipase A2 (PLA2)(Xing et al., 1997), and induce IP and cAMP 
formation (Yang el al., 1997; Post et al., 19%). The pharmacological 
characterisation of cP2Yn was undertaken in canine thymocyte (CF2Th) cells 
stably expressing the receptor. P2Y receptor agonists were able to induce Ca2+ 
mobilisation, and the formation of both IP and cAMP (Zambon et al., 2001). The 
study presented a rank order of potency for IP accumulation (ADP(3S = 
2MeSADP ~ 2MeSATP »  ADP > ATP), and indicated a similar cAMP potency 
order, revealing the cP2Yn receptor possesses a markedly different agonist 
selectivity profile to the hP2Yn receptor.
IP accumulation, Ca2+ mobilisation, and cAMP formation, produced by the 
hP2Yn and cP2Yn receptors in 1321N1 and CHO-K1 cells, was examined in 
further studies to evaluate the coupling efficiency and agonist potency orders 
for the two receptors - within the same cell lines (Qi et al., 2001a). Results, once 
again, highlighted the difference in agonist selectivity; whilst hP2Yn was shown 
to be primarily an adenosine triphosphate nucleotide-preferring receptor, the 
cP2Yn receptor was confirmed as adenosine diphosphate preferring. The
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following agonist potency orders gained from both IP and cAMP accumulation 
assays in CHO-hP2Yn and CHO-cP2Yn were presented for the two receptors:
hP2Yn: ATPyS > 2MeSATP > ATP * ADPpS > ZMeSADP > ADP
cP2Yn: 2MeSADP > ADPpS > 2MeSATP > ADP > ATPyS > ATP
Presented in Qi et al. (2001a) 
Apart from the differences observed in the agonist potency order, key 
differences were found to exist in the maximal agonist induced responses. 
2MeSADP, ADPpS and ADP, found to act as partial agonists upon the hP2Yn 
receptor (Communi et al., 1997; Zambon et al., 2001), were shown to be full 
agonists of the cP2Yn receptor. EC50 values gained from concentration-response 
experiments revealed both receptors were more efficiently coupled to the IP 
formation than cAMP production. However, the 7- to 17.3-fold difference in 
ECso's recorded in the CHO-hP2Yn cells, and the 1.8- to 3.9-fold difference 
observed for the CHO-cP2Yn cells, reveals the hP2Yn receptor possesses a 
markedly larger difference in this efficiency. Antagonist studies of the hP2Yn 
and cP2Yn receptors, however, have shown there is very little difference 
between their sensitivity to the nonselective antagonists: Suramin, Reactive Blue 
and PPADS. Suramin and Reactive Blue are both antagonists of the receptors, 
whilst PPADS is ineffective (Qi et al., 2001b). Despite the different agonist 
sensitivities, the canine receptor is designated as a P2Yn orthologue because of 
its ability to induce dual signalling pathways in response to extracellular 
adenine-nucleotides. The intracellular agonist induced responses of the 
activated hP2Yn receptor are discussed further in section 1.7.4.
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Following the initial pharmacological characterisations, P2Yn signalling has 
been studied in a variety of different cell types and processes, including 
pancreatic duct epithelial cells (Nguyen et al., 2001), cardiomyocytes (Balogh et 
al., 2005), HL-60 cells (Suh et al., 2000) and white cell maturation and 
differentiation (Van der Weyden et al,. 2000a & 2000b; Adrian et al., 1999). These 
studies have extended the pharmacological profile of the receptor and/or 
implicated a role for P2Yn signalling in the different cell types. Further studies 
have also shown the hP2Yn receptor can produce Ca2+ mobilisation through a 
pathway independent of IP3 formation (White et al., 2003). This agonist-specific 
signalling ability is discussed further in section 1.7.2.
1.5 Structure and activation of GPCRs and G protein heterotrimers.
The basic structure of all GPCRs consists an extracellular N-terminal domain, 
linked to an intracellular C-terminal domain via seven transmembrane (TM) 
helices linked in an alternating fashion by. intracellular (il, i2 and i3) and 
extracellular loops (ol, o2 and o3) (Figure 1.1). The helices, which can deviate by 
as much as 25° from a vertical plane, form a tight bundle in a clockwise manner 
(when viewed from above/extracellular side). The importance of the 
extracellular N-terminal domain, intracellular loops and, for some GPCRs, the 
amino acid residues in the upper sections of the TM helices, has been known for 
some years to be critical in ligand recognition and binding (Schwartz 1994). 
More recently, studies involving P2Yi, and P2Y2 receptor chimeras have 
revealed ligand binding is mediated by amino acid residues in the upper 
regions of the TM domains and the extracellular loops (Gearing et al., 2003).
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Figure 1.1
Schematic representations of a G protein-coupled receptor and a heterotrimeric G 
protein.
A, G protein-coupled receptor, showing N-terminal domain, seven tramsmembrane 
domains (I to VII), three extracellular loops (ol-3) and three intracellular loops (il-3). B, 
heterotrimeric guanine nucleotide binding protein (G protein) composed of Ga, GJi and 
Gy subunits are shown with the nucleotide-binding site highlighted in yellow.
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Ligand binding induces conformational change in GPCRs. The intracellular 
consequence of this change has been shown using rhodopsin to induce a 
relatively small outward movement of TMIII and a small change in the 
conformation of i2 (Farahbakhsh et al., 1995). The movements are accompanied 
or mediated by a clockwise rotation in the upper segments of the TM helices 
(Farrens et al., 19%; Dunham and Farrens, 1999). The movement exposes 
residues, primarily in the il and i2 loops, to the cytosol, which may interact with 
intracellular G proteins (Bourne, 1997). In the absence of bound extracellular 
agonist, these residues are shielded within the GPCR structure.
Heterotrimeric G proteins are composed of three subunits: a Ga subunit 
(approximately 40-45 kDa), a Gp subunit (approximately 37 kDa and a GY 
subunit (approximately 8 kDa). The inactive heterotrimer is attached to the cell 
surface plasma membrane via lipophilic tails on the Ga and GY (Figure 1.1). Gp 
and Gy are bound strongly through a coiled-coil interaction. Ga and Gp interact 
through weaker protein and lipophilic interactions. In the inactive state Ga 
contains a GDP molecule in its nucleotide binding site. Activation of the GPCR 
enables Ga to directiy bind the receptor (Conklin and Bourne 1993). Although 
the Ga subunit engages in the primary binding between GPCR and heterotrimer, 
evidence also suggests the Gp and GY may also participate in specific contacts 
with the receptor (Clapham and Neer, 1997). Binding to the activated receptor 
causes a conformational change within the heterotrimer, resulting in GDP-GTP 
exchange which dissociates the heterotrimer, releasing free (although still 
membrane attached) GTP- Ga and GpY subunits. The constitutive GTPase ability 
of the Ga hydrolyses the bound GTP enabling the reformation of the inactive 
heterotrimer.
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There are 18 known G a subunits, which are divided, based solely on their action 
upon their effectors, into four main classes: Gqa ,Gsa, Gia, Gi2/i3a (Simon et al., 
1991; Downes and Gautam, 1999) (Table 1.2). The G a subunits differ from each 
other not only in sequence, but also receptor specificity and effector isoform 
selectivity (Wong, 2003). G protein heterotrimers are usually shown named after 
their Ga subunits. The Gqa class stimulates phospholipase C, inducing 
phosphatidyl inositol 4,5-bisphosphate (PIP2) hydrolysis creating inositol 
(3,4,5)triphosphate (IP) and 1,2-diacylglycerol (DAG). The Gsa and G a classes 
stimulate and inhibit adenylyl cyclase, respectively, affecting cAMP production. 
The Gi2/i3a class acts similarly to Gqa class, but possesses a distinct toxin 
sensitivity and ability to activate the Na+/H + exchanger pathway 
(Dhanasekaran and Dermott, 19% and 2002; Kurose 2003). All known Ga 
subunits undergo post-translational lipid-modifications (Milligan et al., 1995; 
Casey, 1995). The myristoylation and palmitoylation of various Ga subunits has 
been shown to be necessary for both receptor binding and effector activation 
(Wedegaertner et al., 1993). As outlined above the Gp and GY subunits may play 
a role in the activation of GPCR binding. There are currently 5 and 12 known 
subunits of Gp and GY, respectively. Similarly to Ga, following G protein 
activation the dissociated GpY heterodimer may also play a role in activated 
effector proteins. The members of each Ga, Gp and GY class are shown in Table 
1.2.
The activation of certain GPCRs , such as members the P2Y family, may also be 
influenced by the turnover and interconversion of extracellular agonists. ATP- 
generating and ATP-consuming extracellular pathways in various cell types 
have been shown to govern the duration and magnitude of intracellular
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G protein subunits
G protein Ga class members G protein 
Gp subunits
G protein 
Gy subunitsGqa G sa Gja G j2a
Gqa Gsa Gjla G l2a Gip Gly
G na G0ifa Gj2a Gi3a G2p g 2y
G ]4a Gi3a G3p G 3Y
G ) 5a Goaa G4p g 4y
G 16a Goba G5p g 5y
Gtla G 7Y
Gt2a o 00
Ggusta GlOy
Gza Glly
G i 2Y
G cY
Table 1.2
Members of the mammalian G protein subunit families.
The members of the G protein Go, Gp and GY are shown. The Ga m em bers are 
subdivided into their corresponding Ga class (Gqa ,Gsa, Gn, Gi2a).
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signalling responses (Zimmerman, 1992; Lazarowski et al., 1997). These 
responses are controlled by the ability of the extracellular pathways to degrade 
and generate nucleotides in a stepwise manner through the action of various 
nucleotidases and phosphotransfer reactions - enabling the interconversion of 
ATP, ADP and AMP. The presence of Ecto-5'-nucleotidase and Adenosine 
Deaminase may complicate signalling responses further by enabling the 
sequential degradation of AMP into Adenosine and Inosine.
1.5.1 Production of second messengers following G protein activation.
Following the activation of the G protein heterotrimer, as outlined in section 1.5, 
the dissociated GpY heterodimer and GTP-bound Ga subunits may activate many 
different cellular targets. The activation of target enzymes may produce 
molecules known as second messengers - effectively acting as intracellular 
representations of the extracellular signal. Most primary messengers, such as 
nucleotides, are unable to permeate the plasma membrane; second messenger 
formation therefore enables the diffusion and amplification of this extracellular 
signal throughout the cytosol. Following ligand binding, P2Y receptors have 
been shown, through the activation of G proteins, to act upon adenylyl cyclase 
and phospholipase C-p. The key signalling components, responses and 
regulation of these enzymes and their second messengers are presented in the 
following sections.
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1.6 Adenylyl cyclase and cAMP.
One of the first second messengers to be documented was cyclic adenosine 3',5,- 
monophosphate (cAMP)(Sutherland, 1970). cAMP is synthesised intracellularly 
by adenylyl cyclase (AC), also known as adenylate cyclase. Molecular cloning 
has enabled the discovery of multiple genes encoding nine distinct isoforms of 
membrane-bound mammalian AC, detailed in Table 1.3. Activated adenylyl 
cyclase catalyses the elimination of a moiety of diphosphate from ATP, creating 
cAMP and inorganic pyrophosphate (PPi)(reaction shown in Figure 1.2). cAMP 
is used as a second messenger in many different prokaryotic and eukaryotic 
organisms (Danchin, 1993).
As previously outlined in section 1.5.1 and Table 1.3 GPCRs that can, upon 
activation, couple to and stimulate the G3 or G! heterotrimeric G-proteins are 
able to stimulate and inhibit adenylyl cyclase activity, respectively. The basic 
regulatory pathways involved in adenylyl cyclase stimulation and inhibition are 
shown in Figure 1.3. Some of the downstream targets, which may be activated 
as a consequence of raised cAMP levels, namely PKA (Protein Kinase A), ion 
channels and GEP (GTP exchange proteins), are also shown in Figure 1.3, and 
are discussed further in Sections 1.6.5 and 1.6.6. The multiple isoforms of the 
components are not shown to simplify the schematic representation.
1.6.1 Structural topology of adenylyl cyclase.
All nine different isoforms of adenylyl cyclase share the same predicted basic 
structure. They are composed of two membrane-anchoring domains (Ml and
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Adenylate
cyclase
isoform
Regulatory Signals
g sb Gja G fr Protein
Kinase
Ca2+/CaM
I ft 41 4 ft (PKC) ft
II ft ft ft (PKC)
f f l f t u ft  (W OO ft
IV ft ft ft (PKC)
V ft u # C P K C )4 c H C A )
VI ft u ft (PKA)
vn f t ft f t  0 * 0
VIII ft ft
IX ft
Table 1.3
Summary of the regulatory inputs affecting adenylyl cyclase isoforms.
The stimulatory (ft ) and inhibitory (U)effect o f Gsa, Gia, GpY, protein kinases (A and C), 
and Ca2+/CaM, upon the nine mammalian membrane-bound adenylyl cyclase isoforms 
(AC I to IX) are presented in the above table.
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M2), each containing six transmembrane helices, and two structurally related 
intracellular domains (Cl and C2). The Cl domain connects the Ml and M2 
domains, whereas the C2 domain is present at the C-terminus of the M2 
domain. The M2 domain in each of the AC isoforms contains one or more sites 
that may be glycosylated. Crystal structure determination of adenylyl cyclase 
undertaken in the presence and absence of GTPyS-GSa has enabled the 
visualisation of the spatial arrangement of these domains and the configuration 
of the catalytic site (Zhang et al., 1997; Tesmer et al., 1997 & 2002). The basic 
topology of these different domains is shown in a diagrammatic representation 
of a generic adenylyl cyclase isoforms in Figure 1.2.
1.6.2 G protein activation of adenylyl cyclase.
The heterotrimeric G protein Gs is able to activate AC through the interaction of 
the dissociated GTP-bound Gas subunit with the intracellular C2 domain. 
(Whisnant et al., 1996). Gsa binding initiates a conformational change in the AC, 
altering the interaction between the Cl and C2 domains. Upon activation, amino 
acid residues from both Cl and C2 domains create a substrate binding site 
which can catalyse the formation of cAMP (Sunahara et al., 1997). Adenylyl 
cyclase remains in an active state whilst the GTP-Gsa subunit is bound to the C2 
domain. The inherent GTPase activity of the Gas subunit hydrolyses the bound 
GTP permitting the dissociation of the AC and Gsa. Following GTP hydrolysis, 
the GDP-GSa subunit may reassociate with the GpY heterodimer.
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Figure 1.2
Adenylyl cyclase: Reaction catalysed and structural topology.
A. Adenylyl cyclase catalyses the elimination of a diphosphate moiety (inorganic 
pyrophosphate, PPi) from adenosine 5’-triphosphate (ATP) to create adenosine 3 \5 ’- 
phosphate (cAMP). B. Schematic representation o f the structural topology o f the 
membrane anchoring (Ml and M2) and catalytic (Cl and C2) domains of adenylyl 
cyclase.
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In addition to the stimulatory effect of the Gsa subunits, the dissociated GpY 
heterodimer may also stimulate adenylyl cyclase. As oudined in Table 1.3, Gpv is 
able to influence the ability of certain AC isoforms to produce cAMP. It must be 
noted however, that ability of the GpY heterodimer to activate certain AC 
isoforms in only achieved in the presence of GTP-Gsa (Feinstein et al., 1991; Gao 
<fe Gilman, 1991).
1.6.3 Adenylyl cyclase inhibition through G protein interaction.
As outlined in Figure 1.3 and Table 1.3, GTP-Gia can inhibit various AC isoforms 
(Chen and Iyengar, 1993). Following appropriate GPCR activation, the direct 
binding of GTP-Gia to AC reduces its ability to catalyse cAMP production. In a 
similar manner to the Gsa subunit, the intrinsic GTPase activity of G,a subunit 
induces conformational change of the Ga subunit through GTP hydrolysis, 
reducing the binding affinity between G a and AC. The resulting dissociation 
terminates the inhibitory action of Gia. Contrary to its ability to stimulate 
various AC isoforms, Table 1.3 reveals the GpY heterodimer has also been shown 
to inhibit the AC I isoform (Tang <fc Gilman, 1991). The ability of the different G 
protein subunits to stimulate and inhibit the various AC isoforms stems from 
their ability to bind different regions of the catalytic domain (Taussig et al., 
1994), inducing distinct conformational changes.
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Ligand
Bound
Ligand
cAMP + PPi PKA
ion channels 
GEP
Stimulatory 
G protein 
complex
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G protein 
complex
Figure 1.3
Activation and inhibition of adenylyl cyclase mediated by stimulatory and 
inhibitory G protein complexes.
Following ligand binding to the appropriate GPCR, stimulation and inhibition of 
adenylyl cyclase (AC) is primarily mediated by the Gsa (stimulatory) and Gja (inhibitory) 
subunits, released from the activated G protein complexes. In addition, various isoforms 
of AC may also be regulated by the dissociated Gpy heterodimer. cAMP formation, 
through AC activation, and degradation by cyclic nucleotide phosphodiesterases (PDE), 
is shown, along with some of the cellular targets of cAMP.
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1.6.4 Other regulatoiy inputs affecting adenylyl cyclase activity.
A variety of other regulatory factors that also influence the activity of AC are 
also presented in Table 1.3. The table reveals Ca2+, which can stimulate AC 
activity, through the action of Calmodulin (as is the case with ACI and 
ACVIII)(Cooper et al., 1998; Lee et al., 1999), has also been found to inhibit AC 
activity via direct binding (ACV and ACVI)( Cooper et al., 1998). In addition 
Ca2+ may inhibit AC indirectly through the activation of Calcineurin (affecting 
ACIX)(Paterson et al., 1998) and calmodulin-dependent protein kinase II (CaM 
Kinase II)(inhibiting ACIII)(Wayman et al., 1995). The ability of Ca2+ or Ca2+- 
calmodulin (CaM) to regulate AC activity is presented in Table 1.3. In addition 
to the regulatory action induced by G protein subunits and Ca2+ on AC 
activation, the level of cAMP may also be regulated by protein kinases. As 
outlined in Table 1.3 various AC isoforms are stimulated and inhibited by 
protein kinase C (Jacobowitz et al., 1993; Lusitg et al., 1993; Hellevuo, 1995) and 
protein kinase A (Chen et al., 1997; Iwami et al,. 1995).
1.6.5 cAMP activation of Protein kinase A.
cAMP-Dependent Protein Kinase A (PKA) is an ubiquitous serine/threonine 
protein kinase present in many different varieties of tissues. PKA is composed 
of two regulatory subunits (R) and two catalytic subunits (C), creating an R2C2 
holoenzyme OTaylor et al., 1992; 2Taylor et al 1992). Intracellular cAMP 
regulates the activation of PKA by binding to the regulatory subunits, causing 
the inactive tetramer to dissociate. Two cAMP molecules bind to each regulatory
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subunit; binding and subsequent dissociation creates R2-CAMP4 and two active 
catalytic subunits. The free catalytic subunits of PKA can phosphorylate a wide 
range of intracellular target proteins, including, as outlined above, AC. The 
inhibitory phosphorylation of certain AC isoforms, performed by the cAMP- 
activated PKA may therefore act as a negative feedback mechanism, ultimately 
reducing the ability of AC to produce cAMP.
1.6.6 Activation of GTP exchange proteins and ion channels by cAMP.
cAMP has also been found to play a pivotal role in the stimulation of exchange 
proteins activated by cAMP (EPAC)(de Rooij et al., 1998 and 2000). The cAMP 
bound EPAC are GTP exchange proteins (GEP), which control the turnover of 
GTP bound to the Rapl (Ras-related protein-1) GTPase. The GTPase 
superfamily consists of various GTP-binding switch proteins (including the Ga 
subunits and Ras protein), which alternate between active and inactive states 
depending on the presence of a bound GTP molecule. GEPs in partnership with 
GTPase activating proteins (GAPs) play an essential role in the regulation of 
GTPases activity, through their control of GTP turnover and hydrolysis (Hall, 
1992). The ability of cAMP to activate Rapl, through the activation of EPAC, 
enables cAMP to modulate the mitogen-activated protein-kinase (MAP-kinase) 
pathway. Activated Rapl influences the MAP-kinase pathway by binding to 
and activating BRaf and/or inhibiting the Ras-Raf pathway (Fimia and Sassone- 
Corsi, 2001).
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The MAPK proteins form a superfamily of enzymes which play a critical role in 
transducing a large array of signals generated by a variety of extracellular and 
intracellular mediators. These signals include, and are in no way limited to, 
those generated by the activated P2Y receptors. There are, of course many 
signalling pathways that operate independently of Ca2+ and cAMP activation 
that are not detailed in this thesis, examples of which include the MAPK and 
PI3K pathways.
As indicated in Figure 1.3 cAMP may also bind and activate cyclic nucleotide 
gated ion channels (Yau, 1994), which, apart from their ability to conduct 
various ions including Na+ and K+, may also influence the activity of AC 
through their ability to conduct Ca2+ (Wei et al,. 1998). The ability of cAMP to 
control ion channel conductance (in addition to PKA and GEP activation), 
enables cAMP to indirectly regulate various metabolic, cytochemical and 
transcriptional events.
1.6.7 Regulation of cAMP concentration by phosphodiesterases.
The indefinite presence of cAMP in cells would result in the continual activation 
of various target proteins listed above. cAMP breakdown into AMP is achieved 
by cyclic nucleotide phosphodiesterases (PDEs)(Houslay, 1998). Similar to AC, 
multiple subtypes of PDEs exist (PDE I to VIII), which respond (in terms of 
stimulation and/or inhibition) in various degrees, to the regulatory control of 
Ca2+ and protein phosphorylation (Beltman et al., 1993). The activities of PDEs
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are therefore an important mechanism in regulating the concentration of 
intracellular cAMP.
1.7 IP and Ca2* responses.
Although the ability of Ca2+ to function as a second messenger was well 
established through investigations of muscle and secretory cells (Douglas et al., 
1963), and agonist induced PI hydrolysis was known to occur (Hokin & Hokin, 
1953), these early studies did not investigate the interaction between the two 
signalling responses. The mechanism by which cell surface receptors elicit 
intracellular calcium mobilisation was initially proposed following the 
observation that activated receptors that generate PI turnover are also 
responsible for Ca2+ signalling (Michell, 1975). Subsequent investigations 
revealed IP3 was the molecule responsible for Ca2+ mobilisation (Streb et al., 
1983). Inositol (3,4,5-)triphosphate (Ins?3), referred to (as with many other P2Y 
studies) as TP' throughout this thesis, is produced following receptor-triggered 
hydrolysis of phosphatidyl inositol 4,5-bisphosphate (PIP2). The reaction results 
in the creation of IP and 1,2-diacylglycerol (DAG) (Figure 1.4). The following 
sections describe the processes involved in the creation, targeting and regulation 
of the IP, DAG and Ca2+ responses.
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1.7.1 Phospholipase activation through G protein interaction.
Phospholipase C (PLC) proteins are soluble membrane anchored cytosolic 
proteins, belonging to a family of lipase enzymes that catalyse the hydrolysis of 
glycerophospholipids (other members include PLAi, PLA2, PLB, and PLD). To 
date, 10 isoforms of PLC have been cloned in mammals. All ten of these PLC 
isoforms share the same predicted topology; composed of catalytic X, Y and C2 
(complement component 2) domains. The ten PLC proteins are further 
classified, by their structure and function, into four classes: PLC-p(l-4), PLC-y(l- 
4) and PLC-6 (1-2). As outlined previously, following appropriate GPCR 
stimulation, PLC proteins are activated by the activated Gq G protein 
heterotrimer. PLC-p-1 and PLC-(3-2 are activated by the GTP bound Gqa subunit,
1.7.2 Cellular targets of IP, DAG and Ca2+.
As outlined in Figure 1.4, GPCR activation of PLC-p results in the creation of IP 
and DAG. Following activation, IP, which is now free of its membrane anchor 
may diffuse freely within the cytosol. IP may bind IP-sensitive Ca2+ channels 
present on the endoplasmic reticulum (Bosnac et al., 2004). These channels are 
composed of four subunits, which may each bind an IP molecule (Bosnac et al., 
2002). IP binding activates the channel, releasing sequestered Ca2+ into the 
cytosol (increasing cytosolic Ca2+ levels from nM to pM concentrations) (Evenas 
et al., 1998a).
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Figure 1.4
Reaction and pathways catalysed by stimulated mammalian PLC-p.
A. PLC-P catalyses the hydrolysis o f phosphatidyl inositol 4,5-bisphosphate (PIP2), 
creating inositol (3,4,5-)triphosphate (IP) and 1,2-diacylglycerol (DAG). B. Schematic 
representation of the pathways activated following ligand binding to the appropriate 
GPCR, stimulation of PLC-P is mediated by the Gpy and GTP bound Gqa subunits 
(depending on PLC-P isoform) released from the activated G protein heterotrimer.
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whilst PLC-p-3 is activated by the dissociated GpY heterodimer. Appropriate 
GPCR activation therefore stimulates IP and DAG formation.
The released cytosolic Ca2+ may serve as a second messenger, regulating almost 
every aspect of cellular activity (Berridge et al. 2000), ranging from exocytosis to 
contraction (Bruzzone, 1990; Harnett, 2003). Ca2+ produces these effects through 
binding and activating various intracellular protein targets. Ca2+ may bind (in a 
cooperative manner) to the ubiquitous protein, calmodulin (Evenas et al., 1998*). 
Calmodulin, which binds three or four Ca2+ ions via four separate EF-hand 
binding motifs, may activate a variety of different targets either on its own 
(including: Ca2+,Mg2+ ATPases, AC and myosin light chain kinase) or as part of 
a protein, such as calmodulin-dependent protein kinase (CaM-kinase). Ca2+ may 
also stimulate the two major families of intracellular Ca2+ channels, the IP3- 
sensitive channel and the ryanodine receptor. The activation and subsequent 
release of Ca2+, is known as Ca2+induced Ca2+release (CICR). The process 
enables amplification and oscillations in the concentration of free intracellular 
Ca2+.
As previously outlined in section 1.4.1, the hP2Yn receptor has been shown to 
produce, in response to UTP, Ca2+ mobilisations using a pathway independent 
of IP formation (White et al,. 2003). This work concurs with previous studies, 
which have shown nucleotides may stimulate Ca2+ mobilisation in an IP- 
independent manner following receptor activation (Frelin et al., 1992). The 
signalling ability of the hP2Yn receptor is therefore not limited to the 
stimulation of AC and PLC-p. The hP2Yn receptor may produce Ca2+ 
mobilisation through a similar pathway to that described for a novel
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temperature-sensitive Ca2+ release mechanism (Wissing et al., 2002), or, as 
previously stated (White et al., 2001), through the action of NAADP (Gallione et 
al., 2000; Churchill and Galione, 2001). The mobilisation may, however, be 
produced by an, as yet, unknown second messenger and/or signalling pathway. 
The intracellular signalling responses of P2Y receptors (including the typical IP- 
induced Ca2+ response pathway of the P2Yn responses), are discussed and 
shown in section 1.7.4, and Figures 1.5 and 1.6.
In addition to Ca2+ mobilisation, the DAG released by PIP2 hydrolysis may 
activate (in conjunction with Ca2+) PKC (Hannun et al., 1985; Bell et al., 1986). 
DAG may therefore stimulate a wide variety of proteins and signalling cascades 
through the ability of PKC to activate various target proteins such as AC, Ras- 
MAPK (Zheng et al., 2005) and Nuclear Factor Kappa -B (NF-kB) (Arenzana- 
Seisdedos et al., 1993).
1.7.3 Regulation of Ca2+, IP and DAG.
Ca2+ release from the endoplasmic reticulum is quickly removed from the 
cytosol by ATPases present in the endoplasmic reticulum and plasma 
membranes (Guerini et al,. 2005). Because of the rapid removal of free Ca2+ from 
the cytosol, Ca2+ must rapidly bind to proteins such as calmodulin (outlined 
above) in order to transduce its activity. The effect induced by free IP is negated 
by its hydrolysis to an inactive 1,4-bisphosphate conformation, which is unable 
to bind IP-sensitive Ca2+ channels. DAG is also rapidly metabolised, either 
through hydrolysis (generating glycerol and a fatty acid) or phosphorylation
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(creating diacylglycerol 3-phosphate, also known as phophatidate). The initial 
creation of IP and DAG may also be regulated by the phosphorylation of PLC 
itself by PKA (Liu et al., 19%).
Rapid Ca2+ release into the cytosol, inducing CICR, and its equally rapid 
removal enables Ca2+ oscillations to occur- often visualised in studies as spikes 
of free intracellular Ca2+ concentrations. These oscillations enable the 
amplification and regenerative propagation of the intracellular Ca2+ response. 
The range of calcium oscillations, with varying amplitudes, frequencies and 
number of Ca2+ rises, allows a large degree of control over many cellular 
processes such as parental and zygotic gene expression and (Dean et al., 2003; 
Malcuit et al., 2005).
1.7.4 P2Y Activation of adenylyl cyclase and phospholipase C-p.
Following the examination of cAMP , IP and Ca2+ production (sections 1.6 to 
1.7.3), the following sections examine the cellular mechanisms involved in 
second messenger production activated by the P2Y receptors. As outlined 
previously, pharmacological characterisations of the P2Y receptors have often 
examined their ability to produce Ca2+, IP and cAMP responses. A schematic 
representation of the activation of the AC and PLC-p second messenger 
signalling pathways induced by activated P2Y receptors is shown in Figure 1.5. 
The activation and inhibition of the pathways, produced by the subunits of 
activated membrane-bound G proteins are shown following appropriate 
extracellular ligand binding to the receptors. In order to simplify the schematic
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representation, stimulation and inhibition of AC and PLC isoforms induced by 
GpY heterodimers are not shown. The IP, Ca2+ and cAMP second messengers, are 
shown in red.
As described previously, multiple components and targets of the stimulated AC 
and PLC-p pathways may interact with upstream components of the cascades, 
effectively acting as negative and /o r positive feedback loops. In order to 
visualise some of the key feedback mechanisms influencing AC and PLC, Figure
1.6 highlights the positive and negative effects of these downstream components 
(shown with green and red arrows, respectively). Where the isoforms of AC or 
PLC direct whether the feedback is positive or negative, the arrows are shown 
in blue. Figure 1.6 reveals the intricacies of the interaction occurring between the 
AC and PLC signalling pathways following stimulation of the P2Y receptors. In 
the same way as Figures 1.3 and 1.4, Figures 1.5 and 1.6 are first-level 
representations, where the multiple isoforms of the components are not shown. 
The various isoforms of and PKA, PKC, PDE, AC, PLC and subtypes of Ga, Gp 
and GY, reveal multiple responses can be produced by the P2Y receptors 
depending on the expression pattern of these proteins. The cross talk between 
the pathways is therefore also complicated further by the various sensitivities 
exhibited by these isoforms in response to their effectors.
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Figure 1.5
Second messenger production following P2Y receptor activation.
Schematic representation of the pathways activated following appropriate agonist 
binding to the P2Y receptors. Stimulation of PLC-p and the stimulation and inhibition o f 
adenylyl cyclase (AC) and the subsequent signalling cascades produced by the P2Y 
receptors are shown. Second messengers, which have been used extensively to 
pharmacologically characterise the P2Y receptors are shown in red.
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1.7.5 Factors influencing the second messenger production of the P2Y 
receptors.
Certain GPCRs have been shown to function as dimeric or oligomeric 
complexes. Studies investigating heterodimerisation of the GABAb (Kaupmann 
et al./1998; Marshall et al., 1999) and, separately, opioid receptors (Jordan and 
Devi 1999; Snyder and Pasternak, 2003) have revealed the pharmacologies of the 
heterodimerised GPCRs are different to those of the individual GPCR's. In a 
similar manner, hetero-oligomerisation has been shown to occur between the 
P2Yi and adenosine Ai receptors, generating an Ai with P2Yi-like 
pharamacology (Yoshioka et al., 2001 and 2002). The interaction of the other P2Y 
receptors with additional GPCRs may, in the same way as P2Yi, potentially 
affect the pharmacology of the receptors. Heterodimerisation may explain why 
pharmacological studies of some of the so-called orphan P2Y receptors have, to 
date, been unsuccessful in recording second messenger responses.
As highlighted previously, the second messenger responses produced by the 
P2Y receptors are subject to negative feedback from downstream elements of the 
activated signalling cascades. This control is sometimes referred to as 
heterologous desensitisation, because the phosphorylation by PKA or PKC may 
occur independently of the receptor's activation, as is shown in Figure 1.6. 
Homologous desensitisation may also occur, where activated GPCRs interact 
with arrestins, following phosphorylation by G protein-coupled receptor 
kinases (GRKs), thus reducing the ability of the receptor to bind G proteins 
(Simon, 2003). Down-regulation of plasma membrane bound GPCRs through 
endocytosis may also occur, resulting in the internalisation of the receptor,
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Figure 1.6
Interaction of downstream effectors with PLC-P and AC following P2Y receptor 
activation.
Schematic representation o f the pathways activated following agonist binding to the P2Y 
receptors, highlighting the interaction o f downstream effectors with PLC-P and AC. 
Stimulation and inhibition of PLC-P and AC are denoted with green and red arrows, 
respectively. Where the stimulation or inhibition is subject to the isoforms o f AC or 
PLC-P, the arrows are shown in blue.
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which may either be recycled back to the plasma membrane or subjected to 
proteolytic degradation in lysosomes (Tulapurkar et al., 2005; Jacob et al., 2005).
1.8 Introduction to the XlP2Yn receptor.
Xenopus laevis is used as a developmental model organism because of its well- 
studied patterns of external development and ease of manipulation ( Vignali et 
al., 1994; Jones, 2005). Following a search of the African clawed-toed frog 
Xenopus laevis (X.laevis) GenBank EST database, a P2Y-like sequence was 
isolated by the laboratory of Dr L. Dale (Anatomy Department, UCL). Isolation 
of the sequence, followed by mRNA synthesis was undertaken; revealing the 
presence of 7 potential TM domains within a 313 amino acid (aa) sequence, 
translating a protein of approximately 35kDa (data not shown). ClustalW 
analysis of the deduced amino acid sequence revealed the potential receptor 
shared the highest aa identities with the hP2Yn receptor, it was therefore 
putatively designated as /XlP2Yn/. Figure 1.7 shows the amino acid sequence 
comparison of the hP2Yn, cP2Yn and the novel XlP2Yn sequence. The 
comparison reveals the XlP2Yn sequence shares approximately 40 percent 
identity with the hP2Yn amino acid sequence (NP_002557), and approximately 
32 percent identity with published cP2Yn amino acid sequence (Zambon et al., 
2001). The hP2Yn and cP2Yn sequences share approximately 65 percent identity. 
The alignment reveals XlP2Yn possesses the least aa's of the three sequences 
analysed (hP2Yn, 374aa; cP2Yn, 370; XlP2Yn, 313). Figure 1.7 also shows the 
putative transmembrane domains of all three sequences.
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Figure 1.7
Multiple Sequence alignment of XlP2Yn ’s deduced amino acid sequence with 
human and canine P2Yn orthologue (hP2Yn and cP2Yn) amino acid sequences.
ClustalW was used to align the deuced amino acid sequence of the X1P2Y11 receptor, 
the hP2Yu amino acid sequence (NP_002557) and the published cP2Yn amino acid 
sequence (Zaqmbon et al., 2001). Shaded residues indicate sequence identities and 
similarities. The putative positions o f the 7 transmembrane domains are underscored in
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Currently, there are two P2Y receptors that have been cloned and characterised 
from X.laevis. These have been shown to possess P2Yi (Cheng et al., 1993) and 
P2Y4-like pharmacologies (Bogdanov et al., 1997). When compared to hP2Yi 
receptor, the XlP2Yi receptor shares approximately 85 percent sequence identity. 
Because of the relatively low identity shared between the XlP2Yn sequence, and 
the known P2Y receptors, the translated XlP2Yn sequence does not therefore 
necessarily encode a functional receptor. Only pharmacological analysis enables 
the identification of XlP2Yn protein as a functional P2Y receptor.
1.9 Aims and outline of this study.
The aim of this work was to pharmacologically investigate the human P2Yn 
receptor (hP2Yn) and the Xenopus laevis P2Yn (XlP2Yn) receptor. As outlined 
previously, the ability of the hP2Yn and cP2Yn receptor orthologues to couple 
to two different stimulatory signal transduction pathways is unique amongst 
the P2Y family. Investigating the hP2Yn receptor was undertaken to, first, use 
the receptor's unique ability to induce Gqa and Gw pathways to establish 
appropriate assay conditions required for determining Ca2+ and cAMP 
responses, and secondly, to obtain a pharmacological profile with which to 
compare the second messenger responses of the XlP2Yn receptor. Using a range 
of P2Y agonists and antagonists, the work presented in this thesis extends the 
current pharmacological profile of the hP2Yu receptor and identifies the XlP2Yn 
receptor as a functional P2Y receptor, capable, upon nucleotide stimulation of 
producing cAMP and Ca2+ second messengers.
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2.1 Molecular Biology Techniques.
The molecular biology techniques presented in the following sections were used 
upon pcDNA3.1-XlP2Yn (supplied by the laboratory of Dr L. Dale - Anatomy 
Department, UCL) and pcDNA3.1-hP2Yn in order to create and use 
pcDNA3.1G418-hP2Yn and pcDNA3.1G418-XlP2Yn constructs in 
pharmacological studies (described in Section 2.3). These constructs were 
created by the sequential digestion and isolation of the XlP2Yn and hP2Yn (a 
gift from Dr Jean-Marie Boeynaems, Genbank accession number AF030335) 
coding sequences from pcDNA3.1 followed by their ligation into 
pcDNA3.1G418. Small and large scale preparations of plasmid DNA were 
undertaken in order to produce a large quantity of the constructs.
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2.1.1 Restriction endonuclease digestion of DNA.
Where digestion of plasmid DNA or PCR products was required, specific 
restriction endonuclease(s) (Promega and New England Biolabs), at a 
concentration of approximately 1/10* of the total reaction volume were used. 
Digests were incubated for a minimum of one hour at a suitable temperature 
(typically 37°C) and in the appropriate lx buffer - as specified by the 
manufacturers. BSA was added where required.
2.1.2 Ligation of DNA fragments.
50-1 OOng of cut plasmid DNA was incubated with approximately three times 
the concentration of insert DNA (from restriction digest or PCR), 1 pL of T4 
DNA Ligase and lpL of T4 DNA Ligase Buffer (lOx concentration, containing 
lOmM ATP) (New England Biolabs M0202S and B0202S, respectively). Total 
reaction volume was increased to lOpL with distilled water where necessary. 
Reactions were incubated at either room temperature for 1-2 hour or overnight 
at 14°C or 4°C. The whole ligation reaction mixture was then used to transform 
competent E.coli cells.
2.1.3 Transformation of E.coli cells.
Plasmid DNA or recombinant plasmid DNA produced as a result of ligation 
reactions was added to approximately 50pL of competent One Shot ® TOP10F' 
chemically competent E.coli cells (Invitrogen, C3030-03), melted on ice. The 
reaction was incubated on ice for a further 30-minutes, before undergoing heat-
- 6 0 -
Chapter 2: Materials and Methods.
shock treatment at 42°C for 90-seconds. The mixture could then be stored on ice 
before the addition of warmed SOC media to increase the total volume to 
approximately 200pL. The mixture was then incubated at 37°C for 10- to 30- 
minutes to enable the activation of the antibiotic resistance gene (encoded for in 
the plasmid DNA). The transformed Bacteria were then plated onto LB-agar 
plates containing lOOpg/ml Ampicillin (Boehringer Mannheim) and incubated 
overnight at 37°C.
2.1.4 Creating LB stocks and plates for bacterial growth.
LB Broth Base (Lennox L Broth Base, Invitrogen) and LB Agar (Lennox L Agar, 
Invitrogen) were used, according to the manufacturer's instructions, to create 
bacterial LB culture media and LB-agar plates. All media stocks and glassware 
used in the growth of bacterial cultures was autoclaved at 121 °C for 15-minutes. 
Where required, the antibiotic Ampicillin was added, after autodaving, to a 
final concentration of 100fig/ml.
2.1.5 Small scale preparation of plasmid DNA (Miniprep).
Using a sterile pipette tip or loop, 2.5mL of LB containing 100fig/ml Ampicillin 
in a 14mL round-bottom Falcon 2059 tube was inoculated with a single plasmid- 
containing bacterial colony grown overnight on LB-agar plates. The inoculated 
LB-medium was grown overnight at 37°C in a shaking incubator.
Following overnight growth, lmL of the saturated bacterial culture was placed 
in a 1.5mL Eppendorf tube. The bacteria were pelleted by centrifugation at a
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relative centrifugal field (xg) of 13,000. Following aspiration of the supernatant, 
the pellet was resuspended in lOOpL of Solution I (50mM glucose, 25mM Tris- 
HC1 (pH8), lOmM EDTA (pH8)) containing 50mg/mL lysozyme (Roche), and 
incubated at room temperature for five minutes. 200pL of Solution II (0.2N 
NaOH, 1 percent SDS) was then added and mixed. After a 5-minute incubation 
at room temperature, 150pL of ice-cold Solution III (11.5 percent v /v  glacial 
acetic acid, 3M KAc) was added and mixed before undergoing a further 
incubation, this time on ice, for 15-minutes. The mixture was then pelleted by 
centrifugation (13,000g for 5-minutes) and the supernatant transferred to a new 
1.5mL Eppendorf tube containing a 0.5 to 1 volume of phenolxhloroform. 
Phenol chloroform extraction was then performed; whereupon the upper 
aqueous phase was removed and transferred to a new 1.5mL tube.
Ethanol precipitation was then undertaken on the contents of the new tube. lmL 
of ethanol (EtOH) was added and the mixture was shaken thoroughly before 
incubation at room temperature for 2-minutes. The tube was then spun at 
13,000g for 10-minutes before aspiration of the EtOH. The same ethanol 
precipitation procedure was then repeated with 70% EtOH. The final pellet 
following centrifugation and aspiration of the EtOH, was then resuspended in 
TE buffer (with or without lOpg/ml RNaseA - depending on future use) 
following a brief period of air-drying. The plasmid DNA product suspended in 
the TE was then quantified using the protocol outlined in section 2.1.7 and /o r 
verified using restriction enzyme digestion and agarose gel analysis also 
described in this chapter (section 2.1.18). The unused saturated bacterial culture 
could be used to either create a glycerol stock (typically 500pL culture to 
approximately 500pL sterile glycerol) (stored at -80°C) or used to directly
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inoculate a larger volume of LB for the large scale isolation of plasmid DNA 
(Maxiprep).
2.1.6 Large scale preparation of plasmid DNA (Maxiprep).
The inoculation of a flask containing 500mL of LB containing lOOpg/ml of the 
antibiotic Ampicillin was undertaken with the product of a previous inoculation 
and overnight growth of bacteria in 2.5mL of LB containing Ampicillin (as 
described in section 2.1.5). The flask was placed in a 37°C shaking incubator and 
left overnight to produce a saturated bacterial culture. lmL of this overnight 
culture was used to create a glycerol stock as previously described in section 
2.1.5, whilst the remainder of the culture was centrifuged (either in separate, 
balanced centrifuge bottles or undertaken sequentially within the same bottle) 
for 25-minutes at approximately 5,000g. Following aspiration of the supernatant 
and pellet resuspension in the centrifuge bottle with 18mL of Solution I (50mM 
glucose, 25mM Tris-HCl (pH8), lQmM EDTA (pH8)), a further 2mL of Solution I 
with lOmg/mL of lysozyme (lmg/mL final concentration) was added to the 
mixture and left to sit at room temperature for 10-minutes. 40mL of Solution II 
(0.2N NaOH, 1 percent SDS) was then added before further incubation at room 
temperature for a 5-minutes. 20mL of cold Solution III (11.5 percent v /v  glacial 
acetic acid, 3M KAc) was then added to the centrifuge bottle, gently mixed, and 
left on ice for 15-minutes. 5mL of distilled water was added to the mixture 
before being spun at approximately 5,000g for 15-minutes.
Following the centrifugation, the supernatant was poured through double 
layered gauze into smaller centrifugation bottles, to which 45mL of isopropanol
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was added whilst gently shaking. The bottle was then spun for 15 minutes at 
approximately 7,000g, before aspiration and pellet resuspension in 6.5mL of TE. 
150pL of 0.5M EDTA and approximately 90pL of 2M TRIZMA®base (Sigma)(or 
enough to achieve a pH level of approximately 7.5) was added before adjusting 
the final volume to lQmL with TE. This entirety of the lQmL was then added to 
12g of accurately weighed CsQ powder in a 14mL falcon tube. After shaking the 
tube to fully dissolve the CsQ, ethidium bromide was added to a final 
concentration of 0.5mg/mL. The content of the falcon tube was then carefully 
placed into a 10ml Beckman Quick-seal centrifuge tube, which, before heat- 
sealing using the Beckman tube-sealer (Beckman, Palo Alto, California), was 
balanced precisely against a second centrifuge tube.
The balanced tubes were spun in a Beckman Coulter OPTIMA L-100 XP 
centrifuge at 60,000rpm for 24 hours. The gradient produced by the 
centrifugation, typically concentrates two distinct bands of DNA towards the 
top of the tube. These correspond to 'nicked' plasmid DNA (higher band) and a 
covalently closed circular super-coiled plasmid DNA species (lower band). After 
piercing the top of the centrifuge tube, the lower band was removed using a 
syringe with an 18-gauge needle and placed in a 14mL falcon tube. 2 to 3mL of 
butanol were then added to the falcon tube, and, after shaking, the top organic 
phase was removed using a Pasteur pipette. Further butanol was added and the 
process was repeated until the lower phase was clear and the CsQ was 
bordering on falling out of the solution. The lower phase was then removed 
from the tube and placed into dialysis bags (created from 15.9mm dialysis 
tubing from Medicell) and dialysed for 2 to 3 hours in 2L of lxTE (or until the 
CsQ stopped falling out of the dialysis membrane). The contents of the
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membrane was then placed in a new 14mL falcon tube and RNase A added to 
final concentration of lOpg/mL. The tube was then incubated for one hour at 
65°C. The tube was then incubated for a further hour at 37°C/ after the addition 
of proteinase K and SDS (added to final concentrations lOOpg/mL and 0.2 
percent, respectively). Following the incubation, phenol-chloroform extraction 
was performed and the aqueous phase was placed in 30mL glass Corex tubes. 3 
to 5 volumes of ethanol was added to the tubes with NaCl at a final 
concentration of 250nM present. The tube was spun for 30-minutes at 
approximately 15,000g. Following aspiration of the EtOH, the precipitate 
formed was resuspended in 500pL of TE after a brief air-drying period.
The resuspended DNA could then undergo quantification (using the 
spectrophotometer) and verification (using restriction enzyme analysis).
2.1.7 Quantitation of DNA.
DNA quantities were assayed on a single-beam Pharmacia Biotech Gene Quant 
II spectrophotometer (Amersham Pharmacia Biotech, Piscataway, NJ). DNA 
was diluted with distilled water and placed in Hellma Precision Far-UV quartz 
cells (Hellma cells, Plainview, NY) and read against a distilled water blank. 
Readings were taken at 260 nm wavelengths (OD260). DNA quantity could be 
calculated in mg/mL and pmol/pL using the following equations:
Equation 1
[ ODread at 260 x dilution factor x K1] /  1000 = pg of oligonucleotide per pL 
Equation 2
[ pg /  pL ] /  [ length of oligo in kb x 0.330 ] = picomoles (pmol) oligo per pL
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Where lK is the specific absorption coefficient (double-stranded DNA: 50; 
single-stranded RNA: 40; single-stranded DNA: 37).
The ratio of absorbance at 26Qnm to absorbance at 280nm (OD260/OD280) was 
used as an indicator of nucleic acid purity. Ratios of approximately 1.8 and 2.0 
reveal pure samples of DNA and RNA, respectively.
2.1.8 Analysis using agarose gels.
Plasmid DNA, PCR products and DNA products from restriction digests were 
separated by electrophoresis on 1% agarose gels. The gels, made with IX TAE 
buffer (0.4M Tris-acetate, ImM EDTA) containing 0.5pg/ml ethidium bromide 
(added from a lOmg/mL stock created with ethidium bromide tablets, E-2515) 
and agarose (A9539), were microwave-heated and briefly cooled prior to 
pouring into gel trays with appropriately sized combs. Following further 
cooling and solidification of the gel, the DNA samples were mixed with 5xDNA 
BlueRun™ loading dye (IH0023e, Hybaid), and loaded into the wells. 0.5pg to 
1.5pg of 1Kb DNA ladder (GIBCO BRL lkb PLUS, 10787-018), used as a distance 
marker, was also loaded into wells alongside the samples.
The gels were electrophoresed at for approximately 20 to 80 minutes at 110 to 
140 volts (or until the DNA samples had undergone sufficient progression) in a 
gel tank containing lxTAE buffer. A short-wave UV transilluminator was used 
to visualise the displacement of the fragments, and used in conjunction with a 
digital camera to record the result. If required, DNA fragments were excised 
from the gel.
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2.1.9 Purification of DNA from agarose geL
DNA fragments were excised from agarose gel using a scalpel and purified 
using the Wizard ® PCR Preps DNA Purification System (Promega, 
A7170)(undertaken according to the manufacturer's instructions).
2.1.10 Oligonucleotide primers for use in PCR.
Oligonucleotide primer sequences, designed using MacVector (Accelrys) and 
created by ThermoHybaid, were received by the laboratory in a dried state. The 
oligonucleotides were resuspended in a volume of dhhO as directed by the 
quality certificate supplied by Thermo Hybaid. The resuspended DNA 
oligonucleotides were then quantified using the protocol outlined in section 
2.1.7, and the volume of dPhO was adjusted in order to create lOOpmol/pL (100 
pM) stocks.
Z1.12 Amplification of DNA sequences using Polymerase Chain Reaction 
(PCR).
Where PCR was used for the amplification of DNA fragments, two methods 
were employed:
Method 1: Using Biomix Red polymerase (Bioline, Boston, MA).
1 pL of template DNA (at concentrations ranging from 0.1 to 0.5 pg/pL) and 
lpL of each appropriate oligonucleotide primer (at lOpmol/pL) were added to
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Biomix Red ready-to-go format (Bioline, BIO-25005), a 2x reaction mix 
containing BIOTAQ Red DNA polymerase, 1.5mM MgCh and ultra-pure 
dNTPs. The reaction total volume was increased with distilled water to 25pL to 
achieve a lx  concentration of the Biomix Red. Where 50 pL total volume 
reactions were used, 2pL of each primer and additional distilled water were 
added to 25pL of Biomix Red.
Method 2: Using AGS gold DNA polymerase (Hybaid, Ashford, UK).
The following reactions were created:
0.5 to 2 pL Template DNA (0.1 to 0.5 pg/pL)
2.5 pL lOx buffer
1 pL.............. Primer 1 (lOpmol/pL)
1 pL.............. Primer 2 (lOpmol/pL)
1 pL.............. dNTPs (**)
0.5 pL AGS Gold taq DNA polymerase (5 units per pL)
17 to 18.5 uL... dH?Q 
25pL final volume
PCR reactions were performed in a Hybaid PCR Express ® Thermocycler 
under standard conditions. Typical cycles consisted of:
1st stage:
1 cycle of 95°C for 5 minute 
2nd stage (repeated 20-30 times):
1 cycle of 95°C for 1 minute.
1 cycle of optimal annealing temperature of primer pair, for 1 minute.
1 cycle of 72°C for 1 minute.
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3rd stage:
1 cycle of 72°C for 4 minutes.
Temperature, time and repetition of second stage was altered to accommodate 
the various differences in optimal annealing temperature (appropriate for 
oligonucleotide primer pairs) and size of both template DNA and primer pair 
product. PCR fragments, where indicated, were cleaned using the Wizard ® 
PCR Preps DNA purification system (Promega, A7170).
2.1.13 Direct PCR amplification of plasmid DNA from bacterial colonies.
Lyse-N-Go™ PCR reagent (Pierce) was used as outlined in the manufacturer's 
instructions to lyse cells picked from a single plasmid-containing bacterial 
colony grown overnight on LB-agar plates. PCR amplification was performed 
after the addition of the appropriate primers and amplification mixture (as 
outlined in section 2.1.12) made up to 9 times the volume of lysate. The PCR 
product was then run out on an agarose gel for analysis.
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2.1.14 Preparing samples for Sequencing DNA.
ABI PRISM® BigDye™ Terminator Cycle Sequencing Kits (version 3.1) were 
used as described below to amplify specific regions of plasmid DNA that 
required sequencing.
PCR reaction content:
2.0 pL BigDye Dilution Buffer
2.0 pL BigDye 3.1
0.5 - 3.5 pL Template DNA (500ng)
2.0 pL Primer (2 pM)
0.5 pL DMSO
0 - 3.0 pL dH2Q
10 pL final volume
PCR Thermocycler protocol:
1st stage:
1 cycle of 95°C for 5 minute 
2nd stage (repeated 25 times):
1 cycle of 95°C for 30-seconds.
1 cycle of 50°C for 30-seconds.
1 cycle of 60°C for 4-minutes.
3rd stage:
1 cycle 65°C for 4 minutes.
Following the PCR amplification of the sequence of interest The reaction was 
placed in a new 1.5mL Eppendorf tube and lOpL of dFkO was added before the
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addition of 2pL of 3M Sodium Acetate and 50pL of EtOH. The mixture was then 
incubated on ice for 10-minutes. Following the incubation, ethanol precipitation 
was undertaken on the contents of the new tube; whereby the tube was spun at 
13,000g for 20-minutes before aspiration of the EtOH. The procedure was then 
repeated with 70% EtOH. The pellet was left to air-dry before being 
resuspended in lOpL of Formamide. The resulting suspension of DNA was then 
sequenced as outlined in section 21.14.
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2.1.11 Oligonucleotides used in the polymerase chain reaction (PCR).
Target
receptor and 
primer name
Oligonucleotide sequence (5'-3') Primer-pair
annealing
temperature
(°C)
Product 
size ( bp)
hP2Yi
hP2Yl-F CAATGACAGGGTTTATGCCACG
hP2Yl-B AGGTGTTTGGAGATTCTTGTGCC 55.0 253
hP2Y2
hP2Y2-F ATCAATGGCACCTGGGATGG
hP2Y2-B CGGCACAAGAAGATGTAGAGCG 57.9 149
hP2Y4
hP2Y4-F CAAGTTCATCCTGCTGCCTGTG
hP2Y4-B TCCCTTTGTTGCTGGTTGTGAC 59.3 443
hP2Ys
hP2Y5-F CATCTGCGTCCTCAAAGTCC
hP2Y5-B ACTGAACAAAAACGGCGG 52.0 341
hP2Y6
hP2Y6-F TTTCCTCATCTGCTGCCTCTCC
hP2Y6-B TGAACTCCGCCTTCCAAAGC 57.2 200
hP2Yn
hP2Yll-F TGCCGACGACAAACTCAGTGG
hP2Yll-B GATGAAGATGACGCTGCCAG 61.4 307
hP2Yiz
hP2Y12-F GATTCTCTCTGTTGTCATCTGGGC
hP2Y12-B GGGC ACTTC AGC AT ACTT ATC A AGG 54.2 522
Xlp2yll
X1P2Y11-F TGCTACCAGGAGAGCCAAGATG
X1P2Y11-B TGGGTTCAAGAGGATGCTTCC 55.3 410
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2.1.15 Dideoxy sequencing.
DNA was sequenced on an ABI PRISM® 3100-AVANT automated DNA 
capillary sequencer (ABI Applied Biosystems, Lingley House, 120, Birch wood 
Boulevard, Warrington) using BigDye™ Terminator Cycle Sequencing 
chemistry (ABI PRISM® BigDye™ Terminator Cycle Sequencing Kits, version 
3.1). Sequencing reactions were both assembled and precipitated as described in 
section 2.1.13.
Sequences were resolved on a 50 cm standard sequencing capillary, running 
optimal ABI PRISM® 3100 POP6™ polymer. Sequence data was extracted and 
analyzed using ABI PRISM® Data Collection Software v2.0 and DNA 
Sequencing Analysis Software v5.1.1 respectively.
Sequence data was exported in the ABI format (.abi) to the sequence analysis 
program Trace Viewer®. The fluorescence traces were manually verified against 
the automated sequence data. Verified sequences were converted to FASTA 
format for further use and analysis using the MacVector® sequence analysis 
program (Accelrys).
2.1.16 Isolation of RNA from cultured cells.
TRIZOL® Reagent (Invitrogen, cat#: 15596-026), was used to facilitate the 
purification of RNA from cultured 1321N1 human astrocytoma cells. TRIZOL® 
enables the isolation of total RNA by an acid guanidinium thyocyanate-phenol-
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chloroform single extraction method. RNA isolation and extraction was 
performed according to the manufacturer's instructions.
2.1.17 Reverse Transcription Polymerase Chain Reaction (RT-PCR).
A two-tube RT-PCR method was used in order to allow multiple PCR 
experiments to be undertaken, using the cDNA product of the reverse- 
transcription reaction.
2.1.17.1 Making template cDNA.
Following the manufacturer's instructions, Qmniscript ® RT Kit (Qiagen, cat#: 
205110) was employed for first-strand cDNA synthesis. 01igo(dT) and random 
hexamer (dN6) primers were used (separately) in conjunction with the 
Omniscript ® RT Kit, and 50ng to 2pg of template RNA, isolated from cultured 
plasmid-transfected and untransfected 1321N1 human astrocytoma cells.
2.1.17.2 Performing PCR on the cDNA.
PCR was performed with specific oligonucleotide primers (as outlined in section 
2.1.12) using the cDNA, synthesised in the reverse-transcription reaction, as the 
template DNA. Appropriate negative controls were created for each set of 
reactions (-RT; reactions undertaken without template cDNA).
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2.2 Cell culture Techniques.
The following sections describe the cell culture techniques used in order to create 
1321Nl-hP2Yn and XlP2Yn cells, and the method required for the isolation of 
RNA from transfected and untransfected 132INI cells - for use in RT-PCR 
experiments (previously described in Section 2.1.17).
2.2.1 Cell lines and culture conditions.
Adherent 1321N1 human astrocytoma cells acquired from the European 
Collection of Cell Cultures (Porton Down, Salisbury) were cultured in 
Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) supplemented with 10% 
fetal calf serum (FCS) and L-glut (where required, added to a final concentration 
of 2mM). Cells were grown at 5% CO2 in a 37°C humidified incubator and were 
manipulated in a Qass II laminar flow safety cabinet.
2.2.2 Passaging, splitting and counting.
To passage, cells were washed with Hanks' Balanced Salt Solution (Sigma) 
before incubation in an appropriate volume of PBS-EDTA at 37°C in the ceil- 
culture incubator for 5 minutes. Volume of PBS-EDTA was adjusted depending 
cm the size of the plate or flask used. The resuspended cells could then be used 
to either seed further flasks, used to create freezer amplues for long term 
storage of cell lines, or used for calculating the number of cells present in the 
solution (shown below).
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Cells were counted after PBS-washing and incubation/lifting in PBS-EDTA. 
200pL of the resuspended cells were added to 200p,L of 0.4% trypan blue 
solution (Sigma). Two to three drops of the mixture were then placed under a 
glass coverslip on a bright light counting chamber (Hausser Scientific 
Company). The number of viable cells (not dyed blue by the tryptan blue) was 
then counted in each of the five 1mm2 sections of the counting chamber. The 
following equation could then be used to calculate the number of cells 
resuspended in the PBS-EDTA. 
equation 3
cells per square mm x dilution factor (typically 2) x 10,000 = cells per ljiL
Transfected stable cell lines used in the experiments presented in this thesis 
were used between passage numbers 5 and 20.
2.2.3 Transfection of cells with plasmid DNA.
Transfection of cells in 10cm Petri plates was undertaken using the 
LipofectamineTM2000 (Invitrogen) and calcium phosphate methods. 
Lipofectamine™ 2000 was used as in accordance with the manufacturer's 
instructions.
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2.2.3.1 Calcium phosphate transfections (modified from Chen and Okayama, 
1987).
20pg of plasmid DNA mixed with 50pL of 2.5M CaQ2 and 450pL dH20 was 
gently vortexed whilst 500pL of 2xBBS was added drop-wise. Following 30- 
minutes of incubation at room temperature, the entire mixture was added to 
untransfected 1321N1 cells, grown for one day in 10cm Petri plates (at initial 
concentrations of approximately 20,000 to 25,000 cell/cm2). The plates were 
gently swirled to allow the uniform dilution of the mixture in the DMEM. The 
plates were then placed in a container, filled with an air mixture containing 3% 
CO2, and incubated at within the 37°C incubator for 24 hours. The plates were 
then removed from the container with 3% CO2 and replaced in the 5% CO2 
incubator. Antibiotic selection was initiated following 24 hours of incubation. 
Method was modified from Chen and Okayama, 1987.
2.2.4 Generation of stable cells lines.
Antibiotic selection of cells was undertaken following transfection of 1321N1 
cells as outlined in section 2.23. After a PBS-wash, the antibiotic neomycin 
(Geneticin®, Gibco) was added at a final concentration of 400(ig/mL to the 10cm 
plates with new DMEM. The process of washing the cells with PBS and 
replacing the media with fresh DMEM containing the antibiotic was repeated 
once every 2 to 3 days for approximately three weeks. Within this period, cell 
death of untransfected cells, and the expansion of cell foci containing 
Geneticin® resistant cells, was observed. Previous studies undertaken in the
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laboratory have found the replenishment of selective media in this way, 
containing 400pg/mL of Geneticin, prevents the growth of untransfected cells 
within two to three weeks.
2.2.41 Isolation of cell pellet from cultured cells for isolating RNA.
Following one to two weeks of cell growth after the antibiotic selection, a 
proportion of the cultured cells were isolated after washing with PBS and lifting 
with PBS-EDTA as described in section 2.22. The cells were then spun in a 
15mL screw-top tube for 2 minutes at lOOOrpm in an Eppendorf 5804R 
centrifuge (approximately 500g). After removal of the supernatant, the pellet of 
cells could then either be stored (at -80°C or -20°C for long or short-term storage, 
respectively) or treated directly with TRIZOL ® Reagent to isolate the total 
RNA. This was then used in RT-PCR experiments to examine the presence or 
absence of transfected DNA (undertaken as described in sections 2.1.16 and 
2.1.17).
225 Freezing stocks of stable cell lines.
Multiple freezer ampules were created for the long term storage of transfected 
cell lines. Following a PBS-wash and lifting of the cells in lOmL of PBS-EDTA 
from a Tiso flask, 5 to 8 mL of the PBS-EDTA containing the cells was placed in a 
15mL screw top tube, centrifuged for 2 minutes at 500g before aspiration of the 
supernatant. At the same time, 9mL of thawed FBS was added to lmL of DMSO, 
this mixture was then used to fully resuspend the cell pellet (avoiding any
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clumping of cells). The resuspended cells were then aliquotted into multiple 
NUNC™ Cryotube™ 2mL vials.
2.3 Pharmacology Techniques.
The following techniques were used in order to pharmacologically characterise 
the cAMP and Ca2+ second messenger responses of the 1321Nl-hP2Yn and 
1321Nl-XlP2Yn cells.
2.3.1 The cAMP accumulation assay:
The assay is a modification of the techniques described by White and Zenser, 
1970; Salomon et al,. 1973 and Johnson and Salomon (1991).
Z3.1.1 cAMP assay: Tissue culture preparation.
After performing a PBS-wash on a confluent monolayer of cells in a Tiso flask. 
The cells were incubated and suspended in 20mL of PBS-EDTA after a 10- 
minutes incubation. 2mL of the PBS-EDTA containing the cells was then added 
to 48mL of DMEM. lmL of this final dilution was then added to each well of a 
Costar® Tissue Culture Treated 24 well plate (Coming), the cells were plated at 
approximately 20,000 cells/cm2. In this way 2 plates could be created. Where 
required, different quantities of a similar dilution could be created to produce a 
larger number of plates. The plates were incubated in the cell culture incubator 
for 2 to 3 days (or until approaching 100 percent confluency).
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2.3.1.2 cAMF assay: 3H adenine loading.
50pL of 8-3H Adenine ([8-3H] Adenine in aqueous solution containing 
2% ethanol; 27.0 Ci/mmol)(Amersham Biosciences) was added to 25mL of 
Hanks' Balanced Salt Solution (Sigma) in a 50mL falcon tube and mixed. After 
aspiration of the media present on the 24 well plates, lmL of the 3H-Hanks 
media was added to each well of the plate (2pCi/well). The plates were then 
returned to the incubator. Following 2 hours of incubation the media was 
aspirated and each well was washed with 1.5mL of Hanks buffer, this washing 
procedure was repeated 3 times to remove unloaded 3H. Following the final 
wash an appropriate volume* of Hanks containing phosphodiesterase inhibitor 
(Ro20-1724, a type 4 phosphodiesterase inhibitor; added to a final concentration 
of lpM) and adenosine deaminase (ADA, type VI inhibitor; added to a final 
concentration of 1 unit/mL).
If an antagonist experiment was conducted, the appropriate concentrations of 
antagonists were added at this point to allow the compound to reach a binding 
equilibrium with the receptors. Following 30-minutes of incubation in the cell 
culture incubator, the appropriate concentration of compounds required for the 
stimulation or inhibition of cAMP response was added to each well. A vehicle 
control (10pL of PBS) and control response to isoproterenol (added to a final 
concentration of lOpM), was undertaken for each plate in triplicate. The 
incubation with the compounds was terminated after exactly ten-minutes with 
the addition of 50pL of concentrated HC1 (11.91M), inactivating the metabolism
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of the cells in each well of the plate. The plate could either be stored at -20°C or 
used directly in the quantification of de novo cAMP (described below).
*(Total volume in each well after the addition of agonists (or agonists and 
antagonists) was exactly 1000p,L. Depending on the individual experiments 
conducted, the volume of Hanks containing Ro20-1724 and ADA was therefore 
adjusted appropriately).
2.3.1.3 cAMP assay: Column preparation for chromatography.
Dowex columns were prepared after the creation and addition of 2.4mL of a 
50:50 slurry of AG®50W-X4 cation exchange resin (Bio-Rad) and distilled water. 
Addition of the mixture to 9cm poly-prep columns (Bio-Rad) resulted in the 
accumulation of approximately 1.2mL of Dowex resin in the columns. lOmL of 
dH20 was added to the top of the columns before the addition of 5mL of 1M 
HC1, which was followed by a further 20mL of dH20 (added in 2xl0mL 
aliquots). Altunina columns were also created in 9cm poly-prep columns; 
whereby 0.6g of neutral alumina was placed in the columns before the addition 
of 20mL of 0.1M imidazole (added in 2xlQmL aliquots). Each addition of liquid 
to both sets of columns was allowed to drain fully through the columns before 
further additions of liquid.
2.3.1.4 Sample preparation and chromatography.
The entire lmL was removed from each of the 24 wells and placed into new 
1.5mL Eppendorf tubes and centrifuged for 10-minutes at 13,000g to pellet the
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cell debris. If stored at -20°C, the plates were given enough time to thoroughly 
defrost. The supernatant was then removed and placed into new 1.5mL tubes. 
50pL was taken from each of the new tubes and placed into numbered 20mL 
scintillation vials (Packard) containing 5mL of Optiphase 'HiSafe'3 scintillation 
fluid (Perkin Elmer). 50pL of a prediluted stock of 14C-cAMP ([adenine-U- 
14C]cyclicAMP)(256 mCi/mmol) was added to the remainder of the supernatant 
in the new 1.5mL tubes. The tubes were then carefully sealed and briefly 
vortexed to mix.
The contents of the vortexed tubes were then added to individual Dowex 
columns (prepared as outlined in section 2.3.1.3). 2mL of dt^O, added to each 
column, was left to drip through the columns, permitting the size-elution of the 
non-cyclic nucleotides. The columns were then placed on top of the Alumina 
columns (prepared as outlined in section 2.3.1.3) before the addition of a further 
4mL of dH20. The eluate, containing the 3H-labelled cAMP, was therefore 
collected within the alumina columns. The cAMP was then eluted from the 
alumina columns, after the addition of 4mL of 0.1M imidazole, into 20mL 
scintillation vials - to which 15mL of 'HiSafe'3 scintillation fluid was then 
added. 15mL of the scintillation fluid was also added to three vials containing 
50pL of 14C-cAMP only, these vials were created in order to gauge the efficiency 
of the columns.
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2.3.1.4 cAMP assay: Column regeneration and Scintillation counting.
Following the chromatography stages, the dowex and alumina colums were 
regenerated for future use. Dowex columns were washed with 7.5mL 1M HQ 
and 20mL of H2O, whilst the alumina columns were subjected to 2GmL of 
imidazole. Further regeneration was performed once every 10 uses in order to 
strip the columns of any bound nucleotides, with the addition of 5mL of IN 
NaOH. The columns were then subjected to a typical regeneration procedure 
(outlined above).
The vials containing 5mL and 15mL scintillation produced before, and as a 
result of, the chromatography procedure, outlined above, were placed in the a 
liquid scintillation analyser (Tri-CARB 2900TR, Packard). The vials containing 
5mL of scintillant were subjected to a 1-minute 3H count, whilst the 15mL 
scintillant vials underwent a five-minute 3H and 14C count. The interaction 
between the 3H and 14C isotopes (both possessing beta-emission) and the solute- 
solvent cocktail allowed the counts per minute to be recorded and outputted via 
the Quanta smart V.1.31 program (Packard). Results were inputted and 
manipulated using Excel and GraphPad Prism © V.3.0.
The use and disposal (by either: sink, scintillation and solid waste) of 
radioactive material in the assay was logged during and after the assay.
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2.3.2 The Ca2+ mobilisation assay.
2.3.2.1 Tissue culture preparation.
After performing a PBS-wash and resuspending a confluent monolayer of cells 
from a T150 flask in PBS-EDTA. An appropriate portion of the PBS-EDTA was 
added to Ca2+ free DMEM and lOOpL of the mixture was used to seed each well 
of a 96-well poly-D-Lysine black plastic plate with clear bottoms in each well 
(BD BioCoat™, BD Biosciences) (final concentration approximately 10,000 cells 
per well). The cells were then incubated overnight at 37°C in the cell-culture 
incubator or until a confluent monolayer of approximately 80,000 cells was 
observed per well.
Z3.2.2 Dye loading.
A lx stock of Reagent B (lOxHanks' BBS with 20mM HEPES at pH 6.0) from the 
Calcium Plus assay kit (cat.#: R-8051)(Molecular Devices) was initially created; 
whereby 5mL of lOx Reagent B and 600pL of IN NaOH was added to 45mL of 
H2O in a 5GmL falcon tube. This was then added to the Calcium Plus 
Component A bottle and left to incubate at room temperature for 5-minutes.
Approximately 30mg of probenecid was added to a 1.5mL Eppendorf tube 
before the addition of 210jaL of IN NaOH and 210|i.L of lxDPBS (vortexing 
thoroughly in-between each addition). 105jj.L of this probenecid mixture was 
then added to the component A bottle. The mixture was pipetted up and down 
to ensure thorough mixing of the components. 10.5mL of the solution was 
placed into a plastic reservoir before lOOpL of the solution was dispensed using
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a multipipette, into each of the 96 wells of the plate. The plate was then covered 
with foil and left for 30-minutes for the dye to load. Using the Calcium Plus 
assay kit in conjunction with the FLIPR machine avoids any wash steps, which 
may damage the cells and thus the assay precision.
2.3.Z3 Creating the ligand plates.
Following the calculation of the correct volumes and concentrations of the 
appropriate drugs to be pharmacologically tested, the drugs dilutions were 
created in PBS and placed into clear V-bottom 96-well plates. The antagonist 
dilutions, created in the same way with PBS as the diluent, where required, 
were then added to the incubating cells within the first 5-minutes of the 30- 
minute incubation in order to allow a minimum of 25 minutes for antagonist- 
receptor binding equilibrium to occur.
2.3.Z2 Using the FLIPR machine to measure Ca2+ mobilisation.
A FLIPR (fluorometric imaging plate reader) machine (Molecular Devices, 
Sunnyvale, California) was used in conjunction with Coherent™ Innova 90C 
argon LASER, producing a 1.5mm diameter beam at a wavelength of 488nm. 
Data collection was undertaken with a CCD camera within the FLIPR machine 
coupled to a computer running software supplied by Molecular Devices. The 
FLIPR machine allows the real-time recording of fluorescence change emitted by 
the dye (dye content not named by Molecular Devices) loaded into the 1321N1 
cells in the presence of Ca2+ released from intracellular Ca2+ stores.
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After the 30-minute incubation, the 96 well plate was placed in the FLIPR 
machine. Before the addition of any agonists using the robotic delivery system, 
an initial reading, in arbitrary fluorescence units, was undertaken in order to 
measure the fluorescence emission for each well. Following dye excitation with 
488nm wavelength light, the FLIPR machine collects emission data through a 
standard 510-570 nm emission filter (the dye emits at a wavelength of 515nm). 
This was done in order to adjust the exposure length, shutter speed (of the 
camera) and/or power of the LASER. Saturation of the CCD occurs at 
approximately 64,000 arbitrary fluorescence units. Therefore, if initial readings 
are too high, the software cannot successfully resolve the change in fluorescence 
induced by the addition of agonists.
The internal robotic system of the FLIPR machine could be programmed to add 
a specified volume of agonist or antagonists from the V-bottom to the 96-well 
plate to the 96-well plate containing the cells loaded with fluorescent dye. A 
typical volume of 22pL of agonist dilution was added, to increase the total 
volume of each well 220jxL. This volume was added at the slowest dispensing 
speed to avoid unnecessary disruption of the cells. Agonists were typically 
added at the 10-second time-point in order to visualise a basal fluorescence 
level. Following agonist addition the fluorescence change as a result of Ca2+ 
mobilisation from intracellular stores was recorded for 3 minutes. The initial 
fluorescence reading and the real-time fluorescence change was recorded and 
available for transfer between computers in Excel format. These files were then 
analysed to calculate the intracellular Ca2+ response.
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2.4 Data handling and figure creation.
All data handling and statistical analysis was carried out using Excel and 
GraphPad Prism © V.3.0. T-testing (Student's two-tailed paired f-test, using 95 
and 99 percent confidence intervals) and one-way analysis of variance 
(ANOVA) (using confidence intervals of 95 percent), were undertaken where 
required using Graphpad.
Each data set was comprised of a 3 or more replicates for each time point and /  
or concentration level. All concentration-response curves in figures showing the 
pharmacological concentration-responses were chosen for presentation because 
they represent the curve with the closest EC/ICso value to the mean EC/ICso 
value calculated for the ligand. All concentration-response curves were analysed 
using the non-linear regression sigmoidal dose response equation (variable and 
non-variable). None of the data analysed preferred the non-variable sigmoidal 
dose response equation. Where Kd is displayed the following equations were 
used:
equation 4
dose ratio = ECso of agonist in presence of antagonist 
EC50 of agonist without antagonist
equation 5
Kd = [antagonist]/dose ratio -1 
Figures showing second messenger responses were created using GraphPad 
Prism © V.3.0. Figures showing response pathways were created using Pathway 
Builder VI .0. Chemical reactions were drawn using the MDL ISIS™/DRAW 
V2.5 chemical drawing program.
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Pharmacological characterisation of the hP2Yn receptor.
3.1 Introduction
As described in Chapter 1, the conformational change of P2Y purinoceptors 
following the binding of specific extracellular ligands conveys a signal to 
intracellular G proteins which, in turn, transduce the signal further 
downstream. This signal transmission leads to the creation of second messenger 
molecules, able to transduce and amplify the signal generated by extracellular 
receptor-ligand interaction. The pharmacological characterisation of P2Y 
receptors, therefore, is achieved using assays that are able to record these 
changes in intracellular second messenger responses generated following 
receptor activation.
The transfection, and subsequent generation of cell lines stably expressing a 
receptor of interest, from a parent cell line shown to be devoid of endogenous
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P2Y receptor expression, simplifies the process of second messenger 
pharmacological characterisation by negating the possibility of unwanted 
ligand-P2Y receptor interactions. In this way, second messenger responses 
generated by a single receptor subtype may be examined without the generation 
of multiple or overlapping second messenger responses.
This chapter endeavours first to confirm the absence of any endogenous P2Y 
receptor subtypes from the reportedly P2Y-null 1321N1 human astrocytoma cell 
line, using the RT-PCR technique described in Chapter 2, and, subsequently, to 
establish the appropriate assay conditions for determining Ca2+ and cAMP 
responses in the cell line. These assays will be established using 
pharmacological ligands shown to act as agonists upon receptors endogenous to 
1321N1 cells. These control responses will subsequently be used in the 
evaluation of second messenger responses from the transfected receptor of 
interest, allowing the normalisation of the experimental recordings to a known 
endogenous response. This transformation of data will allow the results to be 
expressed in percentage terms and making it possible to directly compare data 
from different experiments.
Following the initial examination of second messenger responses induced by 
endogenous receptors in untransfected 1321N1 cells; this chapter also presents a 
pharmacological characterisation of the human P2Yn receptor, a G8 and Gq- 
coupled receptor (stably expressing in 1321N1 cells) able to produce Ca2+ and 
cAMP second messengers in response to agonist stimulation. As outlined in 
Chapter 1, previous studies of the P2Yn receptor orthologues, both human 
(hP2Yn) and canine (cP2Yn), have shown this subtype, upon activation, is able
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to promote both de novo inositol phosphate and cyclic AMP production, and 
increase Ca2+ mobilisation (Communi et al. 1997; Zambon et al., 2001). The 
hP2Yn receptor's unique ability amongst the known P2Y subtypes to promote 
dual signalling pathway responses, allows the study of both functional 
responses within a single cell line.
In addition to establishing the conditions for both cAMP and Ca2+ second 
messenger assays, the characterisation of the human P2Yn receptor was 
undertaken in preparation for the pharmacological characterisation of the 
XlP2Yn receptor. Using a variety of agonists and antagonists, including ligands 
previously untested on the hP2Yn receptor, this chapter endeavours to use the 
cAMP and Ca2+ assays to extend the pharmacological profile of the hP2Yn 
receptor.
3.2 RT-PCR analysis of untransfected and transfected 1321Nl-cells.
Using the molecular biology methods described in Chapter 2, large scale 
preparations of plasmid DNA constructs (pcDNA3.1G418) containing hP2Yn 
and XlP2Yn coding sequences were created. BBS transfection of the constructs 
into 1321N1 human astrocytoma cells followed by antibiotic selection was used 
to create stable 1321Nl-hP2Yll and 1321Nl-XlP2Yn cell lines. RT-PCR analyses 
were performed on the untransfected 1321N1, 1321Nl-hP2Yn and 1321N1- 
XlP2Yn cell lines to determine whether any P2Y receptor subtypes were 
expressed. The analyses were undertaken in order to complement previous 
studies, which have stated the 1321N1 cells possess no detectable Ca2+
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mobilisation or IP responses when tested with a variety of P2Y receptor agonists 
(Filtz et al., 1994; Patel et al, 2001). Figure 3.1 presents agarose gel analyses of 
PCR and RT-PCR products. Panels A to F examine the presence, in 
untransfected 1321N1 cells, of RNA encoding hP2Yi (A), hP2Y2 (B), hP2Y4 (C), 
hP2Y6 (D), hP2Yn (E), hP2Yi2 (F). The figure reveals that none of these receptors 
were detected in the untransfected 1321N1-cells. Panels G and H reveal the 
presence of RNA encoding the hP2Yn and Xlp2yll receptors in 1321Nl-hP2Yn 
and 1321N1-Xlp2yll cells, respectively.
The expected PCR primer-pair products sizes for each panel are as follows: 
hP2Yi (A) 253 bp, hP2Y2 (B) 149 bp, hP2Y4 (C) 443 bp, hP2Y6 (D) 200 bp, hP2Yn 
(E) 307 bp, hP2Yi2 (F) 522 bp, hP2Yn (G) 307 bp, XlP2Yn (H) 410 bp. RNA 
extraction, RT-PCR, PCR and agarose gel analyses were performed as described 
in Chapter 2. The cultured untransfected 1321N1 cells and 1321Nl-hP2Yu cells 
were used in the experiments presented in this chapter. The experiments 
undertaken on the 1321Nl-XlP2Yii cells are shown in subsequent results 
chapters.
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Figure 3.1
RT-PCR analysis of untransfected and transfected 1321N1 cells.
For each panel 1st lane: DNA Marker, 2nd lane: negative control (no template DNA), 3rd 
lane: positive control, 4th lane: negative control (no RT used), 5th lane: RT-PCR 
undertaken with oligo d(T) primers followed by P2Y-primer specific PCR. P2Y primer 
pair used in each experiment: hP2Y, (A), hP2Y2 (B), hP2Y4 (C), hP2Y6 (D), hP2Yn 
(E), hP2Y12 (F), hP2Y„ (G) X1P2Y,, (H). RT-PCR in panels A to F undertaken with 
RNA from untransfected 132 IN 1-cells. Panels G and H show products of the RT-PCR 
experiments undertaken with 1321Nl-hP2Yn and 1321Nl-XlP2Yn cell RNA, 
respectively.
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3.3 cAMP production in untransfected 1321N1 cells and 1321Nl-hP2Yn 
cells.
The initial part of this study focuses on recording de novo cAMP synthesis 
following the incubation of untransfected 1321N1 cells with isoproterenol. 
Isoproterenol activates the p2-adrenoceptor endogenous to 1321N1 cells, causing 
synthesis of intracellular cAMP (Haragughi and Rodbell, 1991). Isoproterenol- 
induced cAMP response will be of use as a control in further investigations of 
transfected 1321N1 cells, enabling the normalisation of various ligand-induced 
exogenous receptor cAMP responses. By determining the concentration- 
dependent cAMP responses of the p 2-adrenoceptor, it will be possible to 
determine the appropriate supramaximal concentration of isoproterenol 
required for its use as an endogenous cAMP response standard.
The measurement of the cAMP response is achieved by recording the 
accumulation of, over a set period of time, intracellular radiolabelled-cAMP, 
which has been created following adenylyl cyclase activation in 1321Nl-cells 
loaded with [S-^ H] Adenine. Using the appropriate conditions and inhibitors, as 
described in Chapter 2, prevents radiolabelled-cAMP production, causing an 
intracellular accumulation of de novo cAMP production. Because total de novo 
cAMP production is recorded over a fixed period of time, the cAMP assay will 
also be used to quantify the time-dependency of the cAMP accumulation in 
1321Nl-hP2Yn cells. The second part of this study examines the de novo cAMP 
production of 1321N1 cells stably expressing the hP2Yn receptor in responses to 
a variety of P2Y agonists and antagonists.
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3.3.1 Isoproterenol produces concentration-dependent cAMP accumulation 
in 1321N1 human astrocytoma cells.
Untransfected 1321Nl-cells are able, in response to treatment with 
isoproterenol, to produce concentration-dependent cAMP accumulation. Figure
3.2 presents the cAMP responses (expressed in disintegrations per minute of the 
accumulated radiolabelled-cAMP) of untransfected 1321N1 cells following 
incubation with PBS (■) and isoproterenol (Y)(added to final concentrations 
ranging from O.lnM to lOpM; log values: -10 to -5). Ten minute ligand 
incubations were undertaken, in accordance with previous cAMP 
pharmacological studies presented for the P2Yn receptor (Qi et al., 2001a; 
Zambon et al., 2001). The data in Figure 3.2 represent one experiment of the 
three identical independent experiments performed.
Figure 3.2 reveals that de novo cAMP was produced in a concentration- 
dependent manner in untransfected 1321Nl-cells following the addition of 
increasing concentrations of isoproterenol. The mean ECso value (61.4nM, log 
ECso = - 7.21 + 0.05) was determined following non-linear regression analysis of 
each of the three independent isoproterenol concentration-response 
experiments. The addition of the PBS vehicle-control not only confirms the 
purity of the PBS (also used to dilute the isoproterenol), but also reveals the 
mechanical pressure exerted on the 1321N1 cells during ligand addition is 
unable to release sufficient ATP to produce an intracellular cAMP response.
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Figure 3.2
Concentration-response curve of isoproterenol on cAMP accumulation in 
untransfected 132 INI human astrocytoma cells.
The cAMP response to PBS (■) and increasing concentrations of isoproterenol (▼) was 
measured in cultured cells as described in the Materials and Methods. Results are 
expressed as disintegrations per minute. The data are the mean + s.e.m. of one 
representative experiment of 3 performed.
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The PBS-induced cAMP response also reveals that the cAMP produced by the 
incubation of the 1321N1 cells at the lower concentrations of isoproterenol 
(O.lnM and InM; log values: -10 and -9) are at a basal level. The figure reveals a 
10pM final concentration of isoproterenol is sufficient to produce a 
supramaximal cAMP response. Further experiments investigating the cAMP 
response of exogenous receptors will be normalised to the cAMP response 
generated by the 10pM isoproterenol control included in each experimental data 
set, thus negating any fluctuations in the magnitude of the cAMP responses 
which may be produced by a direct comparison of different experiments.
3.3.2 1321Nl-hP2Yn cells express a functioning hP2Yn receptor.
The ability of untransfected 1321N1 human astrocytoma cells to produce cAMP 
in response to ATP was examined. Figure 3.3 shows the percentage cAMP 
response generated in 1321N1- hP2Yn cells and untransfected 1321Nl-cells 
following ten-minute incubations with PBS and ATP (added to a final 
concentration of lOOpM). ATP, able to induce a sizeable cAMP response (34.6 +
1.4 percent) in the 1321Nl-hP2Yn cells, was unable to elicit similar cAMP 
accumulations in the untransfected cell line. Statistical analysis shows a 
significant difference between the PBS and ATP responses recorded in the 
transfected 1321N1 cells (p value < 0.01 by Student's two-tailed paired f-test), 
revealing functional expression of hP2Yn in the 1321Nl-hP2Yn cells.
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Figure 3.3
1321Nl-hP2Yn ceils express a functioning hP2Yn receptor.
Untransfected 132INI human astrocytoma cells and 1321N1 cells stably expressing 
hP2Y 11 were screened for their ability to produce a cAMP second messenger signal in 
response to ATP. De novo cAMP production was measured after a ten-minute 
incubation with ATP at a final concentration of lOOpM. Results are expressed as a 
percentage of the cAMP response to a supramaximal concentration of isoproterenol 
(10pM). The data displayed are the mean ±  s.e.m. of three experiments, each performed 
in triplicate. **, p < 0.01, compared with control, Student’s t-test.
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3.3.3 ATP elicits a time-dependent cAMP response in 1321N1 human 
astrocytoma cells stably expressing the hP2Yn receptor.
Previously published studies examining the cAMP production of hP2Yn and/or 
cP2Yu receptors have presented a wide variety of cAMP-assay incubation 
periods ranging from three minutes (Dixon et al., 2004) to twenty minutes (Suh 
et al., 2000). Typical incubation periods of either ten minutes (Qi et al., 2001a; Qi 
et al., 2001b; Zambon et al., 2001) or 15 minutes are the most common (Communi 
et al., 1997 & 1999). For this reason drug challenges in sections 3.3.1 and 3.3.2 
were carried out for ten-minutes. Before conducting further pharmacological 
studies, a time-course experiments was performed on 1321Nl-hP2Yn cells to 
determine the optimal incubation time.
Figure 3.4 shows the cAMP response of 1321N1 human astrocytoma cells stably 
expressing hP2Yn. De novo cAMP production, generated by ATP added to final 
concentrations of either O.lmM (■) or lOpM (A)(log values: -4 and -5), was 
measured across six different incubation periods (1, 5, 7.5, 10, 15 and 20 
minutes). The results are expressed as a percentage cAMP response, normalised 
to the control isoproterenol. The data shown are from one representative 
experiment of three identical independent experiments performed for each 
concentration of ATP. The curves plotted to the data were generated following 
non-linear regression analysis using the one-site binding hyperbola.
The cAMP accumulation generated by ATP is incubation-time dependent at 
early time points, leading to a plateau in the response at later time points. The 
half-maximal value was achieved at approximately 2 to 3 minutes for both ATP
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Figure 3.4
Time-dependent cAMP response generated by ATP in 1321N1 human astrocytoma 
cells stably expressing the human P2Yn receptor.
The cAMP response to lOOpM (■) and 10pM (A) concentrations of ATP were 
measured in cultured cells (as described in the Materials and Methods) following a range 
of different incubation periods. Results are expressed as a percentage of the cAMP 
response to a supramaximal concentration of isoproterenol (lOpM). The data are the 
mean + s.e.m.
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concentrations. Statistical analysis reveals no significant difference exists 
between the percentage cAMP response recorded for the ten- and twenty- 
minute incubation periods (where p value > 0.05 by Student's two-tailed paired 
f-test) for all three experiments undertaken at both concentrations of ATP, 
illustrating that no substantial increase in cAMP accumulation is generated 
beyond the initial ten minutes for either concentration of ATP. These data 
confirm that the maximal response to the agonist is reached within the ten- 
minute incubation period. This incubation period was used in all subsequent 
studies.
3.3.4 1321N1- hP2Yn cells are activated by nucleotides, producing a cAMP
response.
Figure 3.5 shows the percentage cAMP response generated in 1321Nl-hP2Yn 
cells following ten-minute incubations with lOOpM of: UTP, ADP, BzATP, ATP, 
p,y-meATP and a ,[3-meATP. The figure reveals the 1321Nl-hP2Yn cell line was 
able to successfully generate a cAMP second messenger response following 
activation by extracellular nucleotides and nucleotide analogues, further 
confirming successful expression of the hP2Yn receptor and coupling to the 
cAMP transduction pathway. UTP and ADP elicited a minimal cAMP response 
(2.9 + 1.9 and 5.4 + 0.3 percent, respectively) when compared to BzATP (31.6 + 
0.2 %) or ATP (35.7 + 1.1 %). Interestingly, the two methylenephosphonate 
compounds produced the greatest cAMP responses: p,y-meATP (41.0 + 0.3 %) 
and a,p-meATP (47.4 + 3.3 %).
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Figure 3.5
hP2Ylt is activated by nucleotides, producing a cAMP response.
Nucleotides and nucleotide analogues were screened for their ability to induce a cAMP 
response in 1321N1 human astrocytoma cells stably expressing the hP2Yn receptor. De 
novo cAMP production was determined after incubation with: UTP, ADP, BzATP, ATP, 
P,y-MeATP and a, P-Me ATP (each added to final concentration of IOOjxM). Results are 
expressed as a percentage of the cAMP response to a supramaximal concentration o f 
isoproterenol (10pM), and represent the mean + s.e.m. o f three different experiments, 
each performed in triplicate. *, p < 0.05, by ANOVA with Tukey’s post-test, comparing 
each with the control response. The data shown are control response deducted.
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Statistical analysis has shown, that whilst the cAMP responses generated by 
BzATP, ATP, p,y-meATP and a,p-meATP are significantly different to that 
generated by the PBS vehicle-control (used to dilute the ligands)(response not 
shown), the UTP and ADP induced cAMP responses are not (p value > 0.05 by 
one-way ANOVA followed by Tukey's post-test).
These experiments do not allow a detailed analysis of the potency of the ligands 
tested; however, the ability of ATP to produce a higher cAMP response than 
ADP is in accordance with the preferential ATP signalling capability exhibited 
in previously published hP2Yn receptor data (Communi et al. 1997 <fe 2001; Qi et 
al., 2001^ ).
3.3.5 Concentration-response curves of nucleotides on cAMP accumulation 
in 1321Nl-hP2Yi, cells.
Having shown, in section 3.3.4, that the hP2Yn receptor is able to induce cAMP 
production in the 1321Nl-hP2Yn cells in response to various nucleotide 
analogues, the concentration-responses of these agonists on cAMP production 
was examined. Figure 3.6 shows the percentage cAMP response of 1321N1- 
hP2Yn cells following ten minute incubations (with: UTP, ADP, BzATP, ATP, 
p/y-meATP or a,p-meATP). These agonists were applied at varying 
concentrations (ranging from O.OlpM to lOOpM; log values: -8 to -4). Figure 3.6 
reveals that most of the agonists were able to successfully increase the cAMP 
production in the 1321Nl-hP2Yn cells in a concentration-dependent manner.
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Non-linear regression analysis was performed on each of the three to five sets of 
data for each ligand. The representative experiments presented in Figure 3.6 
show curves fitted to ADP ( a ) ,  BzATP (▼) ATP (♦) p,y-meATP (■) and a,J3- 
meATP (a). The analysis was unable to fit a curve to the cAMP responses 
produced throughout the range of UTP concentrations. The UTP (□) data is 
shown with a dotted connecting line. The regression analysis has enabled the 
calculation of the ECso value for: BzATP (0.9pM, log EC50 = -6.05 + 0.06), ATP 
(5.7pM, log EC50 = -5.24 + 0.07), <x,(3-MeATP (23.0pM, log ECso = -4.64 + 0.07) 
and (3,y-MeATP (24.4pM, log ECso = -4.61 + 0.14)(also shown in Table 3.1). 
Consistent with previous pharmacological characterisations (Communi et al., 
1997, White et al., 2003), Figure 3.6 reveals maximal cAMP responses are 
achieved for the agonists within approximately 2 to 2.5 log units of the agonist 
concentration required to produce a minimal/basal cAMP level.
Although a 'curve' has been plotted to the ADP data in Figure 3.6, the minimal 
responses recorded, and the fact that this clearly does not reach a maximal 
response within the range of ADP concentrations tested here, does not allow an 
ECso value to be calculated accurately for this ligand. The minimal cAMP 
concentration-responses produced by UTP and ADP conform to the data 
recorded in the single-concentration ligand screen undertaken in section 3.3.2.
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Figure 3.6
Concentration-response curves of nucleotides on cAMP accumulation in 1321N1 
human astrocytoma cells stably expressing the hP2Yu receptor.
The cAMP response was measured following the incubation of 1321Nl-hP2Yn cells 
with increasing concentrations of: UTP (□), ADP (a ) ,  BzATP (▼), ATP (♦), p,y- 
meATP (■) and a,(3-meATP (A). Results are expressed as a percentage of the cAMP 
response to a supramaximal concentration of isoproterenol (lOpM). The data are the 
mean + s.e.m. of one representative experiment of three to five performed for each 
ligand.
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Calculation of the EC50 values enables the relative effectiveness of the agonists to 
be compared and the rank order of potency of these in producing a cAMP 
response at the hP2Yn receptor is:
BzATP > ATP > a,P-meATP = P,y-meATP
3.3.6 Reactive Red is an antagonist of the cAMP response induced by the 
activated hP2Yn receptor.
In order to expand the current pharmacological profile of the hP2Yn receptor, 
the ability of Reactive Red (a P2Y-receptor antagonist)(Biiltmann et al., 1995) to 
inhibit hP2Yn-mediated cAMP responses was investigated. The percentage 
cAMP response generated by BzATP (used at a final concentration of lOpM) 
when added alone, and the response induced by lOpM BzATP in the presence of 
Reactive Red, added at a final concentration of ImM is shown in Figure 3.7. 
BzATP was chosen for this experiment because of its potency and high efficacy 
at a final concentration of 10|iM (previously presented in sections 3.3.4 and 
3.3.5). Consistent with the agonist characterisations of the hP2Yn receptor 
shown in these previous sections, the cAMP responses are presented normalised 
to the control isoproterenol response. As Figure 3.7 shows, Reactive Red (ImM) 
is able to fully inhibit BzATP-induced cAMP production in the 1321Nl-hP2Yn 
cell line, decreasing the BzATP-induced cAMP BzATP-induced cAMP response 
to a minimal value shown by statistical analysis to be indistinguishable from the 
PBS control response (p value < 0.05 by Student's two-tailed paired f-test).
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Figure 3.7
Reactive Red inhibits cAMP accumulation produced by BzATP activation of 
hP2Y„.
Reactive Red’s ability to inhibit cAMP accumulation produced by BzATP activation o f 
hP2Yn . Following pre-incubation with Reactive Red (added to a final concentration o f 
ImM), de novo cAMP production was measured after incubation with lOpM of BzATP. 
Results are expressed as a percentage of the cAMP response to a supramaximal 
concentration of isoproterenol (lOpM). The data represent the mean + s.e.m. of three 
different experiments each performed in triplicate. *, p < 0.05, Student’s t-test. The 
results shown are control response deducted.
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3.3.7 Reactive Red reduces agonist-induced cAMP responses of the hP2Yu 
receptor in a concentration-dependent manner.
To determine the nature of the antagonism produced by Reactive Red, 
concentration-response experiments were carried out on the 1321Nl-hP2Yn 
cells. Figure 3.8 shows the percentage cAMP response of 1321Nl-hP2Yn cells 
induced by BzATP addition alone (▼; added to a final concentration of lOpM), 
and the response generated in the presence of different concentrations of 
Reactive Red (v; used at final concentrations ranging from lQnM to lQmM; log 
values: -8 to -2).
Figure 3.8 reveals that Reactive Red is able to affect a concentration-dependent 
decrease in the BzATP-mediated cAMP response. The IC50 value calculated for 
Reactive Red is 1.7pM, log IC50 = -5.76 + 0.07 (shown in Table 3.2). Statistical 
analysis has shown the percentage cAMP responses produced by 10pM BzATP 
in the presence of higher concentrations of Reactive Red (above 5pM; log value - 
5.3) are indistinguishable from the PBS-induced negative control responses (p 
value < 0.05 by Student's paired f-test). The ability of Reactive Red to reduce the 
agonist-induced response to a basal level over approximately 2 log units of 
concentration change is characteristic of previously studied P2Y antagonists (Qi 
et al., 2001b) and reveal the novel finding that Reactive Red is able to fully 
inhibit the cAMP responses of the hP2Yn receptor.
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Figure 3.8
Concentration-inhibition curves of Reactive Red on cAMP accumulation generated 
by BzATP, in 1321N1 human astrocytoma cells stably expressing the hP2Yn 
receptor.
The cAMP response to lOpM BzATP was measured in 1321Nl-hP2Yn cells, alone (▼) 
and following pre-incubation with increasing concentrations of Reactive Red (v). 
Results are expressed as a percentage of the cAMP response to a supramaximal 
concentration of isoproterenol (10pM). The data are the mean ± s.e.m. of a 
representative experiment of three independent experiments performed.
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3.4 Ca2+ mobilisation in untransfected 1321N1 cells and 1321Nl-hP2Yn 
cells.
Whilst I was developing the cAMP assay, the Ca2+ assay was also being 
established in the laboratory. The results of the Ca2+ assays, performed by Dr 
Townsend-Nicholson and analysed by myself, are presented in the following 
sections of this chapter.
Similar to the methodology applied to the establishment of the cAMP 
accumulation assay, the appropriate assay conditions were established for the 
determination, upon receptor stimulation, of intracellular Ca2+ mobilisation in 
1321Nl-cells. The first part of this investigation was performed in order to 
examine the ability of carbachol to stimulate a Ca2+ second messenger response 
in untransfected 1321N1 cells. Carbachol, an agonist of the muscarinic receptor 
(M3), endogenous to 1321N1 cells (Stephan and Sastry, 1992), has been shown to 
stimulate inositol phosphate (IP) accumulation in a concentration-dependent 
manner. Similarly to the use of isoproterenol as a control response in the cAMP 
assay (Section 3.3.1), the concentration-dependence of carbachol-induced Ca2+ 
mobilisation was undertaken to determine the supramaximal concentration of 
carbachol for use as an endogenous control responses in 1321N1 cells. The use of 
an endogenous standard allows the normalisation of intracellular responses 
produced by exogenous receptors. The second part of the study examines the 
intracellular Ca2+ responses induced by the activated hP2Yn receptor, beginning 
with the characterisation of the Ca2+ response of the 1321Nl-hP2Yn cells to 
ligands previously shown to act at the hP2Yn receptor.
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As described in Chapter 2, the Ca2+ assay utilises a fluorescent dye, which 
fluoresces at a specific wavelength in the presence of free Ca2+, i.e. Ca2+, released 
from intracellular stores following receptor activation. This fluorescence change 
is measured by the fluorometric imaging plate reader (FLIPR). Unlike the cAMP 
assay, which can only be used to record total de novo cAMP production over a 
set period of time, quantification of the Ca2+ response is achieved by recording 
the increase in fluorescence at any given time point, as opposed to the 
accumulated fluorescence over the total time point, following the addition of 
ligand. The fluorescence difference between basal levels and the peak of an 
agonist induced fluorescence change is used to quantify the Ca2+ response.
3.4.1 Carbachol produces concentration-dependent Ca2+ mobilisation in 
1321N1 human astrocytoma cells.
The addition of carbachol to the 1321N1 cells is able to successfully mobilise 
Ca2+ from intracellular stores (Figure 3.9). The fluorescence responses (expressed 
in relative fluorescence units) of untransfected 1321N1 cells, generated by 
intracellular Ca2+ mobilisation in response to the addition of PBS (■) and various 
concentrations of carbachol (▼) ranging from InM to ImM (log values: -9 to -3) 
are shown in the figure. The data are the means + s.e.m. of one representative 
experiment taken from one of the three independent experiments performed.
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Figure 3.9
Concentration-response curve of carbachol on Ca2+ mobilisation in untransfected 
1321N1 human astrocytoma cells.
The Ca2+ response to PBS (■) and increasing concentrations of carbachol (Y )  was 
measured in cultured cells as described in the Materials and Methods. Results are 
expressed as fluorescence units. The data are the mean ± s.e.m of one representative 
experiment of 3 performed
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The carbachol-induced response, presented in Figure 3.9, is shown to be 
concentration-dependent, with increasing concentrations of carbachol able to 
mobilise increasing amounts of intracellular Ca2+. Non-linear regression analysis 
was performed on each carbachol response data set (as described in Chapter 2). 
From these analyses, concentration-response curves were plotted, and the ECso 
values for each of the three independent experiments were calculated - enabling 
the mean ECso value (+ s.e.m) of ll.OpM (log ECso = -4.96 + 0.12) to be 
determined. Figure 3.9 also reveals that the addition of the PBS vehicle-control is 
unable to elicit any substantial Ca2+ mobilisation. The minimal Ca2+ response 
exhibited by the addition of the PBS control confirms that the response levels 
achieved by the addition of the lower concentrations of carbachol (InM, lOnM 
and O.lpM; log values: -9 to -7) are at basal levels. The maximal Ca2+ response 
recorded is induced by carbachol at ImM final concentration and this 
concentration was used in subsequent experiments to normalise the Ca2+ 
responses of exogenous receptors.
3.4.2 hP2Yn is activated by nucleotides, producing a Ca2+ response.
ATP and BzATP, previously presented in sections 3.3.2 and 3.3.5 as agonists of 
the hP2Yn cAMP response, are also able to induce Ca2+ mobilisation in 1321N1 
cells stably expressing the hP2Yn receptor. Figure 3.10 shows the Ca2+ response 
of 1321Nl-hP2Yn cells following the addition of BzATP and ATP (each added to 
a final concentration of O.lmM). This single high-concentration ligand-screen 
reveals that FLIPR is a suitable means of quantifying Ca2+ mobilisation in 
response to P2Y receptor activation.
- 1 1 2 -
Chapter 3: Characterisation of the hP2Yn receptor.
4 0 —i --------------------
BzATP ATP
Figure 3.10
hP2Yn is activated by nucleotides, producing a Ca2+ response.
BzATP and ATP were screened for their ability to induce a Ca2+ response in 1321N1 
human astrocytoma cells stably expressing hP2Yu. Ca2+ mobilisation was measured 
after the addition of BzATP and ATP (each at 100 pM). Results are expressed as a 
percentage of the Ca2+ response to a supramaximal concentration of carbachol (ImM) 
and represent the mean ± s.e.m. of at least three different experiments, each performed 
in triplicate. ***, p < 0.005, compared with the control response, Student’s t-test. The 
data shown are control response deducted.
-113 -
Chapter 3: Characterisation of the hP2Yn receptor.
Similarly to the ligand-screening experiments undertaken with the cAMP assay 
(section 3.3.2), the results of these experiments offer no insight into the potencies 
of each ligand. However, the Ca2+ responses produced by BzATP (33.6 +_0.5 %) 
and ATP (33.9 + 0.8 %) reveal these agonists to be similarly efficacious at the 
concentrations tested. An examination of the ability of untransfected 1321N1- 
cells to induce Ca2+ mobilisation to P2Y agonists was not undertaken as it has 
been shown that there is no Ca2+ mobilisation in response to a wide range of 
P2Yn agonists, including ATP, p,y-MeATP and a,p-MeATP (Patel et al., 2001, 
A. Townsend-Nicholson, personal communication) and my own data (section
3.2) confirm the absence of P2Y receptor expression in these cells.
3.4.3 The time-course of Ca2+ responses in 1321N1 human astrocytoma cells 
stably expressing the hP2Yu receptor.
In order to better understand the profile of intracellular Ca2+ mobilisation in 
1321Nl-hP2Yn cells, the changes in fluorescence (expressed in fluorescence 
units) produced by concentrations of carbachol, BzATP and PBS were 
investigated. Figure 3.11 shows the Ca2+ responses produced by 1321Nl-hP2Yn 
cells before and after the addition of the ligands. Carbachol and BzATP, 
previously shown to be agonists of the muscarinic receptor (M3) (Stephan and 
Sastry, 1992) and hP2Yn receptor (section 3.3.2 and 3.4.2) respectively, were 
added to a final concentration of ImM (carbachol) and lOpM (BzATP). An equal 
volume of PBS was added into the control wells.
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Figure 3.11
Fluorescence response over time generated following the addition of PBS, BzATP 
and carbachol to 1321N1 human astrocytoma cells stably expressing the human 
P2Yn receptor.
The Ca2+ response to carbachol (ImM final concentration), BzATP (lOpM final 
concentration) and PBS was measured over time in cultured cells as described in the 
Materials and Methods. Ligands, or the PBS control, were added at t=10 seconds. 
Results are expressed as fluorescence units. The data are the mean from a single 
representative experiment. Error bars have been omitted to more clearly visualise the 
shape of the curves.
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The assay was run for 180 seconds with fluorescence measured once a second. 
For this reason the resulting 180 data points are shown with a connecting line 
only (large data point symbols and s.e.m. error bars are excluded to ease the 
visualisation of the connecting line). All of the ligands were added at the 10 
second time point in the assay. The real-time fluorescence response of the 
1321Nl-hP2Yn cells shown in Figure 3.11 is a representative experiment 
(undertaken in triplicate) taken from one of three independent experiments 
performed. It is the peak height of the response that is used to determine the 
magnitude of the Ca2+ response, and represents Ca2+ entry and Ca2+ mobilisation 
from intracellular stores.
Figure 3.11 demonstrates that intracellular Ca2+ is released following addition of 
both carbachol, which acts at the endogenous muscarinic receptor, and BzATP, 
which acts upon the transfected hP2Yn receptor. The maximum response 
generated by each of these agonists is achieved within the 180 second time 
course of the experiment. Carbachol, added at the supramaximal concentration 
of ImM, has created the largest fluorescence change of the two agonists tested, 
representing the largest Ca2+ release from intracellular stores. Following the 
rapid increase in the recorded fluorescence there is an equally rapid decrease, 
representing the release and subsequent use /  chelation of Ca2+ by intracellular 
proteins and reabsorbtion of Ca2+ into intracellular stores. This initial rapid 
decreasing gradient becomes less steep from approximately 40 seconds 
onwards, with a decrease of approximately 800FU (fluorescence units) observed 
every 10 seconds. This gradient eventually levels at approximately 150 seconds. 
The dual fluorescence peaks created following the addition of carbachol was 
seen in each of the three independent experiments performed and is typical of
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the carbachol response. This fluorescence pattern may represent the result of 
different downstream effector proteins activated by the muscarinic receptor 
(M3), or the release of Ca2+ from a more rapidly deployable store.
BzATP, an agonist of the hP2Yn receptor, is also able to generate a fluorescence 
response in the 1321N1 cells stably expressing hP2Yn. The response rapidly 
increases following agonists addition before degrading at a gradient comparable 
to that of carbachol. A similar decrease of approximately 800FU every ten 
seconds was observed, ultimately reaching a basal level at approximately 150 
seconds.
The low fluorescence response of PBS shown in Figure 3.11 confirms that the 
vehicle control is unable to produce any sizeable fluorescence response. It also 
shows that the flow rate and pressure of drug addition do not cause 
mechanosensory release of ATP in quantities sufficient for P2Yn receptor 
activation. The initial decrease in fluorescence shown in Figure 3.11 (at 
approximately 10 seconds), exhibited by all three of the ligands tested is likely a 
result of the addition of the ligand itself, which may dilute the fluorescent dye in 
the surrounding media loaded onto each well of the 96-well plate, causing a 
reduction in the background fluorescence. This drop in fluorescence is also seen 
in the PBS control.
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3.4.4 Concentration-response of nucleotides on Ca2+ mobilisation in 1321N1 
human astrocytoma cells stably expressing the hP2Yn receptor.
Following the identification of Ca2+ mobilisation in the 1321Nl-hP2Yn cell line 
in response to several nucleotide analogues, the potency of each of these ligands 
was investigated. Figure 3.12 shows the percentage Ca2+ response of 1321N1- 
hP2Yn cells following the addition of BzATP (▼) and ATP (♦). These agonists 
were applied at varying concentrations (ranging from InM to ImM; log values: - 
8 to -4). These agonists are able to successfully induce Ca2+ mobilisation in a 
concentration-dependent manner.
The concentration-response curves shown in Figure 3.12 were calculated and 
plotted following non-linear regression analysis of the data. Similar to the cAMP 
concentration-response experiments, Figure 3.12 shows that a maximal response 
is achieved for the ligands over approximately 2 log units of agonist 
concentration. The non-linear regression analysis enables the calculation of ECso 
values for each of the agonists (BzATP: 5.5pM, log ECso = -5.26 + 0.10; ATP: 
8.5pM, log ECso = -5.07 + 0.03), revealing the agonists to be similarly potent:
ATP « BzATP
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Figure 3.12
Concentration-response curves of Ca2+ mobilisation following nucleotide activation 
of 1321N1 human astrocytoma cells stably expressing the hP2Yn receptor.
The Ca2+ response to increasing concentrations of ATP (♦) and BzATP (▼) was 
measured in 1321Nl-hP2Yn. Results are expressed as a percentage of the Ca2+ response 
to a supramaximal concentration of carbachol (ImM). The data are the mean ± s.e.m. of 
one representative experiment of three performed.
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3.4.5 Various antagonists inhibit Ca2+ mobilisation induced by the activated 
hP2Yn receptor.
Following the identification of Reactive Red as a novel antagonist of hP2Yn- 
mediated cAMP responses in section 3.3.6, the ability of the Reactive Red and 
other P2Y antagonists to inhibit Ca2+ responses induced by the agonist-activated 
hP2Yn receptor was investigated. In addition to data analysis, I was also 
involved in the set-up of the antagonist experiments presented in the following 
sections and created the antagonist drug plates for use in the FLIPR machine.
The ability of Acid Blue, Phenol Red, Reactive Red and Suramin to reduce 
BzATP-induced Ca2+ mobilisation in the 1321Nl-hP2Yn cells was examined. 
BzATP was used as a reference agonist in these experiments due to its ability to 
induce Ca2+ mobilisation in the 1321Nl-hP2Yn cells, and its previous use in the 
cAMP antagonists experiments (presented in sections 3.3.6 and 3.3.7). Figure 
3.13 shows the percentage inhibition of the Ca2+ response generated by BzATP 
(added to a final concentration of lOpM) in 1321Nl-hP2Yn cells, following pre­
incubation with Acid Blue, Phenol Red, Reactive Red and Suramin. Owing to 
the solubility of Acid Blue, the compound was used at a final concentration of 
lOpM, whereas Phenol Red, Reactive Red and Suramin were all added to final 
concentration of O.lmM.
Several of the compounds were able to inhibit the hP2Yn functional response. 
Suramin (78.1 + 1.2 % inhibition) was found to give the greatest inhibition 
followed by Reactive Red (42.8 + 3.9%). Statistical analysis has shown the 
antagonist-induced percentage Ca2+ inhibition generated by Phenol Red and
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Figure 3.13
Antagonists inhibit Ca2+ mobilisation produced by BzATP activation of hP2Yn.
Several ligands were screened for their ability to inhibit Ca2+ mobilisation generated by 
BzATP (lOpM) activation o f hP2Yn. Ca2+ mobilisation was measured after the addition 
of BzATP, following pre-incubation o f 1321Nl-hP2Yn cells with: Phenol Red, Reactive 
Red, Suramin (each at O.lmM final concentration) and Acid Blue (added to lOpM final 
concentration). Results are expressed as a percentage inhibition o f the Ca2+ mobilisation 
produced by the addition o f the BzATP. Results are the mean + s.e.m. of three different 
experiments each performed in triplicate. **, p < 0.01; *, p < 0.05; when compared with 
control, by ANOVA with Tukey’s post test.
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Acid Blue to be indistinguishable from control responses used in the 
experiments (p value > 0.05 by one-way ANOVA followed by Tukey's post­
test), revealing that, at the concentrations used, these two ligands do not act as 
antagonists at the human P2Yn receptor.
3.4.6 Concentration-inhibition of antagonists on Ca2+ mobilisation induced 
by the activated hP2Yu receptor.
In order to determine the potency of the antagonists identified in section 3.4.5, 
the concentration-response of different antagonists was determined. Phenol Red 
(•), Reactive Red ( v )  and Suramin ( a ) were used at concentrations ranging from 
InM to ImM (log values: -9 to -3). Due to the solubility of Acid Blue (o), 
concentrations ranging from InM to 50pM were used (log values: -9 to -4.3). The 
Ca2+ response of the BzATP-activated hP2Yn receptor (BzATP, used at a final 
concentration of lOpM) in the presence and absence of the different 
concentrations of antagonists was examined.
Suramin and Reactive Red were able to affect the BzATP-mediated hP2Yn Ca2+ 
response in a concentration-dependent manner (Figure 3.14). Suramin ( a ) was 
the most potent antagonist of the ligands tested, followed by Reactive Red ( v ) .  
The figure also shows Phenol Red (•) and Acid Blue (o) do not antagonise the 
BzATP induced Ca2+ response within the range of concentrations tested. Non­
linear regression analysis was performed for each concentration-response 
experiment. The curves generated by the analysis are shown fitted to Suramin
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Figure 3.14
Inhibition curves for antagonists on Ca2+ mobilisation produced by BzATP, in 
1321N1 human astrocytoma cells stably expressing the hP2Yn receptor.
The Ca2+ response to lOpM BzATP in 1321Nl-hP2Yn cells was measured, following 
pre-incubation with increasing concentrations of Suramin ( a ),  Reactive Red ( v ) ,  Phenol 
Red (•) and Acid Blue (o ) .  Results are expressed as a percentage of the Ca2+ response to 
a supramaximal concentration of carbachol (ImM). The data are the mean ± s.e.m. of a 
representative experiment.
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and Reactive Red, which gave IC50 values of 28.3 + 9.43 pM (Suramin) and 270 + 
98.4 pM (Reactive Red). Phenol Red and Acid Blue were unable to act as 
antagonists and these data are, therefore, shown with connecting lines drawn 
between the data points.
-124-
Chapter 3: Characterisation of the hP2Yn receptor.
Cyclic AMP accumulation Ca2+ mobilisation
Nucleotide EC50(fiM) LogEC50 EC5o(/jM) Log EC50
BzATP 0.9 -6.05 ± 0.06 5.5 -5.26 ± 0.10
ATP 5.7 -5.24 ± 0.07 8.5 -5.07 ± 0.03
a,(3-MeATP 23.0 -4.64 ± 0.07
P,y-MeATP 24.4 -4.61 + 0.14
ADP NDa + ND
UTP ND + ND
Table 3.1
EC50 values of nucleotides and nucleotide analogues recorded with the cAMP 
accumulation and Ca2+ mobilisation assays in 1321Nl-hP2Yn cells.
EC50 values were calculated after non-linear regression analysis of the agonist 
concentration-response experiments. Results are expressed as the mean EC50 value (in 
pM), and log EC50 ± s.e.m., of three to five independent experiments - each performed in 
triplicate. aND, not determined, indicates that the responses generated could not be used 
to calculate an EC50 value.
Ca2+ mobilisation Cyclic AMP accumulation
antagonist IC50 (dM) Log IC50 ICSo(dM) LogIC50
Suramin 28.3 -4.55 ± 0.15
Reactive Red 270.0 -3.57 ± 0.17 1.7 -5.76 ± 0.07
Phenol Red NDa ± ND
Acid Blue ND ± ND
Table 3.2
Antagonists IC50 values recorded with the cAMP accumulation and Ca2+ 
mobilisation assays in 1321Nl-hP2Yn cells.
IC50 values were calculated after non-linear regression analysis of the antagonist 
concentration-response experiments. Results are expressed as the mean IC50 value (in 
pM), and log IC50 ± s.e.m., of three independent experiments, each performed in 
triplicate. aND, not determined, indicates that the responses generated could not be used 
to calculate an IC50 value.
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3.5 Summary
RT-PCR analysis on the cell lines used throughout the experiments presented in 
this chapter revealed the absence of RNA encoding various P2Y receptors 
(hP2Yi, hP2Y2, hP2Y4, hP2Y6/ hP2Yn, hP2Yi2) in the untransfected 1321N1 cells, 
and the presence of RNA encoding the hP2Yn receptor in the 1321Nl-hP2Yn 
cells.
Following the creation of the stable cell lines the ability of the (32-adrenoceptor, 
endogenous to 1321N1 cells, to produce cAMP following incubation with 
isoproterenol was examined. Concentration-response experiments were 
undertaken with untransfected 1321N1 cells to investigate the conditions 
required for the use of the (32-adrenoceptor as a cAMP-producing endogenous 
standard. The mean EC50 value, obtained for isoproterenol (61.4nM, log EC50 = - 
7.21 ± 0.05), revealed the cAMP assay could accurately record de novo cAMP 
production in the 1321N1 cells and that cAMP response induced by 10pM 
isoproterenol was appropriate for use as the endogenous standard to which all 
exogenous receptor cAMP responses would be normalised.
The development of the use of an endogenous response was followed by an 
investigation into the ability of 1321Nl-hP2Yn cells to produce a cAMP 
response upon ligand activation. The time-course experiments confirmed 
maximal cAMP accumulation was achieved within the first ten minutes of 
incubation with ligand and this incubation period was used in all subsequent 
experiments. The ability of the agonist stimulated 1321Nl-hP2Yn cells to
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promote cAMP accumulation (and the inability of the untransfected cells to 
induce a similar response) revealed that functional hP2Yn receptors were 
expressed in the cell line.
High-concentration agonist-screening experiments on 1321Nl-hP2Yn cells 
confirmed the ability of the hP2Yn to act as a nucleotide receptor capable of 
inducing intracellular cAMP accumulation in response to BzATP, ATP, py- 
MeATP and aP-MeATP. The activation of adenylyl cyclase by ATP in the initial 
agonist screening experiments, and the absence of any cAMP response in the 
PBS control or UTP and ADP experiments conforms to previous 
pharmacological studies undertaken on the hP2Yn receptor (Communi et al. 
1997), where preferential activation by lOOpM ATP and minimal responses at 
lOOpM ADP or lOOpM UTP are reported. The subsequent concentration- 
response experiments, undertaken with the 1321Nl-hP2Yn cells, revealed de 
novo cAMP accumulation to be agonist-concentration dependent with the 
following cAMP-response agonist rank order of potency for the hP2Yn receptor:
BzATP > ATP > a,p-meATP = p,y-meATP
The antagonist study, which investigated the inhibition of agonist-induced 
cAMP production in the 1321Nl-hP2Yn cells, revealed that Reactive Red, a 
previously unknown hP2Yn receptor antagonist, was able to inhibit cAMP 
accumulation in a concentration-dependent manner.
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Ca2+ mobilisation was examined in the 1321N1 cells and the ability of the 
endogenous muscarinic M3 receptor to generate an intracellular Ca2+ response 
upon stimulation with carbachol was investigated. Carbachol was found to 
produce a maximal Ca2+ response at a final concentration of ImM (log value -3) 
and was used at this concentration as the endogenous standard in all 
subsequent experiments. The EC50 value calculated for carbachol (ll.OpM, log 
ECso = -4.96 + 0 .1 2 ), is similar to that obtained previously in 1321N1 cells 
(Stephan and Sastry, 1992), however, these EC50 values are not directly 
comparable, as the previous study investigated IP accumulation and not Ca2+ 
mobilisation. The present experiments therefore represent a novel investigation 
into carbachol-induced Ca2+ mobilisation in 1321N1 cells.
Following the development of the endogenous standard for Ca2+ responses, the 
ability of the 1321Nl-hP2Yn cells to induce Ca2+ mobilisation in response to 
known P2Y agonists was examined. The high-concentration agonist screening 
experiments and subsequent concentration-response experiments revealed ATP 
and BzATP to be similarly efficacious and potent. BzATP-evoked Ca2+ responses 
have not been described previously and represent a novel characterisation of the 
human P2Yn receptor. EC50 values for the P2Yn-mediated Ca2+-response give 
the following rank order of potency: BzATP = ATP. In a similar manner to the 
time-course investigations undertaken with the cAMP assay, an examination of 
Ca2+ mobilisation over time, using carbachol, BzATP and PBS revealed the 
maximum fluorescence response was generated within the assay's time frame.
Following the investigation of agonist-induced Ca2+ responses, the ability of 
various ligands to antagonise hP2Yn-mediated Ca2+ mobilisation was examined.
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In addition to Suramin, a previously known non-selective antagonist of hP2Yn 
receptor, Reactive Red was found to inhibit Ca2+ mobilisation in a concentration- 
dependent manner. This antagonist had not previously been characterised at 
P2Yn receptors and this is a novel finding.
This chapter has shown that the 1321Nl-hP2Yn cells express functional hP2Yn 
receptors, confirmed by the activation of the dual signalling pathways 
previously reported for the receptor. The similarities and differences between 
the agonist and antagonist responses presented in this chapter with previously 
published hP2Yn and cP2Yn receptor data are explored further in Chapter 6.
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Agonist responses of the XlP2Yn receptor.
4.1 Introduction
As described in Chapter 1, when stably expressed in 1321N1 human 
astrocytoma and CHO-K1 cells, the human P2Yn receptor has been shown to be 
a selective purinoceptor, activated by various nucleotides and nucleotide 
analogues (Communi et al., 1997 & 2001; Qi et al., 2001a). As outlined in Chapter 
1, a large proportion of the receptors termed valid members of the P2Y receptor 
family have been shown to stimulate PKC and generate an intracellular Ca2+ 
second messenger response. A smaller group of P2Y receptors has been shown 
to inhibit adenylyl cyclase, decreasing cAMP production.
Previous studies on the P2Yn receptor orthologues, both human (hP2Yn) and 
canine (cP2Yn), have shown this receptor subtype to hold a unique position 
within the P2Y purinoceptor family, as it possesses the capacity, upon
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activation, to generate second messenger responses typical of phospholipase C 
and adenylyl cyclase activation, resulting in an increase in de novo cyclic AMP 
production and intracellular Ca2+ mobilisation (Communi et al., 1997; Zambon 
et al., 2001). The work presented in this chapter endeavours to identify whether 
the Xenopus orthologue of the human P2Yn receptor, XlP2Yn, can be justifiably 
termed a valid member of the P2Y purinoceptor family. That is, can it generate a 
second messenger response to extracellular nucleotides. This chapter also 
examines whether XlP2Yn, like the previously characterised hP2Yn and cP2Yn 
orthologues, possesses the unique ability within the P2Y receptor family of 
stimulating phospholipase C (PLC) and adenylyl cyclase (AC) responses upon 
receptor activation. In order to investigate the dual-pathway signalling capacity 
of XlP2Yn, the cAMP accumulation and Ca2+ mobilisation assays (as seen in 
Chapter 3) have been employed to evaluate the second messenger production of 
the novel Xenopus laevis receptor in response to various nucleotide ligands. 
Responses typical of PLC activation will be assessed through the measurement 
of intracellular Ca2+ mobilisation, whilst the activity of AC will be assessed 
through the measurement of de novo cAMP production.
As outlined above, to date, only human and canine orthologues of the P2Yn 
receptor have been cloned and characterised. Consequently, these experiments 
represent the first characterisation of a non-mammalian orthologue of the P2Yn 
receptor. This study provides a unique opportunity to learn more about the 
pharmacological profile of this particular P2Y receptor subtype.
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4.2 Ca2+ mobilisation in 1321N1 human astrocytoma cells stably 
expressing the XlP2Yu receptor.
In order to examine the ability of XlP2Yn to generate a second messenger 
response, the Ca2+ assay was employed to quantify intracellular calcium release 
from 1321N1 cells stably expressing the XlP2Yn receptor. The 1321N1-X1P2Yii 
cells were incubated with nucleotide analogues shown to have activity at 
mammalian P2Yn receptors and the calcium response was determined, as 
described in Chapter 2. The ligands selected for this characterisation were tested 
previously in pharmacological characterisations of the human and canine P2Yn 
orthologues (Communi et al., 1999; Qi et al., 2001a; Zambon et al., 2001). These 
studies, and my own pharmacological characterisation of the hP2Yu receptor, 
shown in Chapter 3, reveal that the most potent agonists are able to generate 
substantial second messenger responses at a final concentration of lOOpM, with 
responses able to be elicited by partial agonists at ImM. Therefore, UTP, ATP, 
2MeSATP, 2MeSADP and BzATP were used in these initial high-concentration 
ligand screening experiments at a final concentration of lOOpM. As outlined in 
Chapter 1, these previous pharmacological characterisations of the human P2Yn 
receptor have shown ADP to be a weak agonist, generating small second 
messenger responses in both PLC and AC activated pathways, in response to 
high concentrations of ligand. Given this, and given the sequence similarity 
between die human and Xenopus P2Yn receptors, ADP was used in these initial 
high-concentration ligand screening experiments at a final concentration of 
ImM.
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4.2.1 XlP2Yu is activated by nucleotides, producing a Ca2+ response.
Figure 4.1 shows the percentage Ca2+ response of 1321N1 human astrocytoma 
cells stably expressing XlP2Yn following addition of: UTP, ATP, 2MeSATP, 
2MeSADP, BzATP (all added to a final concentration of lOpM) and ADP (added 
to a final concentration of ImM). The results are normalised to the Ca2+ response 
produced after the addition of ImM carbachol, and are expressed as a 
percentage of this value.
The 1321N1-X1P2Yii cell line was able to produce a second messenger signal in 
response to extracellular nucleotides and nucleotide analogues (Figure 4.1), thus 
identifying XlP2Yn as a nucleotide receptor capable of causing intracellular Ca2+ 
mobilisation upon the addition of extracellular ligands. The normalised Ca2+ 
responses produced by ATP (7.9 + 0.71 %), 2MeSADP (17.2 + 1.13 %), 2MeSATP 
(12.2 + 4.88 %) and BzATP (20.4 ± 2.94 %) are all significantly different from the 
Ca2+ mobilisation produced by the PBS vehicle control (p value < 0.05 by 
Student's two-tailed paired f-test), whereas the Ca2+ responses generated by 
incubation with UTP (1.3 + 1.03 %) and ADP (3.21 + 0.65%) are not significantly 
statistically different from the negative control.
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Figure 4.1
XlP2Yn is activated by nucleotides, producing a Ca2+ response.
Several nucleotide analogues were screened for their ability to induce a Ca2+ response in 
1321N1 human astrocytoma cells stably expressing XlP2Yn. Ca2+ mobilisation was 
measured after the addition of: UTP, ATP, 2MeSATP, 2MeSADP, BzATP (each at 100 
pM) and ImM ADP. Results are expressed as a percentage o f the Ca2+ response to a 
supramaximal concentration o f carbachol (ImM) and represent the mean ± s.e.m. o f at 
least three different experiments, each performed in triplicate. The data shown are 
control response deducted.
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4.2.2 Concentration-response of nucleotides on Ca2+ mobilisation in 
1321N1- XlP2Yn cells.
Following the initial high-concentration ligand screen of 1321Nl-XlP2Yn cells, 
the Ca2+ assay was employed once again to record the mobilisation of 
intracellular Ca2+, in response to a range of ligand concentrations. 1321N1- 
XlP2Yn cells were incubated with varying concentrations of the same 
nucleotides and nucleotide analogues tested in the ligand screen (ADP, UTP, 
ATP, 2MeSADP, 2MeSADP and BzATP) and the Ca2+ response was measured. 
The concentrations of the ligands tested ranged from O.OlpM to lOOpM. 
Previously published agonist pharmacological characterisations of the P2Y 
family (King & Townsend-Nicholson, 2003; Lazarowski et al., 2003) and my own 
P2Yn characterisation (Chapter 3) have shown that the most potent agonists are 
able to generate their maximal cAMP response within this concentration range. 
This holds true for hP2Yn (Communi et al., 2001; Qi et al., 2001a) and cP2Yn 
(Zambon et al., 2001).
Figure 4.2 shows the concentration-responses of Ca2+ mobilisation to: ADP, 
UTP, ATP, 2MeSATP, 2MeSADP and BzATP. The data displayed in Figure 4.2 
are representative experiments taken from one of the 3 independent experiment 
performed for each ligand. The curves generated by non-linear regression 
analysis are shown fitted to ATP (♦), 2MeSATP, (■) 2MeSADP (▲) and BzATP 
(▼). Curves have not been fitted to the UTP (□) and ADP ( a )  representative 
experiments, which are shown with lines connecting the individual data points.
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Figure 4.2
Concentration-response curves of Ca2+ mobilisation following nucleotide activation 
of 1321N1 human astrocytoma cells stably expressing the XlP2Yn receptor.
The Ca2+ response to increasing concentrations of nucleotides was measured in cultured 
cells as described in the Materials and Methods: UTP (□), ADP ( a ) ,  ATP (♦), 
2MeSATP (■), 2MeSADP ( A )  and BzATP (Y).  Results are expressed as a percentage 
of the Ca2+ response to a supramaximal concentration of carbachol (ImM). The data are 
the mean + s.e.m. of one representative experiment of three performed.
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Each of the ligands tested were successful in eliciting a Ca2+ response in a 
concentration-dependent manner, with increasing concentrations of ligands able 
to mobilise increasing amounts of Ca2+. Consistent with previous P2Y receptor 
characterisations (Marteau et al., 2003; Communi et al., 2001), Figure 4.2 shows 
that the maximal Ca2+ response is achieved over approximately 2 to 2.5 log units 
of ligand concentration. Curves are not fitted to the Ca2+ responses generated by 
ADP and UTP, because a maximal response is not reached in the range of 
ligands tested.
The calculated EC50 values for ATP (2.54 + 1.06 pM), 2MeSATP (1.96 + 0.92 pM), 
2MeSADP (7.49 + 1.52 pM) and BzATP (42.51 + 11.58 pM) (shown in Table 4.1), 
allowing the following Ca2+ response agonist potency order to be formed for the 
XlP2Yn receptor:
ATP * 2MeSATP > 2MeSADP > BzATP »  ADP
4.3 The effect of nucleotides on cAMP accumulation in 1321N1 human 
astrocytoma cells stably expressing the XlP2Yn receptor.
Having shown in section 4.2, that 1321N1-X1P2Yii cells were able to produce an 
intracellular Ca2+ response following treatment with nucleotides, the ability of 
these cells to generate a cAMP response was investigated. 1321N1 cells stably 
expressing the XlP2Yn receptor were incubated with the nucleotides and 
nucleotide analogues (ADP, UTP, ATP, 2MeSADP, 2MeSADP and BzATP) used
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in the characterisation of the 1321Nl-XlP2Yn Ca2+ response (Chapter 4.2.1 and
4.2.2) and de novo cAMP production was quantified.
4.3.1 XlP2Yn is activated by nucleotides, producing a cAMP response.
Figure 4.3 shows the percentage cAMP response of 1321N1 human astrocytoma 
cells stably expressing XlP2Yn following ten-minute incubations with: UTP, 
ATP, 2MeSATP, 2MeSADP, BzATP (each added to a final concentration of 
lOpM) and ADP (added to a final concentration of ImM). The results are 
expressed as a percentage of the response produced after a ten-minute 
incubation in the presence of lOpM isoproterenol.
The normalised cAMP responses produced by UTP (5.4 + 2.23 %), ATP (10.1 + 
1.48 %), 2MeSADP (8.4 + 1.22 %), 2MeSATP (13.0 + 1.02 %) and BzATP (12.0 + 
2.90 %) are all significantly different from the cAMP accumulation produced by 
the PBS/negative vehicle control, (*, p < 0.05, by ANOVA with Tukey's post 
test), whereas the minimal cAMP response generated by incubation with ADP 
(0.2 + 0.09 %) exhibits no statistically significant difference from the PBS control.
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Figure 4.3
XlP2Yn is activated by nucleotides, producing a cAMP response.
Nucleotide analogues were screened for their ability to induce a cAMP response in 
132IN 1 human astrocytoma cells stably expressing XlP2Yu. De novo cAMP production 
was determined after incubation with lOOpM of each of: UTP, ATP, 2MeSATP, 
2MeSADP, BzATP and ImM ADP. Results are expressed as a percentage o f the cAMP 
response to a supramaximal concentration of isoproterenol (lOpM), and represent the 
mean + s.e.m. o f three different experiments, each performed in triplicate. *, p < 0.05, 
by ANOVA with Tukey’s post test. The data shown are control response deducted.
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These data show that, in response to the addition of extracellular nucleotides, 
the 1321Nl-XlP2Yn cell line is able to produce a response typical of adenylyl 
cyclase activation, identifying XlP2Yn as a nucleotide receptor capable of 
coupling to AC and promoting cAMP formation. Figure 4.3 also shows that, in 
line with previously published data (Qi et al., 2001a), the ability of the 2MeSADP 
nucleotide analogue to generate a cAMP response is higher than that generated 
by ADP. Although no further inferences or detailed analysis of the potency of 
the ligands can be deduced from these single concentration experiments, the 
inability of ADP to generate a second messenger response at a final 
concentration of ImM strongly suggests the XlP2Yn receptor is an ATP - 
preferring nucleotide receptor.
4.3.2 Nucleotides produce a concentration-dependent cAMP response in 
1321Nl-XlP2Yn cells.
In order to further examine the signalling ability of the XlP2Yn receptor, the 
cAMP assay was employed to record the accumulation of de novo cAMP 
production in 1321N1-X1P2Yii cells in response to a range of ligand 
concentrations. The cells were incubated with the same nucleotides and 
nucleotide analogues used in the ligand screen of Section 4.3.1 (ADP, UTP, ATP, 
2MeSADP, 2MeSADP and BzATP) and cAMP accumulation was measured.
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Figure 4.4
Concentration-response curves of the cAMP response following nucleotide 
activation of 132INI human astrocytoma cells stably expressing the XlP2Yu 
receptor.
The cAMP response to increasing concentrations of nucleotides was measured following 
incubation with: UTP (□), ATP (♦), 2MeSATP (■), 2MeSADP (A), BzATP (▼) and 
ADP ( a ).  Results are expressed as a percentage of the cAMP response to a 
supramaximal concentration of isoproterenol (lOpM). The data are the mean ± s.e.m. of 
one representative experiment of three to five performed for each ligand.
141
Chapter 4: Agonist responses ot the Xlp2y 11 receptor.
In order to replicate the range of concentrations used in the Ca2+ concentration- 
response experiments (Section 4.2.2), the concentrations of the ligands tested 
ranged from O.OlpM to lOOpM (log values: -8 to -4).
Figure 4.4 shows the percentage cAMP response of 1321Nl-XlP2Yn cells 
following ten-minute incubation with increasing concentrations of: ADP, UTP, 
ATP, 2MeSATP, 2MeSADP, BzATP. The results are normalised to the response 
obtained after a ten-minute incubation in the presence of lOpM isoproterenol. 
The data displayed are representative experiments taken from one of the three 
to five independent experiment performed for each ligand. Non-linear 
regression analysis was performed for each set of ligand data. The curves have 
been fitted to the results for ATP (♦), 2MeSATP (■), 2MeSADP (A), and BzATP 
(▼) in Figure 4.4. Curves have not been fitted to the UTP (□) and ADP ( a )  
experiments, which are shown with lines connecting the individual data points.
Although a curve may be fitted to the representative UTP experiment shown in 
Figure 4.4, the other independent UTP experiments exhibited large fluctuations 
in the percentage cAMP response generated across all concentrations (data not 
shown). The experiment shown in Figure 4.4 has a relatively high cAMP 
response at the lOOpM (log value -4) ligand concentration, which supports the 
previously recorded UTP response in the high-concentration ligand screen 
(Figure 4.3) - found to be significantly different from the PBS control. Curves are 
not fitted to the cAMP responses generated by ADP, because a maximal 
response is not reached in the range of ligands tested. Each of the ligands tested 
elicited a concentration-dependent cAMP response. Consistent with previous
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Ca mobilisation
Nucleotide EC so (nM) Log EC so
ATP 2.5 -5.60 ± 0.19
2MeSATP 2.0 -5.71 ± 0.22
ADP NDa ± ND
2MeSADP 7.5 -5.13 ± 0.08
BzATP 42.5 -4.37 ± 0.12
UTP ND ± ND
Table 4.1
EC$o values of nucleotides able to elicit a Ca2+ response in 1321N1 human 
astrocytoma cells stably expressing the XlP2Yu receptor.
EC50 values were calculated following non-linear regression analysis of the Ca2+ 
concentration-response data obtained for each ligand. Results are expressed as the mean 
EC50 value (in fiM), and log EC50 ± s.e.m., of three to four independent experiments, 
each performed in triplicate. aND, not determined, indicates that an EC50 value could not 
be calculated.
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characterisations (Marteau et al., 2003; Communi et al., 2001) and my own 
pharmacological characterisation in section 4.2.2, the concentration range of 
ligand required to elicit a maximal cAMP response for each of the concentration- 
response curves is achieved over approximately 2 to 2.5 log units.
As with the Ca2+ responses experiments, incubation of 1321Nl-XlP2Yn cells 
with nucleotides produces concentration-dependent cAMP responses. The 
calculated EC50 values for ATP (l.OfiM, log EC50 = -6.02 + 0.01) 2MeSATP 
(1.7pM, log EC50 = -5.76 + 0.11) 2MeSADP (12.6pM, log EC50 = -4.90 + 0.10) and 
BzATP (15.6pM, log EC50 = -4.81 + 0.12) (also shown in Table 4.2) can be used to 
create a cAMP response agonist potency order for the XlP2Yn receptor:
ATP > 2MeSATP > 2MeSADP > BzATP »  ADP
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Cyclic AMP accumulation 
Nucleotide EC50 (fM) Log ECS0
ATP 1.0 -6.02 + 0.01
2MeSATP 1.7 -5.76 + 0.11
ADP NDa + ND
2MeSADP 12.6 -4.90 + 0.10
BzATP 15.6 -4.81 + 0.12
UTP ND + ND
Table 4.2
ECso values of nucleotides able to elicit cAMP accumulation in 1321N1 human 
astrocytoma cells stably expressing the XlP2Yn receptor.
EC50 values were calculated following non-linear regression analysis of the cAMP 
concentration-response data obtained for each ligand. Results are expressed as the mean 
+ s.e.m. of three to four independent experiments, each performed in triplicate. 8ND, not 
determined, indicates that an EC50 value could not be calculated.
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4.3 Summary
The Ca2+ mobilisation assay was initially employed to characterise the 
intracellular second messenger response generated by the XlP2Yn receptor, in 
response to high concentrations of: UTP, ATP, 2MeSATP, 2MeSADP, BzATP 
(each at lOOpM final concentration) and ADP (at a final concentration of ImM). 
The ligands were chosen and used at concentrations shown previously to elicit 
an intracellular Ca2+ response at P2Yn receptors (Qi et al., 2001a; Zambon et al. 
2001). The initial high-concentration ligand screening experiments undertaken 
in 1321Nl-XlP2Yn cells revealed that several of these ligands were able to 
generate a second messenger signalling response in the form of Ca2+ release 
from intracellular stores. Following this initial screening, concentration-response 
curves were generated, providing a more detailed pharmacological profile of 
the receptor. These investigations revealed the activated XlP2Yn receptor was 
able to induce concentration dependent Ca2+ responses when stably expressed 
in the 1321N1 cells with a rank order of potency equal to:
ATP « 2MeSATP > 2MeSADP > BzATP »  ADP
The ability of the receptor to activate the cAMP second messenger signalling 
pathway was also investigated. The initial ligand screening experiments 
revealed that, in addition to Ca2+ mobilisation, the activated Xenopus receptor 
could also generate cAMP in response to the same ligands used in the Ca2+ 
mobilisation experiments. Subsequent agonist concentration-response studies 
revealed the cAMP accumulation to be concentration-dependent. Analysis of the 
concentration-response curves allowed the determination of the EC50 values,
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enabling the construction of a cAMP response agonist potency order for the 
XlP2Yn receptor:
ATP > 2MeSATP > 2MeSADP > BzATP »  ADP
Both the cAMP and Ca2+ second messenger responses reveal ATP and 2MeSATP 
to be more efficacious than ADP and 2MeSADP. The similarities between the 
agonist efficacies and potencies of the XlP2Yn receptor responses in the different 
signalling pathways (and a comparison with previously published P2Yn data) 
are shown in Chapter 6.
When expressed in human astrocytoma 1321N1 cells, the XlP2Yn receptor can 
be activated by nucleotides and nucleotide analogues, to generate two different 
second messenger responses - mobilisation of Ca2+ from intracellular stores and 
an increase in the production of cAMP. The data in this chapter represent the 
first pharmacological characterisation of a non-mammalian P2Yn receptor 
orthologue, defined as such by (1) its response to nucleotides and (2) its ability 
to activate dual signalling pathways.
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Antagonism of the XlP2Yn receptor.
5.1 Introduction
As outlined in Chapter 1, relatively few selective antagonists exist compared to 
the range of P2Y agonists. The use of selective agonists, and the complex activity 
profiles generated by multiple non-selective antagonists, can be used for the 
pharmacological profiling and the subsequent discrimination between P2Y 
purinoceptor family subtypes.
As described in Chapter 4, when stably expressed in 1321N1 human 
astrocytoma cells, the XlP2Yn receptor has been shown to be a selective 
purinoceptor, capable of generating both cAMP and Ca2+ second messenger 
signals in response to the presence of various nucleotides and nucleotide 
analogues. This chapter seeks to examine the ability of known P2Y antagonists 
to inhibit XlP2Yn-mediated second messenger responses. The cAMP
148
Chapter 5: Antagonism of the Xlp2y 11 receptor.
accumulation and Ca2+ mobilisation assays have been employed to identify the 
extent to which XlP2Yn responses are able to be inhibited by known P2Y 
receptor antagonists.
As outlined in Chapters 1 and 4, to date, only human and canine orthologues of 
the P2Yu receptor have been cloned and a pharmacological characterisation 
with agonists and antagonists performed. Therefore, the work described in this 
chapter represents the first antagonist characterisation of a non-mammalian 
P2Yn receptor orthologue. Previous studies on the P2Yn receptor, both human 
(hP2Yn) and canine (cP2Yn), have shown these receptor orthologues to possess 
very similar antagonist sensitivities (Zambon et al., 2001; Qi et al., 2001b). The 
work in this chapter will therefore endeavour to identify whether the XlP2Yn 
receptor possess a similar antagonist profile to its human and canine 
counterparts.
5.2 The effect of antagonists on cAMP accumulation in 1321Nl-XlP2Yii 
cells.
In order to assess the ability of several ligands to act as antagonists, the cAMP 
assay was employed to record the accumulation of de novo cAMP production in 
1321N1 cells stably expressing the XlP2Yn receptor. The ability of 2MeSATP (a 
ligand previously shown in chapter 4 to act as an agonist of the XlP2Yn 
receptor) to generate cAMP was recorded in the presence of these ligands.
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The ability of an antagonist to inhibit a second messenger response can be 
assessed with a greater degree of accuracy and confidence when an efficacious 
agonist is used (allowing clear visualisation of the decrease in agonist response). 
Correspondingly, the ability of an antagonist to shift an agonist induced 
concentration-response curve is easier to visualise when used in conjunction 
with a potent activator of the second messenger response. The ability of 
2MeSATP to potently and efficaciously activate the XlP2Yn receptor makes this 
agonist an ideal candidate to study the ability of antagonists to inhibit XlP2Yn- 
mediated cAMP responses.
The ligands selected for this pharmacological study were used in previous 
antagonist characterisations of the purinoceptor family (as outlined in Chapter 
1) and in characterisations of the human and canine P2Yn receptors (Communi 
et al., 1999; Qi et al., 2001b; Zambon et al., 2001)(Chapter 3). Potent antagonists of 
the hP2Yn and cP2Yn receptors have been shown, in previous characterisations 
(Suramin and Reactive Blue 2) (Qi et al., 2001b) and my own antagonist studies 
(Suramin and Reactive Red) (Chapter 3), to generate substantial second 
messenger inhibition when used at concentrations of approximately lOOpM, 
whereas less effective antagonists have been shown to elicit a smaller agonist 
inhibitions when used at much higher concentrations. Taking this into account, 
high concentrations (ImM final concentrations) were used in the initial 
experiments in order to screen the ligands for any potential antagonist ability.
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5.2.1 Antagonists inhibit cAMP accumulation induced by agonist activation 
of the XlP2Yu receptor.
1321N1 human astrocytoma cells stably expressing the XlP2Yn were pre­
incubated with several different P2 receptor antagonists. PPADS, Suramin, 
Phenol Red, Reactive Blue and Reactive Red were each used initially at ImM 
final concentration, whilst the highest concentration of Acid Blue able to be used 
was lOpM (due to the solubility of this compound). Following antagonist 
preincubation, the ability of 2MeSATP (at a final concentration of lOpM) to 
generate de novo cAMP production was determined. By comparing the agonist- 
induced response, in the presence of antagonist, to that of the agonist alone, the 
ability of the ligands to inhibit the second messenger response was determined. 
Previous experiments, in Chapter 4, have shown that lOpM 2MeSATP induces a 
cAMP response equivalent to approximately 12 percent of the response 
produced by lOpM isoproterenol.
Figure 5.1 shows the percentage inhibition of the 2MeSATP induced cAMP 
response following pre-incubation with PPADS, Suramin, Phenol Red, Reactive 
Blue, Reactive Red (added to ImM final concentrations) and Acid Blue (added 
to a lOpM final concentration). The 2MeSATP control response (data not shown) 
induced a response equal to 14.01 + 1.97 percent of the lOpM isoproterenol 
response. The raw data obtained for the antagonists were transformed from the 
percentage cAMP response obtained to show the percentage inhibition of the 
2MeSATP response generated by each of the ligands. Reactive Red, Reactive 
Blue, Phenol Red and Suramin were each able to inhibit the 2MeSATP response.
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Figure 5.1
Antagonists inhibit cAMP accumulation produced by 2MeSATP activation of 
XIP2Yi,.
Several ligands were screened for their ability to inhibit cAMP accumulation produced 
by 2MeSATP activation o f X1P2YU. Following pre-incubation with: PPADS, Suramin, 
Phenol Red, Reactive Blue, Reactive Red (each at ImM final concentration) and Acid 
Blue (lOpM final concentration), de novo cAMP production was measured after 
incubation with lOpM o f 2MeSATP. Results are expressed as a percentage inhibition o f 
the cAMP response to lOpM 2MeSATP and represent the mean + s.e.m. o f  three 
different experiments, each performed in triplicate. **, p < 0.01; *, p < 0.05; compared 
with control response, by ANOVA with Tukey’s post test.
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Suramin (41.6 + 5.50 percentage inhibition), Phenol Red (55.1 + 5.6 percentage 
inhibition), Reactive Blue (106.9 + 10.4 percentage inhibition) and Reactive Red 
(110.8 + 1.5 percentage inhibition) all show a significant difference in responses 
to the 2MeSATP control (p > 0.05, by ANOVA with Tukey's post test). Statistical 
analysis using the same parameters revealed the percentage cAMP response 
generated by 2MeSATP in the presence of PPADS (11.6 + 10.84 percentage 
inhibition) and Acid Blue (18.8 + 10.31 percentage inhibition) possessed no 
significant difference when compared to the 2MeSATP control response (p < 
0.05).
These experiments reveal several compounds, previously shown to be P2Y 
antagonists, are able to inhibit agonist-induced XlP2Yn cAMP responses. The 
experiments reveal the different ligands tested also possess varying degrees of 
inhibition as antagonists, although, in the same way as the initial agonist 
screening experiments undertaken in previous chapters, no further inferences or 
detailed analysis of the potency of the ligands can be deduced from these single 
concentration experiments.
5.2.2 Antagonists inhibit the cAMP responses of the XlP2Yu receptor in a 
concentration-dependent manner.
In order to further examine the ability of the ligands shown to act as antagonists 
of cAMP response generated by XlP2Yn, the effect of various concentrations of 
each antagonist upon de novo cAMP production generated by lOpM 2MeSATP
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was assessed following 30-minute pre-incubation with increasing concentrations 
of: Reactive Blue, Reactive Red, Suramin and Acid Blue. Reactive Blue and 
Reactive Red were chosen for further study in these experiments because they 
were the only antagonists to induce complete inhibition of the 2MeSATP 
response in the initial antagonist screening experiments (Section 5.2.1). Suramin 
was used in these concentration-response experiments because of its inability to 
completely antagonise the 2MeSATP (whereas previous studies have shown 
Suramin to be one of the strongest hP2Yn and cP2Yn antagonists) (Communi et 
al., 1999; Qi et al., 2001b). Acid blue was selected because it had been shown to 
generate minimal antagonism in the initial screening experiments -  and was 
used as a negative control in this and subsequent experiments. In the same way 
as the antagonist high-concentration screen (Section 5.2.1), 2MeSATP was used 
in these experiments at a concentration of lOpM in order to assess the ability of 
the antagonists to decrease the cAMP response. The antagonists were used at 
final concentrations ranging from lOnM to 5mM. The relative insolubility of 
Acid Blue prevented its use at concentrations higher than lOpM.
Figure 5.2 shows the concentration-response curves of the different antagonists 
in the cAMP assay. The results have been normalised to the supramaximal 
isoproterenol-induced cAMP response generated in the 1321Nl-XlP2Yn cells. 
The data displayed are a representative experiments taken from one of at least 
three independent experiments performed. The antagonists at their highest 
concentrations, elicit similar inhibitions of the 2MeSATP response to those 
recorded in the high-concentration antagonist experiments. The cAMP response
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Figure 5.2
Inhibition curves for antagonists on cAMP accumulation generated by 2MeSATP, 
in 1321N1 human astrocytoma cells stably expressing the XlP2Yn receptor.
Following pre-incubation with increasing concentrations of antagonists (Reactive Blue, 
0; Reactive Red, v; Suramin, a; and Acid Blue, o) the cAMP response was measured 
after incubation with lOpM final concentration 2MeSATP. The cAMP response of 
2MeSATP (lOpM final concentration), in the absence of any antagonist, is also shown 
(■).Results are expressed as a percentage of the cAMP response to a supramaximal 
concentration of isoproterenol (lOpM). The data are the mean ± s.e.m. of one 
representative experiment of 3 independent experiments performed.
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recorded for 2MeSATP alone, shown in Figure 5.2, is typical of the response 
induced by this agonist (approximately 12 percent of the isoproterenol 
response). Non-linear regression analysis was undertaken for each set of data in 
Figure 5.2 and the curves are shown fitted to the responses of 2MeSATP in the 
presence of increasing concentrations of Reactive Blue (0), Reactive Red (v) and 
Suramin ( a ) .  A curve has not been fitted to the cAMP responses of 2MeSATP in 
the presence of Acid Blue (o) - shown with a connecting line. The data points 
shown are the mean + s.e.m. of one representative experiment of three 
independent experiments performed.
Within the range of concentrations tested, Reactive Blue and Reactive Red are 
able to fully antagonise the cAMP response generated by 2MeSATP. The 
percentage cAMP response created by the addition of lOpM 2MeSATP is 
reduced to a basal level, shown by statistical analysis to be indistinguishable 
from the response generated by the PBS control alone (p value < 0.01 by 
Student's two-tailed paired f-test). The effect of increasing concentrations of 
Suramin is less pronounced; the reduction in the 2MeSATP cAMP response at 
ImM of the agonist allows non-linear regression analysis to fit a curve, although 
maximum inhibition is clearly not reached at this concentration. The effect of 
increasing concentrations of Acid Blue produced a negligible decrease in the 
2MeSATP cAMP response. The data obtained in the Acid Blue experiments 
were limited by the relative insolubility of the compound, which prevented the 
use of a wider range of concentrations, and a curve could not be fitted to these 
data.
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The non-linear regression analysis undertaken on each of the 3 independent 
concentration-response experiments gave the following mean IC50 values: 
Reactive Blue, 13.2pM (log IC50 = -4.88 + 0.05); Reactive Red, 100.7pM (log IC50 = 
-4.00 + 0.02)(Table 5.1). The IC50 values for Suramin were not able to be 
calculated from these data. It can be seen from both Figure 5.2 and Table 5.1, 
that three of the antagonists elicit a concentration-dependent inhibition of the 
cAMP response in 1321Nl-XlP2Yn cells. The degree of this inhibition and the 
concentration of ligand required to elicit a half-maximal inhibitory response 
give the following antagonist potency order for XlP2Yu-mediated cAMP 
responses:
Reactive Blue > Reactive Red »  Suramin
5.2.3 Antagonists modify the 2MeSATP induced cAMP concentration- 
response of XlP2Yn.
In order to determine the nature of the antagonism of Reactive Blue, Reactive 
Red and Suramin, a series of experiments were conducted to determine the 
potency of 2MeSATP and the shape of the 2MeSATP concentration-response 
curve in the presence of a fixed concentration of each antagonist.
Figure 5.3 shows the cAMP response of 1321N1 human astrocytoma cells stably 
expressing XlP2Yn after a 10-minute incubation with 2MeSATP in the presence 
of 500pM Reactive Blue, 100pM Reactive Red, 500jj.M Suramin or lpM Acid
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Blue. The data displayed are from a representative experiment performed for 
each ligand. Non-linear regression analysis was undertaken for each set of data. 
The curves generated by the analysis are shown fitted to the responses of 
increasing concentrations of 2MeSATP in the presence of fixed concentrations of 
various ligands. The 2MeSATP concentration response in the absence of
antagonist is also shown in Figure 5.3. The data points shown for each ligand 
are the mean + s.e.m. of one representative experiment of three independent 
experiments performed.
Figure 5.3 shows that Suramin, Reactive Blue and Reactive Red were able to 
affect a rightward shift of the 2MeSATP concentration-response curve. The 
right-shift of the concentration-response curve is more pronounced in the 
presence of Suramin and Reactive Blue. However, the maximum agonist 
response in these experiments was not reached at the highest concentration of 
2MeSATP used.
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Figure S3
Concentration-response curves of 2MeSATP on cAMP accumulation in 132INI 
human astrocytoma cells stably expressing the X1P2Yh receptor, in the presence of 
antagonists.
Following pre-incubation with fixed concentrations of antagonists (500pM Reactive 
Blue, O; lOOpM Reactive Red, V ; 500pM Suramin, A and lpM Acid Blue, O )  the 
cAMP response was measured after incubation with increasing concentrations of 
2MeSATP. 2MeSATP concentration-response curve without antagonist is also shown (-- 
■--). Results are expressed as a percentage of the cAMP response to a supramaximal 
concentration of isoproterenol (10pM). The data are the mean ± s.e.m. of one represen­
tative experiment of 3 independent experiments performed. Analysis shows a significant 
difference between i) the EC50’s of Suramin, Reactive Blue and Reactive Red and the 
curve generated by 2MeSATP alone, ii) the maximal response generated by lOOpM 
2MeSATP in the presence of lOOpM Reactive Red, and iii) the response generated by 
0.1 pM 2MeSATP in the presence of 500pM Reactive Blue (p < 0.05, by ANOVA with 
Tukey’s post-test).
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5.3 Investigating antagonism of Ca2+ mobilisation in 1321N1-X1P2Yii cells.
Having demonstrated that various ligands are able to act as antagonists upon 
the agonist-induced cAMP response of the XlP2Yn receptor, the ability of these 
same ligands to inhibit the receptor's ability to induce Ca2+ mobilisation was 
investigated. In accordance with the previous experiments, 2MeSATP was 
selected as the agonist used to elicit the second messenger response.
5.3.1 Suramin and Reactive Red are unable to inhibit Ca2+ mobilisation 
from the XlP2Yn receptor.
The initial approach to these studies was the same as that employed in section 
5.2.1, with each antagonist tested initially at ImM final concentration. Figure 5.4 
shows the Ca2+ response of 1321N1 human astrocytoma cells stably expressing 
XlP2Yn after the addition of the 2MeSATP alone (at a final concentration of 
lOpM), and in the presence of Suramin and Reactive Red. The results are 
expressed as a percentage Ca2+ response, and have been normalised to the Ca2+ 
mobilisation produced by ImM carbachol. Results shown are the means + s.e.m. 
of three different experiments each performed in triplicate.
Surprisingly, these data show that there is no major inhibition of the agonist- 
induced Ca2+ response in the presence of either Suramin or Reactive Red. Nor is 
there any potentiation of the 2MeSATP response. There is no significant 
difference between the Ca2+ responses in the presence or absence of the
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Figure 5.4
Antagonists do not inhibit Ca2+ mobilisation produced by 2MeSATP activation of 
X1P2Y,,.
Suramin and Reactive Red were screened for their ability to inhibit Ca2+ mobilisation 
generated by 2MeSATP activation o f XlP2Yn . Following pre-incubation with Suramin 
and Reactive Red (each at ImM final concentration), Ca2+ mobilisation was measured 
following the addition o f  lOpM final concentration o f 2MeSATP. Results are expressed 
as a percentage o f  the Ca2+ response to a supramaximal concentration o f carbachol 
(Im M ). Results are the mean ±  s.e.m. o f  three different experiments, each performed in 
triplicate. **, p < 0.01, compared with control (not shown), Student’s t-test.
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antagonists (p value > 0.01 by a Student's f-test). Although previous studies 
have shown that these ligands were able to inhibit agonist-induced cAMP 
responses, they have no antagonist activity upon the 2MeSATP Ca2+ response.
5.3.2 Concentration-inhibition experiments reveal Suramin and Reactive 
Red do not act as antagonists of XlP2Yn induced Ca2+ mobilisation.
In order to examine in greater detail the apparent inability of Suramin and 
Reactive Red to inhibit the 2MeSATP-induced Ca2+ response, full antagonist 
concentration-response curves were constructed. Antagonists were pre­
incubated at concentrations ranging from InM to ImM. Figure 5.5 shows the 
Ca2+ response of 1321N1 human astrocytoma cells stably expressing XlP2Yn 
after the addition of 2MeSATP (added to a final concentration of lOpM) 
following pre-incubation with increasing concentrations of Reactive Red and 
Suramin. The data displayed are the mean + s.e.m. of representative 
experiments taken from the 3 independent experiments performed for each 
ligand.
Increasing concentrations of Suramin and Reactive Red are unable to elicit any 
substantial reduction in the Ca2+ response generated by 2MeSATP. Analysis 
reveals that no significant difference exists between any of the data points, 
suggesting that the Suramin and Reactive Red do not act as antagonists of the 
Ca2+ signalling generated by 2MeSATP (one-way analysis of variance, p> 0.05).
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Figure 5.5
Lack of antagonism on Ca2+ mobilisation generated by 2MeSATP, in 1321N1 
human astrocytoma cells stably expressing the X1P2Yh receptor.
Following pre-incubation with increasing concentrations of antagonists (Reactive Red, 
v; and Suramin, — a —), Ca2+ mobilisation was measured after the addition of 10pM 
final concentration 2MeSATP. Results are expressed as a percentage of the Ca2+ 
response to a supramaximal concentration of carbachol (ImM). The data are the mean ± 
s.e.m. of one representative experiment of three performed.
163
Chapter 5: Antagonism of the Xlp2y 11 receptor.
Antagonists
IC50 (uH) Log IC50
Kd (pM)
Reactive Blue 13.1 -4.88 ± 0.05 4.9 ± 1.8
Reactive Red 100.7 -4.00 ± 0.02 21.6 ± 4.5
Suramin aND 82.8 ± 27.3
Acid Blue ND ND
Table 5.1
IC50 and Kd values for antagonists used on 132INI human astrocytoma cells stably 
expressing the XlP2Ytl receptor.
IC50 values were calculated from linear regression curve analysis of the antagonist 
concentration-response experiments performed in the presence of a fixed concentration 
of 2MeSATP. Kd values were calculated as described in Materials and Methods. Results 
are expressed as the mean IC50, and log of the mean IC50 ± s.e.m., of 3 independent 
experiments, each performed in triplicate. aND, not determined, indicates that the low 
response generated could not be used to calculate an IC50 value.
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5.4 Summary
In order to determine the antagonism at XlP2Yn of several compounds 
previously shown to act as P2Y receptor antagonists, the cAMP assay was 
employed. These experiments successfully identified antagonists of the cAMP 
second messenger response, with Reactive Red and Reactive Blue as the most 
efficacious antagonists, followed by Phenol Red and Suramin.
Concentration-inhibition experiments were then performed and the antagonists 
tested were shown to inhibit the production of cAMP in a concentration- 
dependent manner. Reactive Blue was shown to be the most potent antagonist, 
followed by Reactive Red. While Suramin was able to antagonise the cAMP 
response (although to a much lesser extent than Reactive Blue and Reactive Red) 
Acid Blue was unable to elicit any inhibition. The IC50 values calculated for the 
full antagonists were in the micromolar range (Reactive Blue: 13.1jj,M, log IC50 = 
-4.88 + 0.05; Reactive Red: 100.7pM, log IC50 = -4.00 + 0.02).
To determine the nature of the antagonism, each of these four ligands was 
included at a fixed concentration in 2MeSATP concentration-response curves. 
Reactive Blue, Reactive Red and Suramin were all found to shift the agonist 
induced concentration-response curve to the right. Although Acid Blue did not 
significantly shift the agonist induced concentration-response curve, the 
maximal height of the curve was higher than that of agonist alone, suggesting 
that Acid Blue may potentiate the agonist-induced response at higher 
concentrations. Unfortunately, the solubility of this ligand did not permit these 
experiments to be performed. Reactive Red was also found to reduce the
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maximal height of the agonist-induced curve, suggesting the possibility of this 
ligand acting as a non-competitive antagonist at the XlP2Yn receptor. 
Concentration-response curves performed in the presence of Reactive Blue and 
Suramin were unable to reach a maximum within the range of concentrations 
tested. The significantly right-shifted curve generated by the presence of 
Reactive Blue was also noticeable for its higher basal level of cAMP 
accumulation at low concentrations of agonist, suggesting Reactive Blue may act 
as a partial agonist.
Since the different antagonists were not used at the same concentrations in these 
experiments the corresponding Kd values were calculated for each antagonist 
(shown in Table 5.1). Reactive Blue (log IC50, -4.88 + 0.05; Kd, 4.9 + 1.6 pM) was 
found to be the most potent antagonist, followed by Reactive Red (log IC50, -4.00 
+ 0.02; Kd, 21.6 + 4.5 pM) and then Suramin (Kd, 82.8 + 27.3 pM).
The ability of these antagonists to block XlP2Yn-mediated activation of the Ca2+ 
second-messenger signalling pathway was investigated. Initially, the Ca2+ 
response was determined in the presence of high concentrations of Suramin and 
Reactive Red, but no inhibition was observed. The subsequent concentration- 
response curves for these two antagonists did not show any significant decrease 
in the agonist-induced Ca2+ second messenger response, despite the ability of 
these ligands to antagonise cAMP signalling through XlP2Yn.
166
Chapter 6
Discussion.
6.1 Introduction
The work presented in this thesis describes the pharmacological characterisation 
of the human P2Yn (hP2Yn) and the Xenopus laevis P2Yn (XlP2Yn) receptors. 
Previous studies have shown the hP2Yn receptor and its canine (cP2Yu) 
receptor orthologue are activated by extracellular nucleotides, promoting 
intracellular cAMP production, Ca2+ mobilisation and IP accumulation 
(Communi et al., 1997 & 1999; Qi et al., 2001a; Qi et al., 2001b; White et al., 2003) 
responses typical of phospholipase C and adenylyl cyclase activation (Streb et 
al., 1983; Danchin, 1993). I have shown in the present work that both the hP2Yn 
and the novel Xenopus laevis P2Y receptors are activated by extracellular 
nucleotides and nucleotide analogues, to mobilise intracellular Ca2+ and 
produce cAMP.
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The ligand potencies and dual signal pathway activation lead me to conclude 
that XlP2Yn is the Xenopus laevis orthologue of the P2Yn receptor. This 
conclusion is supported further by the antagonist profiles that I have 
determined for the hP2Yu and XlP2Yn receptors. This chapter presents a 
comparison of my agonist and antagonist data, both with each other, and with 
the previously published data for P2Yn receptor orthologues, from the 
perspective of both ligand activation and second messenger production. This 
chapter is therefore an opportunity to analyse, evaluate and assess the previous 
research into the role of this receptor.
6.2 Determination of agonist potencies at the XlP2Yn and hP2Y« 
receptors.
The pharmacological data obtained for the hP2Yn and XlP2Yn receptors, 
previously presented separately in Chapters 3, 4 and 5, are shown in Table 6.1. 
The agonist log EC50 values and intrinsic activities (IA), determined using the 
Ca2+ and cAMP assays are shown for both receptors, together with the ratios of 
the EC50 values gained for agonist-induced cAMP accumulation to the Ca2+ 
mobilisation EC50 values, in order to compare the magnitude of the two different 
second messenger responses.
The potency orders previously presented in Chapters 3 and 4 (shown below) 
reveal that ATP, when compared to ADP, more potently activates both the 
hP2Yn and XlP2Yn receptors. The ATP and BzATP EC50 ratios of 1321N1- 
XlP2Yn cells (0.40; 0.37, respectively) and 1321Nl-hP2Yn cells (ATP ratio: 0.67;
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BzATP ratio: 0.16) indicate that both agonists are more potent activators of the 
cAMP accumulation response in each of the two cell lines. Analysis of the 2- 
thioether-substituted potencies reveals 2MeSATP conforms to this above 
observation, activating cAMP responses more potently than Ca2+ mobilisation, 
however, contrary to all of the agonists tested on hP2Yn and XlP2Yu, 2MeADP 
more potently activates Ca2+ mobilisation. Analysis of these ECso's values also 
reveals ATP is equipotent with and 6-fold less potent than BzATP, in terms of 
Ca2+ mobilisation response and cAMP accumulation response, respectively at 
the hP2Yn receptor, whereas the same ligand is 16-fold more potent than BzATP 
in both cAMP and Ca2+ responses at the XlP2Yn receptor. These observations 
can be seen in the rank order of potency for these P2Yn receptor orthologues, 
summarised below.
hP2Yu: BzATP > ATP > <x,P-meATP = P/y-meATP
XlP2Yn: ATP > 2MeSATP > 2MeSADP > BzATP »  ADP
The Clustal W alignment of the hP2Yn, cP2Yn and XlP2Yu coding sequences 
(shown in Chapter 1) was undertaken in order to examine the percentage 
identity exhibited between these receptors and showed that XlP2Yn possesses 
approximately 40 percent identity to hP2Yn and approximately 32 percent to 
cP2Yn amino acid sequences. As previously outlined, studies have shown that 
the human P2 Y4 receptor (Communi et al., 1996; Communi and Boeynams, 1997) 
and its rat orthologue, rP2Y4 (Bogdanov et al., 1998), possess distinctly altered 
agonist and antagonist pharmacology, despite sharing approximately 80 percent 
sequence identity. Considering the low sequence identity observed when 
comparing the XlP2Yn sequence against the human and canine P2Yn
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orthologues, the ability of the receptor to induce similar second messenger 
responses to both the hP2Yn and cP2Yn receptor activation is surprising.
The low sequence identity between the hP2Yn and XlP2Yn amino acid 
sequences (32 percent identity) suggests that the conservation of key residues in 
specific locations is crucial to the preservation of the hP2Yu-like agonist 
responses of the XP2Yn receptor. The positively charged basic amino acid 
residues found in the plasma membrane-extracellular interface of 
transmembrane domain 6 (TM6) regions in P2Y receptors are predicted through 
their interaction with phosphate moieties, to bind and stabilise extracellular 
nucleotide agonists (Erb et al., 1995; Jiang et al., 1997; Qi et al., 2001b) and the 
hP2Yn residues, 262His and 265Arg, and their equivalents in the cP2Yn amino acid 
sequence have been shown to dictate the ATP versus ADP selectivity exhibited 
by each of these receptors (Qi et al., 2001b). XlP2Yn contains the identical 
residues when compared with the hP2Yn receptor, notably 262His and 265Arg 
(XlP2Yn equivalent positions: equivalent positions 241His and 245Arg) (shown in 
Figure 6.1), and is different from cP2Yn at these residues. This is likely to 
account for the preference of the XlP2Yn receptor for ATP, rather than ADP.
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Figure 6.1
Partial amino acid sequence alignment o f transmembrane domain 6 in P2Y 
receptors reveals XlP2Yn contains basic residues at residues 241 and 244.
Clustal W alignment o f partial amino acid sequences o f transmembrane domain 6 o f 
multiple P2Y receptors. Conserved residues are shaded black. Similar residues are 
shaded in gray. Numbered residues denote hP2Yn residues predicted to contribute to the 
ATP versus ADP selectivity o f hP2Yn and cP2Yn receptors.
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6.3 Determination of agonist efficacies at the XlP2Yu and hP2Yu 
receptors.
The intrinsic activities of the agonists tested were calculated by normalising the 
maximal response recorded for each agonist to the response induced by lOOpM 
ATP, since this was the most potent of the non-synthetic nucleotides tested on 
these receptors. However, the intrinsic activity presented in Table 6.1 reveal, 
that ATP is not the most efficacious of the agonists tested on either the hP2Yn or 
XlP2Yn receptors. When compared with ATP, both cell lines produce similar or 
higher maximal Ca2+ mobilisation and cAMP accumulation responses to the 
synthetic nucleotide analogues.
The log EC50 values and intrinsic activities of UTP are not shown as the UTP- 
induced cAMP responses for both hP2Yn and XlP2Yn, and the Ca2+ responses 
for XlP2Yn, were found to be indistinguishable from the vehicle control. 
Similarly, the EC50 values for ADP-induced cAMP accumulation responses are 
not shown for either receptor; however, the observation that ADP generates a 
Ca2+ response significantly different from the control in 1321Nl-XlP2Yii cells 
warrants the inclusion of its intrinsic activity in Table 6.1. The table reveals that 
ADP can generate Ca2+ mobilisation levels equivalent to approximately 40 
percent of the Ca2+ mobilisation induced by lOOpM ATP. ADP's inability to 
reach a maximum Ca2+ response within the range of concentrations used does 
not permit an EC50 value to be calculated.
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Nucleotide
Ca2+ mobilisation Cyclic AMP accumulation Ratiob
Log EC so 1A (%)* Log EC so IA (%)
hP2Yn receptor
ATP -5.07 ± 0.03 100 -5.24 ± 0.07 100 0.67
ADP NDC ND
BzATP -5.26 ±0.10 97.1 ±3.2 -6.05 ± 0.06 96.3 ± 2.6 0.16
UTP ND ND
a,p-meATP -4.64 ± 0.07 116.7 ±7.2
p,y-meATP -4.61 ±0.14 110.3 ±0.9
XlP2Yn receptor
ATP -5.06 ±0.19 100 -6.02 ±0.01 100 0.40
ADP ND 40.5 ±13.1 ND ND
BzATP -4.37 ±11.6 178.0 ±35.4 -4.81 ±0.12 153.4 ±28.0 0.37
UTP ND ND ND ND
2MeSATP -5.71 ±0.22 170.0 ±29.6 -5.76 ±0.11 126.0 ± 14.5 0.85
2MeSADP -5.13 ±0.08 180.0 ±17.7 -4.90 ±0.10 121.0 ± 10.0 1.68
Table 6.1
Comparison of agonist activities in 1321Nl-hP2Yu and 1321Nl-XlP2Yncells.
hP2Yn and XlP2Yu receptor log EC50 data from the agonist-induced Ca2+ and cAMP 
responses of 1321Nl-hP2Yn and 1321Nl-XlP2Yn cells. Data are expressed as the 
mean, ± s.e.m of three to five independent experiments, each performed in triplicate. 
alA, intrinsic activity, shows the percentage agonist responses normalised to the maximal 
response of IOOjiM ATP. bRatio, shows the ratio of EC50 for cAMP accumulation to 
EC50 for Ca2+ mobilisation. CND, indicates responses were not determined.
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Despite the consistencies between the two cell lines, key differences exist 
between the intrinsic activities of the agonists at the human P2Yn receptor when 
compared with the Xenopus laevis P2Yn receptor. Table 6.1 reveals that the 
maximal responses produced by BzATP are much higher at the XlP2Yn receptor 
(Ca2+ IA, 178 + 35.4; cAMP IA, 153.4 + 28.0) than at the hP2Yn receptor (Ca2+IA,
97.1 + 3.2; cAMP IA, 96.3 + 2.6 percent).
6.4 Comparison of the agonist-induced responses of XlP2Yn and hP2Yu 
with previously published data.
The previously published P2Yn receptor agonist activities (Qi et al., 2001b) are 
listed in Table 6.2 to highlight key differences between these data and my own 
pharmacological characterisations of the hP2Yn and XlP2Yn receptors. 
Although these data were obtained from hP2Yn and cP2Yn orthologues stably 
expressed in CHO-K1 cell lines, as opposed to the 1321N1 cell line, these data 
were selected for comparison as both functional assays were performed in the 
same cell line (Qi et al., 2001b).
The log EC50 values for agonist-induced cAMP and IP accumulation responses 
are shown, together with the ratio of these EC50 values (cAMP accumulation to 
IP accumulation) for each agonist. The agonist intrinsic activities are also shown. 
The data for hP2Yn are normalised to the maximal response of 300pM ATP and 
the canine P2Yn data are normalised to lOOpM ADP. Although agonist log EC50 
values and intrinsic activities cannot be directly compared between different cell 
lines, previous characterisations in 1321N1- and CHO-K1 cells have revealed the
1 7 4
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agonist potency orders calculated for the receptors remain the same in the 
different cell lines (Communi et al., 1999; Qi et al., 2001b). The differences in the 
second messenger signalling ability as a function of both receptor subtype and 
cell line used is discussed further in section 6.7.
Evaluation of the XlP2Yn agonist results is not possible through direct 
comparison with previous work on this receptor, as I am the first to characterise 
this novel receptor. Although, as previously stated, direct comparison of the 
EC50 and intrinsic activities values cannot be undertaken between different cell 
lines, analysis and inferences can be gained by comparing the order of agonist 
potency. The 1321Nl-XlP2Yn data presented in Table 6.1 and Table 6.2 reveal 
2MeSATP and 2MeSADP to be more potent than their non-synthetic analogues, 
ATP and ADP, in terms of both Ca2+ mobilisation and cAMP accumulation 
responses. XlP2Yn possesses the same ATP > 2MeSATP and ADP > 2MeSATP 
selectivity possessed by the hP2Yn receptor (ATP > 2MeSATP »  ADP > 
2MeSADP) (Communi et al., 1997 & 1999). The XlP2Yu data is more like hP2Yn 
in terms of ATP and ADP responses and differs substantially from the 
previously published cP2Yu data for these agonists, which possess a selectivity 
of 2MeSADP ~ 2MeSATP »  ADP > ATP (Zambon et al., 2001; Qi et al., 2001b).
Direct comparison of the hP2Yn data presented in this thesis is, however, 
possible due to previous Ca2+ and cAMP characterisations of the receptor in 
1321N1 cells. The first published example of cAMP accumulation in 1321N1- 
hP2Yn cells gives an EC50 value of 130 + 10 pM for ATP (Qi et al., 2001a). By 
direct comparison, the 1321Nl-hP2Yn cAMP investigations presented in 
Chapter 3 and Table 6.2 show ATP to be 23-fold more potent than previously
Chapter 6: Discussion.
Ca2* mobilisation d Cyclic AMP accumulation d Ratiob
Nucleotide Log ECso IA (%)a Log ECso IA (%)
h P 2 Y n  r e c e p to r
ATP -5.07 ±0.03 100 -5.24 ±0.07 100 0.67
BzATP -5.26 ±0.10 97.1 ±3.2 -6.05 ±0.06 96.3 ±2.6 0.16
a,|3-meATP -4.64 ± 0.07 116.7 ±7.2
P,y-meATP -4.61 ±0.14 110.3 ±0.9
X lP 2 Y n  re c e p to r
ATP -5.06 ±0.19 100 -6.02 ±0.01 100 0.40
ADP ND 40.5 ± 13.1 ND ND
BzATP -4.37 ±11.6 178.0 ±35.4 -4.81 ±0.12 153.4 ±28.0 0.37
2MeSATP -5.71 ±0.22 170.0 ±29.6 -5.76 ±0.11 126.0 ±14.5 0.85
2MeSADP -5.13 ±0.08 180.0+17.7 -4.90 ±0.10 121.0 ±10.0 1.68
IP accumulation Cyclic AMP accumulation Ratio
Nucleotide Log ECS0 IA (%) Log ECso IA (%)
H u m a n  P 2 Y U
ATP
r e c e p to r  *
-5.44 + 0.15 100 -4.20 ±0.11 100 17.3
ADP -4.30 ±0.19 60.2 ±4.3 ND ND ND
2MeSATP -5.62 ± 0.07 99.4 ± 8.2 -4.58 ±0.06 99.4 ± 5.5 11
2MeSADP -4.84 ±0.10 60.5 ± 6.0 ND ND ND
C a n in e  P 2 Y n
ATP
r e c e p to r  *
-4.48 ±0.19 96.8 ± 9.3 -4.12 ±0.17 94.8 ±9.3 2.3
ADP -5.21 ±0.10 100 -4.96 ±0.15 100 1.8
2MeSATP -6.24 ± 0.08 66.2 ±3.5 -5.66 ± 0.08 74.9 ± 5.0 3.9
2MeSADP -7.10 ±0.05 102 ±6.8 -6.80 ±0.08 84.0 ± 2.5 2.0
Table 6.2
Comparison of agonist activities in 1321Nl-hP2Yn, 1321Nl-XlP2Yn, CHO-hP2Yn 
and CHO-cP2Y„ cells.
hP2Yn and XlP2Yn receptor EC50 data show the responses of agonists in 1321N1- 
hP2Yn and 1321Nl-XlP2Yn cells. Data are expressed as the mean, ± s.e.m of three to 
five independent experiments, each performed in triplicate. * Human and canine P2Yn 
receptor data (taken from Qi et al., 200 lb) show the activities of nucleotides in CHO- 
hP2Yu and CHO-cP2Yn cells, data are mean ± S.D. from three to six separate 
experiments.8 IA, intrinsic activity, shows the percentage agonist responses, normalised 
to the maximal response of lOOpM ATP (hP2Yn and XlP2Yn), 300pM ATP (* hP2Yn) 
and lOOpM ADP (* cP2Yn). b Ratio, shows the ratio of EC50 for cAMP accumulation to 
EC50 for Ca2+ mobilisation (hP2Yu and XlP2Yu), and EC50 for cAMP accumulation to 
IP accumulation (hP2Yn and cP2Yn). CND, indicates responses were not determined. 
dData taken from Table 6.1.
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determined. In addition, although the ECso values were not presented, previous 
studies have reported that agonist potencies for cAMP accumulation recorded in 
1321Nl-hP2Yn and 1321Nl-cP2Yn cells are lower than the potencies recorded 
for both receptors in CHO cells (presented in Table 2) (Qi et al., 2001b). 
suggesting that the previously reported cAMP ECso value for ATP in 1321N1- 
hP2Yn cells would be greater than 62.4 + 15.6 pM. The ATP ECso value 
presented in Chapter 3 for the 13121Nl-hP2Yn cells is, therefore, at least 11-fold 
more potent than this previous cAMP investigation. These data reveal the 
1321Nl-hP2Yn cells used throughout this thesis are more efficient at inducing 
cAMP accumulation than the 1321Nl-hP2Yn cells used in previous studies.
Less information is available to permit direct comparison of the Ca2+ ECso values 
obtained for the 1321Nl-hP2Yn cells in Chapter 3. Initial single-concentration 
pharmacological studies on the hP2Yn receptor reported, in addition to 
generating IP and cAMP accumulation, that ATP also induced intracellular Ca2+ 
mobilisation (Communi et al., 1997). Further inspection of the receptor's 
pharmacological profile, achieved through concentration-response experiments, 
revealed that ATP (as well as ADP, and both 2-thioether analogues) was able to 
produce concentration-dependent Ca2+ responses (Qi et al., 2001b). Although 
ECso values were not presented in either study, visual inspection of the 
published graphs shows that half-maximal ATP-induced Ca2+ response are 
achieved at approximately lOpM. Subsequent investigations into UTP- and 
ATP-induced Ca2+ responses of the hP2Yn receptor (White et al., 2001) have 
yielded ECso values for ATP which may be directly compared to the 1321N1- 
hP2Yn data presented in Chapter 3. The ECso value, presented as log: -4.9 + 0.13,
177
Chapter 6: Discussion.
is of a similar magnitude as the log EC50 value determined for ATP in Chapter 3 
(-5.24 + 0.07).
Comparing the hP2Yn and XlP2Yn receptor data presented in this thesis, with 
previously published hP2Yn and cP2Yn data highlights a number of 
inconsistencies. Firstly, while previously published studies initially revealed, 
that ATP possessed an EC50 value of 38 + 7 pM for IP accumulation in 1321N1- 
hP2Yn cells (Communi et al., 1997), subsequent studies using 1321Nl-hP2Yn 
cells have shown the IP EC50 value for ATP to vary from 65 + 12 pM (Communi 
et al., 2001) to 8.5 + 0.1 pM (Qi et al., 2001a). Similarly, ATP-induced cAMP 
accumulation EC50 values for CHO-hP2Yu cells have been shown to range from 
17.4 + 6.1 (Communi et al., 1999) to 62.4 + 15.6 (Qi et al., 2001a). My own work 
has led to the calculation of an EC50 value of 5.7pM for cAMP response at the 
hP2Yn receptor. These discrepancies, which can arise in the same laboratory, 
may be a function of the techniques and methods used to determine second 
messenger responses. They may also relate to receptor density, as described in 
section 6.5.
6.5 Problems associated with comparing ligand intrinsic activities and 
potencies.
As mentioned in sections 6.3 and 6.4, the direct comparison of agonist intrinsic 
activities and EC50 values cannot be undertaken between different cell lines. 
Agonist intrinsic activities and EC50 values are determined by receptor number 
and differences in receptor expression levels between cell lines may affect these
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values (Kenakin et al., 1997). Despite this, it has been shown, however, that the 
order of agonist potency in cells with different receptor expression levels 
remains the same (Qi et al., 2001b). Different receptor expression levels between 
the 1321Nl-hP2Yn cells used in Chapter 3 of this thesis, and those used to 
produce the previously published cAMP accumulation data, may account for 
some of the differences in intrinsic activities and ECso- As no appropriate 
radiolabelled compounds have been described for the hP2Yn receptor, it is not 
yet possible to accurately determine P2Yn receptor density in any given cell line. 
It must also be noted, that in terms of second messenger signalling, the intrinsic 
activities and ECso values recorded in Ca2+ responses cannot be compared with 
the IP or cAMP values (and vice versa). It is only possible to compare the 
efficiency of coupling to the different second messenger pathways. In this 
regard, it is difficult to analyse the results of the XlP2Yn receptor as the 
efficacies of coupling to the mammalian Gsa and Gq/na proteins are unknown.
6.5.1 Agonist interconversion.
As outlined in Chapter 1, the presence and turnover of extracellular agonists by 
ATP-generating and ATP-consuming extracellular pathways can govern the 
duration and magnitude of intracellular signalling responses (Zimmerman, 
1992; Lazarowski et al., 1997). The stepwise bi-directional interconversion of 
ATP, ADP and AMP (and the ability of Ecto-5'-nucleotidase and Adenosine 
Deaminase to sequentially degrade AMP into Adenosine and Inosine), must be 
taken into consideration when interpreting the agonists responses of the hP2Yu 
and XlP2Yn receptors.
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It may be possible that the Ca2+ mobilisation and cAMP production caused by 
agonists such as ATP are in fact produced by the downstream products of the 
agonists' ectonuclease degradation. However, the lack of any signaling 
responses recorded for ADP in both pharmacological assays suggests very little 
ADP is converted to ATP. The similarity of the responses recorded in the Ca2+ 
assay (which records the intracellular response in real-time -  giving any ecto- 
enzymes very little incubation time with the agonists) to those recorded in the 
cAMP responses also confirms that little or no agonist interconversion occurred 
in relation to ATP and ADP.
6.6 Determination of antagonist potencies at the XlP2Yn and hP2Yn 
receptors.
The inhibition of several antagonists at the hP2Yn and XlP2Yn receptors are 
listed in Table 6.3, which summarises the log IC50 values and intrinsic affinity 
(presented as percentage inhibition of agonist-induced responses), previously 
presented separately in Chapters 3 and 5. ICso's have not been calculated for 
antagonists that either exhibited minimal inhibition throughout the range of 
antagonist concentrations tested, or were unable to develop maximal 
antagonism of the agonist-induced response within this concentration range.
Previous studies of the hP2Yn and cP2Yn receptors that have examined the 
signalling responses induced by non-specific antagonists have shown that 
Suramin and Reactive Blue inhibit IP and cAMP responses in 1321Nl-hP2Yn
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cells, CHO-hP2Yn cells (Communi et al., 1999), and CHO-cP2Yu cells (Qi et al., 
2001b). In line with the previously published cP2Yn and hP2Yu data, Reactive 
Blue fully inhibits the cAMP response in 1321Nl-XlP2Yn cells (Table 6.3). This 
full inhibition of cAMP responses by Reactive Blue has also ben shown for the 
hP2Yn and cP2Yn receptors (Qi et al., 2001b), however, a separate study has 
reported Reactive Blue only produces a partial inhibition of activated hP2Yn 
receptors (Communi et al., 1999). Reactive Red, an antagonist of both agonist- 
induced cAMP accumulation and Ca2+ mobilisation responses generated by the 
hP2Yn receptor, is only able to act as an antagonist upon the cAMP response of 
the XlP2Yn receptor. Similarly, Suramin, shown to fully inhibit the Ca2+ 
response in 1321Nl-hP2Yn cells, is unable to reduce agonist-induced Ca2+ 
mobilisation in 1321Nl-XlP2Yn and is only partially able to inhibit the agonist 
promoted cAMP responses within this cell line.
Suramin, shown in Chapter 3 to act as an antagonist on 1321Nl-hP2Yn cells, is 
in agreement with previous studies, where the ligand has been shown to inhibit 
IP and cAMP responses in 1321Nl-hP2Yn and CHO-hP2Yn cells (Communi et 
al., 1999), and in CHO-cP2Yn cells (Qi et al., 2001b). The inability of Suramin to 
inhibit Ca2+ mobilisation and its partial ability to inhibit cAMP accumulation in 
1321Nl-XlP2Yn cells differs from other P2Yn orthologues studies, where 
Suramin has been shown to act as a full antagonist (Communi et al., 1999, Qi et 
al., 2001b).
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Ca2 mobilisation Cyclic AMP accumulation
antagonist Log IC50 IA (%)a Log IC50 IA (%)a
hP2Yu receptor
Reactive Red -3.57 ±0.17 94.5 ±1.8 -5.76 ±0.07 97.4 ±1.0
Suramin -4.55 ±0.15 96.2 ±1.7
Acid Blue NDb 2.6 ±2.2
Phenol Red ND 10.3 ±7.1
XlP2Yn receptor
Reactive Red ND 8.6 ± 6.4 -4.00 ± 0.02 97.7 ±7.8
Suramin ND 7.4 ±6.0 ND 37.2 ±6.8
Acid Blue ND 15.6 ±9.3
Reactive Blue -4.88 ±0.05 96.3 ±10.6
Table 6.3
Antagonism of responses in 1321Nl-hP2Yn and 1321Nl-XlP2Yn cells.
Log IC50 values were calculated after non-linear regression analysis of the antagonist 
concentration-inhibition experiments. Results are expressed as the mean, ± s.e.m. of 
three independent experiments, each performed in triplicate.a IA, intrinsic affinity, are 
normalised to show the maximal percentage inhibition of second messenger responses 
achieved by the antagonist within the range of concentrations tested. ’’ND, not 
determined, indicates that the responses generated could not be used to calculate an IC50 
value.
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These data suggest a stronger or more efficient coupling of the agonist-activated 
XlP2Yn receptor, in the presence of antagonist, to the pathways involved in Ca2+ 
release. Alternatively, previous investigations have suggested that UTP and 
ATP may induce Ca2+ mobilisation in 1321Nl-hP2Yll cells by means of different 
agonist induced pathways (White et al., 2001). The XlP2Yn receptor, in the 
presence of Suramin, and other antagonists, may be able to promote pathway 
selective inhibition of second messenger responses - highlighting further 
complexities involved in the agonist binding and signal induction of the 
activated P2Yn receptor. However, the small degree of inhibition induced by 
suramin in 1321Nl-hP2Yn and the lack of any recordable inhibition in the 
1321Nl-XlP2Yn cells may also simply reflect an impure Suramin source.
6.7 Signal transduction of the XlP2Yn and hP2Yn receptors.
Although previous studies of the signalling ability of the hP2Yn and cP2Yn 
receptors have examined the potency and efficacy of agonists in promoting 
second messenger signal transduction, the differences in the maximum IP, 
cAMP and Ca2+ responses produced by the most efficacious ligands for each 
receptor have not been discussed (Zambon et al., 2001; Qi et al., 2001b). 
However, these studies have recorded similar maximal Ca2+ mobilisations for 
both hP2Yn and cP2Yn. Antagonist studies have shown that the maximal 
agonist responses generated by the cP2Yn receptor in both IP and cAMP 
accumulation assays are higher than those produced by the hP2Yn receptor (Qi 
et al., 2001b). The IP and cAMP responses induced by ADP in the 1321Nl-cP2Yn 
cells are approximately 25 and 40 percent higher (in cAMP and IP accumulation,
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respectively) than the maximal responses induced by ATP in the 1321Nl-hP2Yn 
cells.
As my experimental results were normalised to an endogenous control, the 
degree of the functional response of the XlP2Yn and hP2Yn receptors may be 
compared directly. A comparison of the ATP-induced cAMP responses is shown 
in Figure 6.2. These data were presented in Chapters 3 and 4. ATP is only able to 
induce a cAMP response in the 1321Nl-XlP2Yn cells that is approximately one 
third (30.5 + 3.8 percent) of the response seen in 1321Nl-hP2Yn cells. Analysis of 
the Ca2+ responses induced by ATP in both 1321Nl-hP2Yn and 1321Nl-XlP2Yn 
cells reveals a similar difference in ATP efficacy between the cell lines (data not 
shown), with ATP inducing a Ca2+ maximal response in the 1321Nl-XlP2Yn 
cells that is approximately 23.5 + 1.9 percent of the maximal response recorded 
in the 1321Nl-hP2Yn cells.
That the XlP2Yn receptor is unable to induce second messenger responses as 
strong as those produced by the hP2Yn receptor in both cAMP and Ca2+ 
pathways may be indicative of the receptor's signalling ability. It may also 
reflect differences in receptor expression levels in the two cell lines. It should 
also be noted that there are inherent differences between Xenopus laevis and 
human G proteins, which may lead to a reduced coupling efficiency for the 
amphipian XlP2Yn receptor when expressed in the mammalian 1321N1 cells.
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